FUNGICIDAL MIXTURES CONTAINING PYRAZOLE DERIVATIVES

Abstract

A fungicidal composition is disclosed comprising (a) at least one compound selected from the compounds of Formula 1, including all geometric and stereoisomers, tautomers, IV-oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, and mn are as defined in the disclosure, and (b) at least one additional fungicidal compound. A method for controlling plant diseases caused by fungal phytopathogens is also disclosed, comprising applying to the plant or a portion thereof, or to the plant seed, a fungicidal amount of a compound of Formula 1, an A-oxide, or a salt thereof (e.g., as a component of the above-mentioned composition). A composition is also disclosed comprising: (a) at least one compound selected from the compounds of Formula 1 described above, A-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

Description

FUNGICIDE MIXTURES CONTAINING PYRAZOLE DERIVATIVES FIELD OF THE INVENTION This invention relates to certain pyrazoles, their / V-oxides, salts and mixtures and compositions comprising such halomethyl ketones and hydrate derivatives and methods of using such halomethyl ketones and hydrate derivatives and their mixtures and compositions as fungicides. BACKGROUND OF THE INVENTION The control of plant diseases caused by fungal phytopathogens is extremely important to achieve high crop efficiency. Damage caused by plant diseases in ornamental, vegetable, field, cereal and fruit crops can cause a significant reduction in productivity and, therefore, an increase in costs for the consumer. In addition to often being very destructive, plant diseases can be difficult to control and can develop resistance to commercial fungicides. There are many products available on the market for these purposes, but there remains a need for new fungicidal compounds that are more effective, less expensive, less toxic, safer for the environment or that have different sites of action. In addition to the introduction of new fungicides, combinations of fungicides are frequently used to facilitate disease control, to broaden the spectrum of control, and to delay the development of resistance. Additionally, certain rare combinations of fungicides demonstrate superior additive (i.e., synergistic) effect in providing commercially important levels of plant disease control. It is recognized in the art that the advantages of particular fungicide combinations vary, depending on factors such as the particular plant species and plant disease to be treated, and whether the plants are treated before or after infection with the fungicide. fungal phytopathogen. Consequently, new advantageous combinations are needed to provide a diversity of options that best meet the particular disease control needs of plants. Now such combinations have been discovered. PCT Patent Publications WO 2018 / 052838, WO 2013 / 192126, WO 2012 / 031061 and WO 2010 / 101973 disclose fungicide pyrazoles and their use in agriculture. PCT Patent Publication WO 2019 / 020981 discloses pyrazole, isothiazole and isoxazole derivatives and their use in agriculture. SUMMARY OF THE INVENTION This invention relates to a fungicidal composition (i.e., a combination) comprising (a) at least one compound selected from the compounds of formula 1 (including all stereoisomers), A / -oxides and salts thereof: M A / t / ZUZZ / U / 4ZÓU where R1 is C1-C2 alkyl; R2 is cyano, halogen, C1-C2 alkyl or C1-C2 haloalkyl; R3 is halogen or methyl; each R4 is independently halogen, cyano, nitro, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy, C2-C6 alkoxyalkyl or C2-C6 alkoxyalkoxy; each R5 is independently halogen, C1-C3 alkyl, C2-C6 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy or C2-C6 alkoxyalkoxy; m and n are each independently 0, 1, 2, or 3; R6is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents independently selected from R6a; or amino, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, CH(=O), S(=O)2OM, S(=O)UR7, (C=W)R8u OR9; each R6a is independently cyano, Ca-Cs cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, CiC3 alkylthio, C1-C3 alkylsulfinyl or C1-C3 alkylsulfonyl; M is K or Na; u is 0, 1 or 2; R7 is C1-C3 alkyl or C1-C3 haloalkyl; W is O or S; R8 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, Ca-Ce dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio or C2-C4 alkylthioalkyl; R9is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents independently selected from R9a; or CH(=O), C3-C6 cycloalkyl, S(=O)2OM or (C=W)R10; each R9a is independently cyano, Ca-Ce cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1C3 alkylthio, C1-C3 alkylsulfinyl or C1-C3 alkylsulfonyl; and R10 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio or C2-C4 alkylthioalkyl; and (b) at least one additional fungicidal compound; provided that the Formula 1 compound is not: 4-(2,6-difluoro-4-methoxyphenyl)-A / -(2,4-difluoro-6-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine; 4-(2-chloro-4-fluorophenyl)-1,3-dimethiI- / \ / -(2-nitrophenyl)-1 / - / -pyrazole-5-amine; 4-(2-chloro-4-fluorophenyl)- / \ / -(2,4-difluoro-6-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine ; 4-(2-chloro-4-fluorophenyl)-3-ethyl-1-methyl-A / -(2-nitrophenyl)-1 / 7-pyrazole-5-amine; 4-(2-chloro-4-fluorophenyl)-1-methyl- / V-(2-nitrophenyl)-3-(trifluoiOmethyl)-1 / 7-pyrazole-5-amine ; 4-(2,6-difluoro-4-methoxyphenyl)-A / -(2-methoxy¡-6-n¡thiophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine; 4-(2-chloro-4-fluorophenyl)-A / -(2-methoxy-6-nitrophenyl)-1,3-dimethyl-1H-pyrazole-5-amine; A / -(2-chloro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / 7-pyrazole-5-amine; / V-(2-chloro-3-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / - / -pyrazole-5amine; 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl- / V-(2-methyl-6-nitrophenyl)-1 / 7-pyrazole-5-amine ; A / -(2-bromo-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine; 4-(2-chloro-4-fluorophenyl)- / V-(4-methoxy-2-nitrophenyl)-1,3-dimethi 1-1 / - / -pyrazole-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-A / -(4-fluoro-2-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-A / -(4-methoxy¡-2-nitrophenyl)-1,3-dimethyl¡l-1 / - / -pyrazole-5-amine ; / V-(4-chloro-2-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / - / -pyrazole-5- am¡na; 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-A / -[2-nitro-4-(2-propyl-1-yloxy)phenyl]-1 / 7- prazole-5amine; 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl- / \ / -[2-nitro-4-(2-propen-1-yloxy)phenyl]-1 / 7-pyrazole5 -amine; / V-(4-bromo-2-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / - / -pyrazole-5- amine; / V-(4-chloro-2-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 H-pyrazole-5amine; 3-chloro-4-(2-chloro-4-fluorophenyl)- / V-(2,4-difluoro-6-nitrophenyl)-1-methyl-1 / 7-pyrazole-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl- / V-[4-methyl-2-nitrophenyl]-1 / 7-pyrazole-5 -amine; 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl- / V-(4-methyl-2-nitrophenyl)-1 / 7-pyrazole-5-amine; and / V-(4-bromo-2-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / 7-pyrazole- 5amine. The present invention also relates to a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, AZ-oxides and salts thereof; and at least one invertebrate pest control compound or agent. The present invention also relates to a composition comprising one of the above-mentioned compositions comprising component (a) and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. The present invention also relates to a method for controlling plant diseases caused by fungal phytopathogens comprising applying to the plant or a portion thereof, or to the seed of the plant, a fungicide-effective amount of one of the aforementioned compositions. previously. M A / í MA / The method described above may also be described as a method of protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying a fungicide effective amount of one of the aforementioned compositions to the plant (or a portion thereof). or plant seed (directly or through the environment (for example, the growing medium) of the plant or plant seed). This invention also relates to a compound of Formula 1 described above, or a Noxide or salt thereof. DETAILS OF THE INVENTION As used herein, the terms comprises, comprising, includes, including, has, having, contains, containing, characterized by or any other variation thereof are intended to encompass non-exclusive inclusion, subject to any Explicitly stated limitation. For example, a composition, mixture, process, method, article or apparatus comprising a list of elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent in such composition, mixture, process, method. , article or device. The transition expression consisting of excludes any unspecified element, step or ingredient. If in the claim, such expression would close the claim to the inclusion of materials other than those listed, except for impurities generally associated with them. When the expression consisting of appears in a clause in the body of a claim, rather than immediately after the preamble, it only limits the element set forth in that clause; other elements are not excluded from the overall claim. The transitional term consisting essentially of is used to define a composition, method or apparatus that includes materials, steps, features, components or elements, in addition to those disclosed literally, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristic or characteristics of the claimed invention. The expression that consists essentially of occupies an intermediate place between that which comprises and that which consists of. Where applicants have defined an invention or a portion thereof with an open-ended expression such as comprising, it should be readily understood that (unless otherwise indicated) the description should be construed to also describe such an invention using the expressions that consists essentially of or that consists of. Furthermore, unless expressly stated otherwise, o refers to an inclusive o and not an exclusive o. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true ( or is present), and both A and B are true (or are present). Likewise, it is intended that the indefinite articles a and one / a that precede an element or component of the invention are not restrictive as to the number of occurrences (i.e., occurrences) of the element or component. Therefore, one or one should be read as including one or at least one, and ΜΛ / the singular word form of the element or component also includes the plural, unless the number is obviously intended to be singular. The term agronomic refers to the production of field crops such as those for food and fiber, and includes the growth of corn, soybeans and other legumes, rice, cereals (for example, wheat, oats, barley, rye and rice ), leafy vegetables (e.g. lettuce, cabbage and other cabbage crops), fruiting vegetables (e.g. tomatoes, peppers, eggplant, cruciferous and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g. , pome, drupe and citrus), small fruits (e.g. berries and cherries) and other specialty crops (e.g. rapeseed, sunflower and olives). The term non-agronomic refers to crops other than field crops, such as horticultural crops (for example, greenhouse, nursery or ornamental plants that are not grown in a field), residential, agricultural, commercial and industrial structures, turf ( for example, sod farms, pastures, golf courses, grass, sports fields, etc.), wood products, stored products, agroforestry and vegetation management, public (i.e. human) health applications and animal health (e.g. example, domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife). The term crop vigor refers to the growth rate or biomass accumulation of a crop plant. An increase in vigor refers to an increase in growth or biomass accumulation in a crop plant relative to an untreated control crop plant. The term crop yield refers to the amount of crop material, both in terms of quantity and quality, that is obtained after harvesting a crop plant. An increase in crop yield refers to an increase in crop yield relative to an untreated control crop plant. The term "biologically effective amount" refers to the amount of a biologically active compound (e.g., a compound of Formula 1) sufficient to produce the desired biological effect when applied to (i.e., contacted with) a fungus that is must control either its environment, or a plant, the seed from which the plant is grown, or the location of the plant (e.g., growing medium) to protect the plant from damage caused by the fungal disease or to another desired effect (for example, increasing plant vigor). As mentioned in the present disclosure and in the claims, plant includes members of the kingdom Plantae, particularly seed plants (Spermatopsida), in all their life stages, including young plants (e.g., germinating seeds that develop into seedlings). ) and the mature and reproductive phases (for example, plants that produce flowers and seeds). The plant portions include the geotropic members that normally grow below the surface of the growing medium (for example, soil), such as roots, tubers, bulbs and corms, and also the members that grow above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds. MA / As mentioned herein, the term seedling, used alone or in a combination of words, means a young plant that develops from the embryo of a seed. As mentioned herein, the term broadleaf used alone or in expressions such as broadleaf crop means a dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons. As mentioned in the present disclosure, the terms fungal pathogen and fungal phytopathogen include pathogens of the phyla Ascomycota, Basidiomycota and Zygomycota, and the fungal-like class Oomycota, which are the causative agents of a wide spectrum of plant diseases. economic importance, affecting ornamental, grass, vegetable, field, cereal and fruit crops. In the context of the present disclosure, the protection of a plant from a disease or the control of a plant disease includes preventive action (interruption of the fungal cycle of infection, colonization, development of symptoms and production of spores) and / or curative action (inhibition of colonization of plant host tissues). As used herein, the term mode of action (MOA) is as defined by the Fungicide Resistance Action Committee (FRAC) and is used to distinguish fungicides according to their biochemical mode of action in the biosynthetic pathways of phytopathogens and their risk of resistance. Modes of action defined by FRAC include (A) nucleic acid metabolism, (B) motor and cytoskeletal proteins, (C) respiration, (D) amino acid and protein synthesis, (E) signal transduction, (F) lipid synthesis or transport and membrane integrity or function, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis, (I) melanin synthesis in the cell wall, (P) induction of defenses in the host plant, (U) unknown mode of action, (M) chemicals with activity at multiple sites, and (BM) biological products with multiple modes of action. Each mode of action (i.e., the letters A through BM) contains one or more subgroups (e.g., A includes subgroups A1, A2, A3, and A4) based either on individual validated target action sites or, on cases where the precise target site is unknown, based on cross-resistance profiles within a group or with respect to other groups. Each of these subgroups (for example, A1, A2, A3 and A4) is assigned a FRAC code (a number and / or a letter). For example, the FRAC code for subgroup A1 is 4. Additional information on target sites and FRAC codes can be obtained from publicly accessible databases maintained, for example, by FRAC. As used herein, the term cross-resistance refers to the phenomenon that occurs when a pathogen develops resistance to a fungicide and simultaneously becomes resistant to one or more other fungicides. These other fungicides usually belong, but not always, to the same chemical class or have the same target site of action, or can be detoxified by the same mechanism. Generally, when a molecular fragment (i.e., a radical) is indicated by a series of atom symbols (e.g., C, Η, N, O, and S), the implicit binding point(s) will be easily recognized. by experts in the art. In some cases of this document, particularly MA / When alternative attachment points are possible, the attachment point(s) may be explicitly indicated with a hyphen. For example, -NCS indicates that the attachment point is the nitrogen atom (i.e. isothiocyanate, not thiocyanate). As used herein, the term alkylating agent refers to a chemical compound in which a carbon-containing radical is attached through a carbon atom to a leaving group such as halide or sulfonate, which can be displaced by the attachment of a nucleophile to said carbon atom. Unless otherwise indicated, the term alkylating agent does not limit the carbon-containing radical to alkyl; Carbon-containing radicals in alkylating agents include the variety of carbon-linked substituent radicals specified, for example, for R5. In the above references, the term "alkyl" used either alone or in compound words such as alkylthio or haloalkyl includes straight chain or branched alkyl, such as methyl, ethyl, npropyl, / -propyl, or the different isomers of butyl, pentyl or hexyl. Alkenyl includes straight chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl and the different isomers of butenyl, pentenyl and hexenyl. Alkenyl also includes polyenes such as 1,2-propadienyl and 2,4hexadienyl. Alkynyl includes straight chain or branched alkynes such as 1-propynyl, 2-propynyl and the different isomers of butynyl, pentynyl and hexynyl. Alkynyl may also include moieties composed of multiple triple bonds such as 2,5-hexadiinyl. Alkoxy includes, for example, methoxy, ethoxy, n-propyloxy, i-propyloxy and the different butoxy, pentoxy and hexyloxy isomers. Alkoxyalkyl indicates a substitution with alkoxy on alkyl. Examples of alkoxyalkyl include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2, and CH3CH2OCH2CH2. Alkenyloxy includes straight chain or branched alkenyl attached to and linked through an oxygen atom. Examples of alkenyloxy include H2C=CHCH2O, (CH3)2C=CHCH2O, CH3CH=CHCH2O, CH3CH=C(CH3)CH2O and CH2=CHCH2CH2O. Alkynyloxy includes straight-chain or branched alkynyl attached to and linked through an oxygen atom. Examples of alkynyloxy include HC^CCHsO, CH3C=CCH2O and CH3C=CCH2CH2O. Alkoxyalkoxy indicates a substitution with alkoxy on another alkoxy residue. Examples of alkoxyalkoxy include CH3OCH2O, CH3OCH2O and CH3CH2OCH2O. Alkylthio includes straight chain or branched alkylthio moieties, such as methylthio, ethylthio and the different isomers of propylthio. Alkylthioalkyl indicates a substitution with alkylthio on alkyl. Examples of alkylthioalkyl include CH3SCH2, CH3SCH2CH2, CH3CH2SCH2 and CH3CH2SCH2CH2. Alkylsulfinyl includes both enantiomers of an alkylsulfinyl group. Examples of alkylsulfinyl include CH3S(=O), CH3CH2S(=O), CH3CH2CH2S(=O) and (CH3)2CHS(=O). Examples of alkylsulfonyl include CH3S(=O)2, CH3CH2S(=O)2, CH3CH2CH2S(=O)2 and (CH3)2CHS(=O)2. Alkylaminoalkyl indicates a substitution with alkylamino on alkyl. Examples of alkylaminoalkyl include CH3NHCH2, CH3NHCH2CH2, CH3CH2NHCH2, CH3CH2CH2CH2NHCH2 and CH3CH2NHCH2CH2. Examples of “dialkylaminoalkyl” include (CH3)2NCH2, (CH3CH2)2NCH2CH2 and CH3CH2(CH3)N CH2CH2. The term cycloalkyl indicates a saturated carbocyclic ring consisting of 3 to 6 carbon atoms linked together by single bonds. Examples of cycloalkyl include cyclopropyl, MA / cyclobutyl, cyclopentyl and cyclohexyl. The term cycloalkylalkyl indicates a substitution with cycloalkyl on an alkyl group. Examples of cycloalkylalkyl include cyclopropylmethyl, cyclopentylethyl and other cycloalkyl moieties attached to straight chain or branched alkyl groups. The term halogen, whether alone or in compound words such as haloalkyl, or when used in descriptions such as halogen-substituted alkyl, includes fluorine, chlorine, bromine or iodine. Furthermore, when used in compound words such as haloalkyl, or when used in descriptions such as alkyl substituted with halogen, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of haloalkyl or halogen-substituted alkyl include FaC, CICH2, CF3CH2 and CF3CCI2. The term haloalkoxy and the like are defined analogously to the term haloalkyl. Examples of haloalkoxy include CF3O, CCI3CH2O, F2CHCH2CH2O and CF3CH2O. Cyanoalkoxy indicates an alkyloxy group substituted with a cyano group. Examples of cyanoalkoxy include NCCH2O, NCCH2CH2O and CH3CH(CN)CH2O. The total number of carbon atoms in a substituent group is indicated by the suffix C1-Cj where i and j are numbers from 1 to 6. For example, C1-C3 alkylsulfonyl designates methylsulfonyl to propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the different isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, including the examples CH3CH2CH2OCH2 and CH3CH2OCH2CH2. The expression unsubstituted with respect to a group such as a ring means that the group does not have any substituent other than its one or more attachments to the remainder of Formula 1. The expression optionally substituted means that the number of substituents may be zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing one hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Typically, the number of optional substituents (when present) ranges from 1 to 3. As used herein, the term optionally substituted is used interchangeably with the term substituted or unsubstituted or with the term (un)substituted. The number of optional substituents may be restricted by express limitation. For example, the term optionally substituted with up to 2 substituents independently selected from R6a means that there may be 0, 1, or 2 substituents present. When a compound is substituted with a substituent that carries a subscript indicating that the number of said substituents can vary (for example, (R4)m in Formula 1 where m is from 0 to 3), then said substituents are independently selected from the group of defined substituents, unless otherwise indicated. When a variable group is shown to be optionally attached to a position, for example, (R4)m where m can be 0, then hydrogen can be at the position even if it is not cited in the definition of the variable group. The naming of substituents in the present disclosure uses recognized terminology that provides conciseness to accurately convey the chemical structure to those skilled in the art. For the sake of conciseness, position descriptors may be omitted. In some cases herein, the point or points of attachment of substituents (e.g., R4 and R5) are indicated by position numbers that may be different from the Chemical Abstracts nomenclature system if the difference does not affect the meaning. The compounds of the present invention may exist as one or more stereoisomers. Stereoisomers are isomers of identical constitution but that differ in the arrangement of their atoms in space and include enantiomers, diastereomers, cis and trans isomers (also known as geometric isomers), and atropisomers. Atropisomers are the result of restricted rotation around single bonds where the rotational barrier is high enough to allow isomeric species to be isolated. A person skilled in the art will appreciate that a stereoisomer may be more active and / or may present beneficial effects when there is an enrichment of it with respect to the other stereoisomer or stereoisomers, or when it is separated from the other stereoisomer or stereoisomers. Additionally, the expert knows how to separate, enrich and / or selectively prepare said stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, 1994. The compounds of the present invention may exist as one or more conformational isomers due to restricted rotation around an amide bond (e.g., C(=O)-N) in Formula 1. The present invention comprises mixtures of conformational isomers. Furthermore, this invention includes compounds that are enriched in one conformer relative to another. The present invention encompasses all stereoisomers, conformational isomers and mixtures thereof in all proportions, as well as isotopic forms such as deuterated compounds. One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form / V-oxides, since nitrogen requires a lone pair available for oxidation to the oxide; One skilled in the art will recognize nitrogen-containing heterocycles that can form / V-oxides. One skilled in the art will also recognize that tertiary amines can form / V-oxides. Synthetic methods for the preparation of / V-oxides of heterocycles and tertiary amines are well known to those skilled in the art, and include the oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as f-butyl hydroperoxide, sodium perborate and dioxiranes such as dimethyldioxirane. These methods for the preparation of / V-oxides have been described and reviewed extensively in the literature, see, for example: T. L. Gilchrist in Comprehensive Organic Synthesis, volume 7, pp. 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, volume 3, pp. 18-20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, volume 43, pp. 149-161, A. R. Katritzki, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, volume 9, pp. 285-291, A. R. Katritzky and A. Sea J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, volume 22, pp. 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press. One skilled in the art recognizes that, because in the environment and under physiological conditions the salts of chemical compounds are in equilibrium with their corresponding non-saline forms, the salts share the biological utility of the non-saline forms. Therefore, a wide variety of salts of the compounds of Formula 1 are useful for the control of plant diseases caused by fungal phytopathogens (i.e., they are suitable from an agricultural point of view). Salts of the compounds of Formula 1 include acid addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic acid. , tartaric, 4-toluenesulfonic or valeric. When a compound of Formula 1 contains an acid moiety such as a carboxylic acid, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1, ZV-oxides and agriculturally suitable salts thereof. The compounds selected from Formula 1, stereoisomers, ΛΖ-oxides and salts thereof, normally exist in more than one form, therefore Formula 1 includes all crystalline and non-crystalline compounds represented by Formula 1. Non-crystalline termas include embodiments that are solid, such as waxes and gums, as well as embodiments that are liquid, such as solutions and melts. Crystal forms include embodiments that essentially represent a single crystal type and embodiments that represent a mixture of polymorphs (i.e., different crystal types). The term polymorph refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these terms having different arrangements and / or conformations of the molecules in the crystalline lattice. Although polymorphs may have the same chemical composition, they may also differ in composition due to the presence or absence of cocrystallized water or other molecules, which may be weakly or strongly attached to the network. Polymorphs can differ in chemical, physical and biological properties such as crystalline form, density, hardness, color, chemical stability, melting point, hygroscopy, suspendability, dissolution rate and availability. biological. One skilled in the art will appreciate that one polymorph of a compound represented by Formula 1 may exhibit beneficial effects (e.g., suitability for the preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound. represented by Formula 1. The preparation and isolation of a particular polymorph of a compound represented by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. As described in the Summary of the Invention, one aspect of the present invention relates to a composition comprising (a) at least one compound selected from Formula 1, ZV-oxides and salts thereof, with (b) at minus one additional fungicide compound. More particularly, the Component MA / (b) is selected from the group consisting of (b1) methylbenzimidazole carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide (PA) fungicides; (b5) amine / morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; (b8) hydroxyl (2-amino-)pyrmidine fungicides; (b9) añilinopyrimidine (AP) fungicides; (b10) M-phenyl carbamate fungicides; (b11) quinone exterior inhibitor fungicides (Qol); (b12) phenylpyrrole (PP) fungicides; (b13) azanaphthalene fungicides; (b14) fungicides inhibiting cellular peroxidation; (b15) melanin-reductase biosynthesis inhibitor (MBI-R) fungicides; (b16a) melanin-dehydratase biosynthesis inhibitor fungicides (MBI-D); (b16b) melanin-polyketide synthase biosynthesis inhibitor (MBI-P) fungicides; (b17) keto reductase inhibitor (KRI) fungicides; (b18) squalene epoxidase inhibitor fungicides; (b19) polyoxin fungicides; (b20) phenylurea fungicides; (b21) quinone interior inhibitory fungicides (Qil); (b22) benzamide and tlazol carboxamide fungicides; (b23) enopyranuronic acid antibiotic fungicides; (b24) hexopyranosyl antibiotic fungicides; (b25) glucopyranosyl antibiotic fungicides: protein synthesis; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamideoxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupling fungicides; (b30) organotin fungicides; (b31) carboxylic acid fungicides; (b32) heteroaromatic fungicides; (b33) phosphonate fungicides; (b34) phthalamic acid fungicides; (b35) benzotriazine fungicides; (b36) benzene-sulfonamide fungicides; M A / (b37) pyridazinone fungicides; (b38) thiophene-carboxamide fungicides; (b39) NADH oxido-reductase complex I inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) quinone exterior and stigmatellin binding inhibitor (QoSI) fungicides; (b46) plant extract fungicides; (b47) cyanoacrylate fungicides; (b48) polyene fungicides; (b49) oxysterol binding protein inhibitor (OSBPI) fungicides; (b50) aryl phenyl ketone fungicides; (b51) host plant defense induction fungicides; (b52) fungicides with multi-site activity; (b53) biological products with multiple modes of action; (b54) fungicides other than the fungicides of component (a) and components (b1) to (b53); and salts of the compounds (b1) to (b54). Noteworthy are the embodiments where component (b) comprises at least one fungicidal compound from each of the two different groups selected from (b1) to (b54). Methylbenzimidazole carbamate (MBC) fungicides (b1) (FRAC code 1) inhibit mitosis by binding to β-tubulin during microtubule assembly. Inhibition of microtubule assembly can alter cell division, transport within the cell, and cell structure. Methylbenzimidazole carbamate type fungicides include benzimidazole and thiophanate type fungicides. Benzimidazoles include benomyl, carbendazim, fuberidazole, and thiabendazole. Thiophanates include thiophanate and thiophanate-methyl. Dicarboximide (b2) fungicides (FRAC code 2) inhibit a mitogen-activated protein (MAP) / histidine kinase in osmotic signal transduction. Examples include clozolinate, dimethaclone, iprodione, procymidone, and vinclozolin. Demethylation inhibitor (DMI) (b3) fungicides (FRAC code 3) (Sterol biosynthesis inhibitors (SBI): Class I) inhibit C14-demethylase, which plays a role in sterol production. Sterols, such as ergosterol, are necessary for the structure and function of membranes, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and ultimately death of sensitive fungi. DMI fungicides are divided into several chemical classes: piperazines, pyridines, pyrimidines, imidazoles, triazoles and triazolinthiones. Piperazines include triforine. Pyridines include butiobate, pyrifenox, pyrisoxazole and (aS)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-413 ¡soxazolyl]-3-pyridinemethanol. Pyrimidines include fenarimol, nuarimol and triarimol. Imidazoles include econazole, imazalil, oxpoconazole, pefurazoate, prochloraz, and triflumizole. Triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazol-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propicon azole , quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, uniconazol-P, a-(1 -chlorocyclopropy l)-a-[2-(2,2-d ichlorocyclopropy l)ethyl]-1 / 7 -1,2,4-triazol-1-ethanol, rel-t [[(2fi,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiraníl] methyl]-1H-1,2,4-triazole, rel-2-[[(2R, 3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)-2-oxy raníl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-thione and re / -1-[[(2 / 3.35)-3-(2chlorophenyl)-2- (2,4-difluorophen¡l)-2-ox¡ran¡l]methyl]-5-(2-propen-1 -ylthio)-1 / 7-1,2,4-triazole. Triazolinthiones include prothioconazole. Biochemical investigations have shown that all of the above-mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides - Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258. Phenylamide (PA) fungicides (b4) (FRAC code 4) are specific inhibitors of RNA polymerase in oomycete fungi. Sensitive fungi exposed to these fungicides show a reduced ability to incorporate uridine into rRNA. Exposure to this class of fungicides prevents growth and development in sensitive fungi. Phenylamide-type fungicides include acylalanine, oxazolidinone, and butyrolactone-type fungicides. Acylalanines include benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl, and metalaxyl-M (also known as mefenoxam). Oxazolidinones include oxadixyl. Butyrolactones include ofurace. Amine / morpholine (b5) fungicides (FRAC code 5) (SBI: Class II) inhibit two target sites within the sterol biosynthetic pathway, Δ8—>A7isomerase and Δ14reductase. Sterols, such as ergosterol, are necessary for the structure and function of membranes, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and ultimately death of sensitive fungi. Amine / morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine, and spiroketalamine fungicides. Morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph, and trimorfamide. Piperidines include fenpropidine and piperaline. Spiroketalamines include spiroxamine. Phospholipid biosynthesis-inhibiting fungicides (b6) (FRAC code 6) inhibit fungal growth by affecting phospholipid biosynthesis. Fungicides that affect phospholipid biosynthesis include phosphorothiolate and dithiolane type fungicides. Phosphorothiolates include edifenphos, iprobenphos and pyrazophos. Dithiolanes include isoprothiolane. Succinate dehydrogenase inhibitor (SDHI) fungicides (b7) (FRAC code 7) inhibit complex II fungal respiration by disrupting a key enzyme of the Krebs cycle (TCA cycle) called succinate dehydrogenase. Inhibition of respiration prevents the fungus from making ATP and, therefore, inhibits its growth and reproduction. SDHI fungicides include type fungicides ΜΛ / t / ZUZZ / U / 4ZÓU M A / phenylbenzamide, phenylxoethylthiophenoamide, pyridinylethylbenzamide, furancarboxamide, oxathiincarboxamide, thiazolcarboxamide, pyrazole-4-carboxamide, / V-cyclopropyl-M-benzylpyrazolecarboxamide, Nmethoxy(phenylethyl)pyrazolecarboxamide, pyridinecarboxamide and pyrazinecarboxamide. Phenylbenzamides include benodanil, flutolanil and mepronil. Phenyloxyethylthiophenamides include isofetamide. Pyridinylethylbenzamides include fluopyram. Furancarboxamides include fenfuram. Oxathiinecarboxamides include carboxine and oxycarboxine. Thiazolcarboxamides include tifluzamide. Pyrazole-4-carboxamides include benzovindiflupyr, bixafen, flubeneteram (provisional common name, Registration Number 1676101-39-5), fluindapir, fluxapiroxad, furametpir, inpirfluxam, isopyrazam, penflufen, penthiopyrad, pyrapropoin (provisional common name, Registration Number 1803108-03-3), sedaxane and A / -[2-(2,4-dichlorophenyl)-2-methoxy¡-1 -methylethyl]-3-(difluoromethi)-1 -methyl-1 / - / -pyrazole- 4-carboxamide. / V-cyclopropyl-N-benzylpyrazolecarboxamides include isoflucipram. Nmethoxy(phenylethyl)pyrazolecarboxamides include pidiflumethofen. Pyridinecarboxamides include boscalide. Pyrazinecarboxamides include pyrazifflumide. Hydroxy-(2-amino-)pyrmidine (b8) fungicides (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimetirimol and etirimol. Anilinopyrimidine (AP) fungicides (b9) (FRAC code 9) are proposed to inhibit the biosynthesis of the amino acid methionine and disrupt the secretion of hydrolytic enzymes used by plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil. / V-phenyl carbamate (b10) fungicides (FRAC code 10) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can alter cell division, transport within the cell, and cell structure. Examples include dietofencarb. Quinone exterior (Qol) inhibitory fungicides (b11) (FRAC code 11) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Ubiquinol oxidation is blocked at the external quinone (Qo) site of the cytochrome bci complex, which is located in the inner mitochondrial membrane of fungi. Inhibition of mitochondrial respiration prevents normal fungal growth and development. External quinone-inhibiting fungicides include methoxyacrylate, methoxyacetamide, methoxycarbamate, oximinoacetate, oximinoacetamide and dihydrodioxazine fungicides (collectively also known as strobilurin fungicides) and oxazolidinedione, imidazolinone and benzylcarbamate fungicides. Methoxyacrylates include azoxystrobin, cumoxystrobin, enoxastrobin (also known as enestroburin), fluphenoxystrobin, picoxystrobin, and pyraxiestrobin. Methoxyacetamides include mandestrobin. Methoxycarbamates include pyraclostrobin, pyrametostrobin, and triclopiricarb. Oxyminoacetates include kresoxim-methyl and trifloxystrobin. Oxyminoacetamides include dimoxystrobin, phenaminestrobin, metominostrobin, and orisastrobin. Dihydrodioxazines include fluoxaestrobin. Oxazolidinediones include famoxadone. Imidazolinones include phenamidone. Benzylcarbamates include pyribencarb. Phenylpyrrole (PP) fungicides (b12) (FRAC code 12) inhibit a MAP / histidine kinase associated with osmotic signal transduction in fungi. Fenplclonil and fludioxonil are examples of this class of fungicides. Azanaphthalene (b13) fungicides (FRAC code 13) are proposed to inhibit signal transduction through a mechanism that is still unknown. They have been shown to interfere with germination and / or appressoria formation in fungi that cause powdery mildew diseases. Azanaphthalene-type fungicides include aryloxyquinolines and quinazolinones. Aryloxyquinolines include quinoxyfen. Quinazolinones include proquinazid. It is proposed that cellular peroxidation inhibitor fungicides (b14) (FRAC code 14) inhibit lipid peroxidation that affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes such as respiration and melanin biosynthesis. Fungicides against cellular peroxidation include aromatic hydrocarbon and 1,2,4-thiadiazole fungicides. Aromatic hydrocarbon type fungicides include biphenyl, chloroneb, dichlorane, quintazene, technazene and tolclofos-methyl. 1,2,4-Thiadiazoles include etridiazole. Melanin biosynthesis-reductase inhibitor (MBI-R) fungicides (b15) (FRAC code 16.1) inhibit the naphthal reduction step of melanin biosynthesis. Melanin is necessary for infection of the host plant by some fungi. Fungicides that act on reductase inhibitors of melanin biosynthesis include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. Isobenzofuranones include phthalide. Pyrroloquinolinones include pyroquilone. Trlazolobenzothiazoles include tricyclazole. Melanin biosynthesis-inhibiting dehydratase (MBI-D) fungicides (b16a) (FRAC code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin is necessary for infection of the host plant by some fungi. Fungicides that act on dehydratase inhibitors of melanin biosynthesis include cyclopropanearboxamide, carboxamide and propionamide type fungicides. Cyclopropanecarboxamides include carpropamid. Carboxamides include diclocimet. Propionamides include fenoxanyl. Melanin-polyketide synthase biosynthesis inhibitor (MBI-P) fungicides (b16b) (FRAC code 16.3) inhibit polyketide synthase in melanin biosynthesis. Melanin is necessary for infection of the host plant by some fungi. Fungicides that act on polyketide synthase inhibitors of melanin biosynthesis include trifluoroethylcarbamate type fungicides. Trifluoroethylcarbamates include tolprocarb. Keto reductase inhibitor (KRI) fungicides (b17) (FRAC code 17) inhibit 3-keto reductase during C4-demethylation in sterol production. Keto reductase inhibitor fungicides (also known as sterol biosynthesis inhibitors (SBIs): Class III) include hydroxyanilides and aminopyrazolinones. Hydroxyanilides include fenhexamid. Amino-pyrazolinones include fenpyrazamine. Quinofumeline (provisional common name, Registration Number 861647-84-9) and ipflufenoquine (provisional common name, Registration Number 1314008-27-9) are also believed to be ΜΛ / í are keto reductase inhibitor fungicides. Squalene epoxidase inhibitor (b18) fungicides (FRAC code 18) (SBI: Class IV) inhibit squalene epoxidase in the sterol biosynthesis pathway. Sterols such as ergosterol are necessary for the structure and function of membranes, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and ultimately death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include thiocarbamate and alllamine fungicides. Thiocarbamates include pyributicarb. Allylamines include naftifina and terbinafine. Polyoxin (b19) fungicides (FRAC code 19) inhibit chitin synthase. Examples include polyoxin. Phenylurea (b20) fungicides (FRAC code 20) are proposed to affect cell division. Examples include pencicuron. Quinone interior inhibitory fungicides (Qil) (b21) (FRAC code 21) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. Ubiquinone reduction is blocked at the internal quinone (Qi) site of the cytochrome bci complex, which is located in the inner mitochondrial membrane of fungi. Inhibition of mitochondrial respiration prevents normal fungal growth and development. Internal quinone inhibitor fungicides include cyanoimidazole, sulfamoyltriazole, and picolinamide fungicides. Cyanoimidazoles include cyazofamid. Sulfamoyltriazoles include amisulbrom. Picolinamides include fenpicoxamid (Registration Number 517875-34-2). The benzamide and thiazole carboxamide (b22) fungicides (FRAC code 22) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can alter cell division, transport within the cell, and cell structure. Benzamides include toluamides such as zoxamide. Thiazolecarboxamides include ethylaminothiazolecarboxamides such as etaboxam. Enopyranuronic acid (b23) antibiotic fungicides (FRAC code 23) inhibit fungal growth by affecting protein biosynthesis. Examples include blasticidin-S. Hexopyranosyl (b24) antibiotic fungicides (FRAC code 24) inhibit fungal growth by affecting protein biosynthesis. Examples include kasugamycin. Glucopyranosyl antibiotic fungicides: protein synthesis (b25) (FRAC code 25) inhibit fungal growth by affecting protein biosynthesis. Examples include streptomycin. Glucopyranosyl (b26) antibiotic fungicides (FRAC code U18, formerly FRAC code 26 reclassified to U18) are proposed to inhibit trehalase and inositol biosynthesis. Examples include validamycin. Cyanoacetamidoxime (b27) fungicides (FRAC code 27) include cymoxanil. Carbamate (b28) fungicides (FRAC code 28) are considered multi-site inhibitors of fungal growth. It is proposed that they interfere with the synthesis of fatty acids in membranes M A / t / ZUZZ / U / 4ZÓU cells, which alters the permeability of membranes. Iodocarb, propamacarb and prothiocarb are examples of this class of fungicides. Oxidative phosphorylation uncoupling fungicides (b29) (FRAC code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibition of respiration prevents normal fungal growth and development. This class includes dinitrophenyl crotonates such as binapacryl, meptyldinocap and dinocap, and 2,6-dinitroanilines such as fluazinam. Organotin (b30) fungicides (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in the oxidative phosphorylation pathway. Examples include fentine acetate, fentine chloride, and fentine hydroxide. Carboxylic acid (b31) fungicides (FRAC code 31) inhibit fungal growth by affecting deoxyribonucleic acid (DNA) type II latopoisomerase (gyrase). Examples include oxolinic acid. Heteroaromatic fungicides (b32) (FRAC code 32) are proposed to affect DNA / ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazoles and isothiazolones. Isoxazoles include himexazole and isothiazolones include octylinone. Phosphonate (b33) fungicides (FRAC code P07, formerly FRAC code 33 reclassified to P07) include phosphorous acid and its various salts, including fosetyl-aluminum. Italic acid (b34) fungicides (FRAC code 34) include teclofthalam. Benzotriazine (b35) fungicides (FRAC code 35) include triazoxide. Benzene-sulfonamide (b36) fungicides (FRAC code 36) include flusulfamide. Pyridazinone (b37) fungicides (FRAC code 37) include diclomezine. Thiophene-carboxamide (b38) fungicides (FRAC code 38) are proposed to affect ATP production. Examples include silthiofam. NADH oxidoreductase complex I (b39) inhibitor fungicides (FRAC code 39) inhibit electron transport in mitochondria and include pyrimidinamines such as diflumetorim, pyrazole-5-carboxamides such as tolfenpyrad and quinazolines such as fenazaquine. Carboxylic acid amide (CAA) fungicides (b40) (FRAC code 40) inhibit cellulose synthase, which prevents growth and leads to the death of the target fungus. Carboxylic acid amide type fungicides include cinnamic acid amide type fungicides, valinamide carbamate and mandelic acid amide type fungicides. Cinnamic acid amides include dimethomorph, flumorph and pirimorph. Valinamide carbamates include bentiavalicarb, bentiavalicarb-isopropyl, iprovalicarb, tolprocarb, and valifenalate (also known as valifenal). Mandelic acid amides include mandipropamid, A / -[2-[4-[[3-(4-chlorophenyl)-2-prop¡n-1-yl]oxy]-3-methoxyphenyl]ethyl]-3 -methyl-2-[(methylsulfon¡l)amino]butanamide and N[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-¡l]oxy]-3-methoxyphen¡l] ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide. Tetracycline (b41) antibiotic fungicides (FRAC code 41) inhibit fungal growth by affecting protein synthesis. Examples include oxytetracycline. Thiocarbamate (b42) fungicides (FRAC code M12, formerly FRAC code 42 reclassified to M12) include metasulfocarb. MA / t / ZUZZ / U / 4ZÓU Benzamide (b43) fungicides (FRAC code 43) inhibit fungal growth by delocalizing spectrin-like proteins. Examples include pyridinylmethylbenzamides such as fluopicolide and fluopimomide. Microbial fungicides (b44) (FRAC code BM02, formerly FRAC code 44 reclassified to BM02) disrupt the cell membranes of fungal pathogens. Microbial fungicides include Bacillus species such as Bacillus amyloliquefaciens strains AP-136, AP-188, AP-218, AP-219, AP-295, QST713, FZB24, F727, MB1600, D747, TJ100 (also called strain 1 BE; known from document EP2962568) and the fungicidal lipopeptides they produce. Quinone exterior, stigmatellin-binding inhibitor (QoSI) fungicides (b45) (FRAC code 45) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase at the quinone exterior (Qo) site, subsite binding to stigmatellin, of the cytochrome bc complex^. Inhibition of mitochondrial respiration prevents normal fungal growth and development. QoSI fungicides include triazolopyrimidylamines such as ametoctradine. Plant extract fungicides (b46) (FRAC code 46) cause alteration of the cell membrane. Plant extract fungicides include terpene hydrocarbons, terpene alcohols and terpene phenols such as Melaleuca alternifolia (tea tree) extract and (mixtures of) plant oils such as eugenol, geraniol and thymol. Cyanoacrylate fungicides (b47) (FRAC code 47) bind to the motor domain of myosin and affect motor activity and actin assembly. Cyanoacrylates include fungicides such as fenamacryl. Polyene (b48) fungicides (FRAC code 48) cause disruption of the fungal cell membrane by binding to ergosterol, the main membrane sterol. Examples include natamycin (pimaricin). Oxysterol-binding protein inhibitor (OSBPI) fungicides (b49) (FRAC code 49) bind to oxysterol-binding protein in oomycetes causing inhibition of zoospore release, zoospore motility and germination of sporangia. Oxysterol-binding fungicides include piperdinylthiazolisoxazolines such as oxathiapiproline and fluoxapiproline. Aryl-phenyl-ketone (b50) fungicides (FRAC code 50, formerly FRAC code U8 reclassified to 50) inhibit mycelial growth in fungi. Phenyl aryl ketone type fungicides include benzophenones such as metrafenone and benzoylpyridines such as pyriophenone. Host plant defense induction fungicides (b51) induce host plant defense mechanisms. Fungicides that induce host plant defenses include benzothiadiazole (FRAC code P01), benzisothiazole (FRAC code P02), thiadiazolcarboxamide (FRAC code P03), polysaccharide (FRAC code P04), and plant extract fungicides (FRAC code P05). , microbial (FRAC code P06) and phosphonate type (FRAC code P07, see (b33) above). Benzothiadiazoles include acibenzolar-S-methyl. Benzisothiazoles include probenazole. Thiadiazolecarboxamides include thiadinyl and isotianyl. Polysaccharides include laminarin. Plant extracts include Fleynoutria sachalinensis (giant bloodroot) extract. The Microbial M A / t / ZUZZ / U / 4ZÓU include Bacillus mycoides isolate J and cell walls of Saccharomyces cerevisiae strain LAS117. Fungicides with multisite activity (b52) inhibit fungal growth through multiple sites of action and have contact / preventive activity. Fungicides with multi-site activity include copper fungicides (FRAC code M01), sulfur fungicides (FRAC code M02), dithiocarbamate type fungicides (FRAC code M03), phthalimide type fungicides (FRAC code M04), chloronitrile type fungicides (FRAC code M05), sulfonamide-type fungicides (FRAC code M06), multi-site contact guanidine-type fungicides (FRAC code M07), triazine-type fungicides (FRAC code M08), quinone-type fungicides (FRAC code M09) , quinoxaline type fungicides (FRAC code M10), maleimide type fungicides (FRAC code M11) and thiocarbamate type fungicides (FRAC code M12, see (b42) above). Copper fungicides are inorganic compounds containing copper, usually in the copper(II) oxidation state; Examples include copper oxychloride, copper sulfate, and copper hydroxide (e.g., including compositions such as Bordeaux mixture (tribasic copper sulfate). Sulfur fungicides are inorganic chemical compounds containing rings or chains of atoms. of sulfur; examples include elemental sulfur. Dithiocarbamate-type fungicides contain a dithiocarbamate molecular moiety; examples include ferbam, mancozeb, maneb, metiram, propineb, thiram, zinc-thiazole, zineb and ziram. Phthalimide-type fungicides contain a phthalimide molecular moiety; examples include folpet, capitan, and tumbafol. Chloronitrile-type fungicides contain an aromatic ring substituted with chlorine and cyano; examples include chlorothalonil. Sulfonamide-type fungicides include dichlofluanid and tolifuanid. Guanidine fungicides contact at multiple sites include guazatine, iminoctadine albesilate and iminoctadine triacetate.Triazine-type fungicides include anylazine. Quinone fungicides include dithianon. Quinoxalin-type fungicides include quinomethionate (also known as cinomethionate). Maleimide fungicides include fluoroimide. Biologics with multiple modes of action (b53) include agents of biological origin that exhibit multiple mechanisms of action without evidence of a dominant mode of action. This class of fungicides includes polypeptide (lectin), phenolic, sesquiterpene, tritepenoid and coumarin fungicides (FRAC code BM01) such as the extract of the cotyledons of lupine seedlings. This class also includes microbial fungicides (FRAC code BM02, see (b44) above). Fungicides other than fungicides of component (a) and components (b1) to (b53); (b54); They include certain fungicides whose mode of action may be unknown. These include: (b54.1) phenylacetamide type fungicides (FRAC code U06), (b54.2) guanidine type fungicides (FRAC code U12), (b54.3) thiazolidine type fungicides (FRAC code U13), (b54 .4) pyrimidinonehydrazone type fungicides (FRAC code U14), (b54.5) 4-quinolyl acetate type fungicides (FRAC code U16), (54.6) tetrazolyloxime type fungicides (FRAC code U17) and glucopyranosyl type antibiotic fungicides (FRAC code U18, see (b26) above). Phenylacetamides include cyflufenamide. Guanidines include dodine. Thiazolidines include flutianil. Pyrimidinonehydrazones include ferimzone. 4-quinolyl acetates include tebufloquine. The MA / t / ZUZZ / U / 4ZÓU tetrazolyloximes include picarbutrazox. Class (b54) also includes betoxazine, diclobenthiazox (provisional common name, Registration Number 957144-77-3), dipimethitrone (provisional common name, Registration Number 16114-35-5), flomethoquine, neo-asozine (ferric methanoarsonate) , pyrrolnitrin, tolnifanide (Registration Number 304911 98-6), / V-[4-[4-chloro-3-(trifluoromethyl)phenoxy¡]-2,5-dimethylphenyl]- / \ / -ethyl- / \ / -methylmetanimídam¡da, 5-fluoro-2-[(4fluorophenyl)methoxy]-4-pyrimidinamine and Λ / -[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl] 4fluorophenyl carbamate. Additional fungicides other than fungicides of classes (1) to (54) whose mode of action may be unknown, or may not yet be classified, include a fungicide compound selected from components (b54.7) to (Ó54.12). , as described below. Component (54.7) refers to A / -[[3-(acet¡lox¡)-4-methoxy¡-2-py¡din¡l]carbon¡l]-L-alananate of (1S )2,2-bis(4-fluorophenyl)-1-methylethyl (provisional common name florylpicoxamid, Registration Number 196131255-9) which is believed to be a quinone internal inhibitor fungicide (Qil) (FRAC code 21) that inhibits Complex III mitochondrial respiration in fungi. Component (54.8) refers to 1-[2-[[1-(4-chlorophenyl)-1 / 7-pyrazol-3-íl]oxy]methyl]-3-methylpheníl]-1, 4dihydro-4-methyl-5 / - / -tetrazol-5-one (provisional common name methyltetraprol, Registration Number 147264901-6) which is believed to be an external quinone (Qol) inhibitor fungicide (FRAC code 45) that inhibits Complex III mitochondrial respiration in fungi and is effective against Qol-resistant strains. Component (54.9) refers to 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenypyridazine (provisional common name pyridaclomethyl, Registration Number 1358061-55-8), which is believed to be promoter of tubulin polymerization, and results in antifungal activity against fungal species belonging to the phyla Ascomycota and Basidiomycota. Component (54.10) refers to (4-phenoxyphenyl)methyl 2-amino-6-methylpyrifen-3-carboxylate (provisional common name aminopyrifene, Registration Number 1531626-08-0) which is believed which inhibits GWT-1 protein in glycosylphosphatidylinositol anchor biosynthesis in Neurospora crassa. Component (b54.11) refers to a compound of Formula b54.11 M A / í where Rb1 and Rb3 are each independently halogen; and Rb2es H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl. Examples of compounds of Formula b54.11 include (b54.11a) / \ / -[[5-[1 -(2,6-difluoro-4formylphenyl)-1 / 7-pyrazol-3-yl]-2-methylphenyl Methyl ]methyl]carbamate, (b54.11b) / V-[[5-[1-(4-cyclopropyl-2,6dichlorophenyl)-1 / 7-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate methyl, (b54.11c) A / -[[5-[1-(4-chloro-2,6 difluorophenyl)-1 / +pyrazol-3-¡l]-2-methylphenyl]methyl]carbamate methyl, (b54.11d) / Methyl V-[[5-[1-(4-cyclopropyl-2,6difluorophenyl)-1 / - / -pyrazol-3-yl]-2-methylphenyl]methyl]carbamate , (b54.11e) A / -[[5-[1 -[2,6-difluoro-4-(1 methylethyl)phenyl]-1 / - / -pyrazol-3-yl]-2-methylphenyl]methyl] methyl carbamate and (b54.11f) / V-[[5-[1-[2,6-difluoro-4(trifluoromethyl)phenyl]-1 / - / -pyrazol-3-yl]-2-methylphenyl]methyl ]methyl carbamate. Compounds of Formula b54.11, their use as fungicides and methods of preparation are generally known; see, for example, Patent Publications WO 2008 / 124092, WO 2014 / 066120 and WO 2020 / 097012. methyl Component (b54.12) refers to a compound of Formula b54.12 ΜΛ / t / ZUZZ / U / 4ZÓU b54.12 where Rb4es Rb6 is C2-C4 alkoxycarbonyl or C2-C4 haloalkylaminocarbonyl; L is CH2 or CH2O, where the atom on the right is connected to the phenyl ring in Formula b54.12; Rb5es Rb7 is C1-C3 alkyl, where the wavy bond indicates the (Z) or (E) configuration of the adjacent double bond or a mixture of these. Examples of compounds of Formula b54.12 include (b54.12a) A / -(2,2,2-trifluoroethyl)-2-[[4-[5(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]-4-oxazolcarboxamide, (b54.12b) 1-[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenoxy]methyl]-1 / 7- ethyl pyrazole-4-carboxylate, (b54.12c) 1-[[4-[[(1 Z)-2-ethoxy-3,3,3-trifluoro-1 propen-1 -yl]oxy]phenyl]met ethyl]-1 / - / -pyrazole-4-carboxylate and (b54.12d) 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan2-¡l]methoxy]phenyl]methyl ]-1 / 7-pyrazole-4-ethyl carboxylate. Compounds of Formula b54.12, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publications WO 2008 / 187553 and WO 2020 / 056090. Embodiments of the present invention, as described in the Summary of the Invention, include those described below. In the following Embodiments, Formula 1 includes MA / stereoisomers, A / -oxides and salts thereof, and reference to a compound of Formula 1 includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments. Embodiment 1. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, where R1 is methyl. Embodiment 2. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, R1 is ethyl. Embodiment 3. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or Embodiments 1 or 2, where R2 is cyano, halogen or C1-C2 alkyl. Embodiment 4. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or Embodiments 1 or 2, wherein R2 is cyano, Br, Cl, F, C1 alkyl -C2 or C1-C2 haloalkyl. Embodiment 5. The composition of Embodiment 4 wherein R2 is cyano, Br, Cl, F, C1-C2 alkyl or halomethyl. Embodiment 6. The composition of Embodiment 5 wherein R2 is cyano, Br, Cl, F, C1-C2 alkyl or CF3. Embodiment 7. The composition of Embodiment 6 wherein R2 is cyano, Br, Cl, F or C1-C2 alkyl. Embodiment 8. The composition of Embodiment 7 wherein R2 is cyano or C1-C2 alkyl. Embodiment 9. The composition of Embodiment 8 wherein R2 is C1-C2 alkyl. Embodiment 10. The composition of Embodiment 8 wherein R2 is cyano or methyl. Embodiment 11. The composition of Embodiment 10 wherein R2 is methyl. Embodiment 12. The composition of Embodiment 7 wherein R2 is Br, Cl or methyl. Embodiment 13. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 12, where R3 is halogen or methyl. Embodiment 13a. The composition of Embodiment 13 wherein R3 is halogen. Embodiment 13b. The composition of Embodiment 13 wherein R3 is Br, Cl, F or methyl. Embodiment 14. The composition of Embodiment 13 wherein R3 is Br, Cl or F. Embodiment 15. The composition of Embodiment 14 wherein R3 is Cl or F. Embodiment 16. The composition of Embodiment 15 where R3 is Cl. Embodiment 17. The composition of Embodiment 15 where R3 is F. Embodiment 18. The composition of Embodiment 13 wherein R3 is Cl, F or methyl. Embodiment 19. The composition of Embodiment 18 wherein R3 is Cl or methyl. Embodiment 20. The composition of Embodiment 19 wherein R3 is methyl. Embodiment 21. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, or any one of Embodiments 1 to 20, wherein each R4 is independently halogen, cyano, alkyl C1-C2, C1-C2 alkoxy, C1-C2 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C2-C4 cyanoalkoxy, C2-C4 alkoxyalkyl or C2-C4 alkoxyalkoxy. MA / Embodiment 22. The composition of Embodiment 21 wherein each R4 is independently halogen, cyano, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C2-C4 cyanoalkoxy, C2-C4 alkoxyalkyl or C2-C4 alkoxyalkoxy. Embodiment 23. The composition of Embodiment 22 wherein each R4 is independently halogen, cyano, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy or C2-C4 cyanoalkoxy. Embodiment 24. The composition of Embodiment 23 wherein each R4 is independently halogen, cyano, methyl, methoxy, halomethoxy or C2-C4 cyanoalkoxy. Embodiment 25. The composition of Embodiment 24 wherein each R4 is independently halogen, cyano, methyl or methoxy. Realization 25a. The composition of Embodiment 25 wherein each R4 is independently halogen, cyano or methoxy. Implementation 25b. The composition of Embodiment 25 wherein each R4 is independently halogen, cyano or methyl. Embodiment 26. The composition of Embodiment 25 wherein each R4 is independently Br, Cl, F, cyano, methyl or methoxy. Embodiment 27. The composition of Embodiment 26 wherein each R4 is independently Br, Cl, F, cyano or methoxy. Embodiment 28. The composition of Embodiment 27 wherein each R4 is independently Cl, F, cyano or methoxy. Embodiment 29. The composition of Embodiment 27 wherein each R4 is independently Br, Cl or F. Embodiment 30. The composition of Embodiment 29 wherein each R4 is independently Cl or F. Embodiment 31. The composition of Embodiment 30 where each R4 is Cl. Embodiment 32. The composition of Embodiment 30 where each R4 is F. Embodiment 33. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, or any one of Embodiments 1 to 32, wherein each R4 is independently halogen, cyano or alkoxy C1-C2. Embodiment 34. The composition of Embodiment 33 wherein each R4 is independently halogen. Embodiment 35. The composition of Embodiment 33 wherein each R4 is independently Br, Cl or F or cyano. Embodiment 36. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 35, where m is 0, 1 or 2. Embodiment 37. The composition of Embodiment 36 where m is 1 or 2. Embodiment 38. The composition of Embodiment 37 where m is 1. M A / Embodiment 39. The composition of Embodiment 38 where m is 2. Embodiment 40. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, or any one of Embodiments 1 to 39, wherein each R5 is independently halogen, C1-alkyl C2, C2-C4 alkoxyalkyl, C1-C2 alkoxy, C1-C2 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C2-C4 cyanoalkoxy or C2-C4 alkoxyalkoxy. Embodiment 41. The composition of Embodiment 40 wherein each R5 is independently halogen, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy or C2-C4 cyanoalkoxy. Embodiment 42. The composition of Embodiment 41 wherein each R5 is independently halogen, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, and C2-C4 cyanoalkoxy. Embodiment 43. The composition of Embodiment 42 wherein each R5 is independently halogen, methyl, methoxy, halomethoxy or C2-C4 cyanoalkoxy. Embodiment 44. The composition of Embodiment 43, wherein each R5 is independently halogen, methyl or methoxy. Embodiment 45. The composition of Embodiment 44 wherein each R5 is independently Br, Cl, F, methyl or methoxy. Embodiment 46. The composition of Embodiment 45 wherein each R5 is independently Br, Cl, F or methoxy. Embodiment 46a. The composition of Embodiment 46 where each R5 is independently Br, Cío F. Embodiment 47. The composition of Embodiment 46 wherein each R5 is independently Cl, F or methoxy. Embodiment 48. The composition of Embodiment 47 wherein each R5 is independently Cl or F. Embodiment 49. The composition of Embodiment 45 wherein each R5 is independently Br, Cl, F or methyl. Embodiment 50. The composition of Embodiment 49 wherein each R5 is independently F or methyl. Embodiment 51. The composition of Embodiment 50 where each R5 is F. Embodiment 52. The composition of Formula 1 or any one of Embodiments 1 to 51 where n is 0, 1 or 2. Embodiment 53. The composition of Embodiment 52 where n is 1 or 2. Embodiment 54. The composition of Embodiment 53, where n is 1. Embodiment 55. The composition of Embodiment 53, where n is 2. Embodiment 56. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 55, where R6 is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 1 substituent selected from R6a; or amino, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, CH(=O), S(=O)2OM, S(=O)uR7, (C=W)R8u OR9. MA / Embodiment 57. The composition of Embodiment 56 where R6 is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 1 substituent selected from R6a; or cyclopropyl, S(=O)2OM, S(=O)uR7, (C=W)R8u OR9. Embodiment 58. The composition of Embodiment 57 where R6 is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R6a; or S(=O)uR7u OR9. Embodiment 59. The composition of Embodiment 58 where R6 is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R6a. Embodiment 60. The composition of Embodiment 59 wherein R6 is H, C1-C2 alkyl or C1C2 haloalkyl. Embodiment 61. The composition of Embodiment 60 wherein R6 is H, methyl or halomethyl. Embodiment 62. The composition of Embodiment 61 wherein R6 is H, methyl or trifluoromethyl. Embodiment 63. The composition of Embodiment 62 wherein R6 is H or methyl. Embodiment 64. The composition of Embodiment 63, where R6 is H. Embodiment 65. The composition of Formula 1 or any one of Embodiments 1 to 64 wherein each R6a is independently cyano, C3-C6 cycloalkyl or C1-C3 alkoxy. Embodiment 66. The composition of Embodiment 65 wherein each R6a is independently cyano, cyclopropyl or methoxy. Embodiment 67. The composition of Embodiment 66 wherein each R6a is independently cyano or cyclopropyl. Embodiment 68. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 58, where u is 0. Embodiment 69. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 58, where R7 is methyl or halomethyl. Embodiment 70. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or in any one of Embodiments 1 to 57, where W is O. Embodiment 71. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, or any one of Embodiments 1 to 57, wherein R8 is C1-C3 alkyl, C1 alkoxy -C3 or C1-C3 alkylthio. Embodiment 72. The composition of Embodiment 71 wherein R8 is methyl, ethyl, methoxy, ethoxy, methylthio or ethylthio. Embodiment 73. The composition of Embodiment 72 wherein R8 is methyl, methoxy or methylthio. Embodiment 74. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 58, where ΜΛ / R9is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 1 substituent selected from R9a; or CH(=O), cyclopropyl, S(=O)2OM or (C=W)R10. Embodiment 75. The composition of Embodiment 74 where R9 is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R9a. Embodiment 76. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, or any one of Embodiments 1 to 75, wherein each R9a is independently cyano, C3-cycloalkyl C6 or C1-C3 alkoxy. Embodiment 77. The composition of Embodiment 76 wherein each R9a is independently cyano, cyclopropyl or methoxy. Embodiment 78. The composition of Embodiment 77 wherein each R9a is independently cyano or cyclopropyl. Embodiment 79. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 78, wherein R10 is C1-C3 alkyl, C1 alkoxy -C3 or C1-C3 alkylthio. Embodiment 80. The composition of Embodiment 79 wherein R10 is methyl, ethyl, methoxy, ethoxy, methylthio or ethylthio. Embodiment 81. The composition of Embodiment 80 wherein R10 is methyl, methoxy or methylthio. Embodiment 82. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 81, where m is 1 and R4 is in position 4 (or para position), in relation to the connection of the phenyl ring with the rest of Formula 1. Embodiment 83. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 81, where m is 1 and R4 is in position 6 (or ortho position), in relation to the connection of the phenyl ring with the rest of Formula 1. Embodiment 84. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 81, where month 1 and R4 is in position 4 (or position for); om is 1 and R4 is in position 6 (or ortho position), relative to the connection of the phenyl ring with the rest of Formula 1. Embodiment 85. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 81, where m is 2 and an R4 is in position 4 (or para position), and the other is at position 6 (or ortho position), relative to the connection of the phenyl ring with the rest of Formula 1). Embodiment 86. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 81, where m is 1 and R4 is in position 4 (or position for); or m is 1 and R4 is in position 6 (or ortho position); or m is 2 and one R4 is in position 4 (or position for), and the other is in M A / position 6 (or ortho position), related to the connection of the phenyl ring with the rest of Formula 1. Embodiment 86a. The composition of Embodiment 86 where m is 1 and R4 is in position 4 (or position para); or m is 2 and one R4 is in position 4 (or para position), and the other is in position 6 (or ortho position), relative to the connection of the phenyl ring with the rest of Formula 1. Embodiment 87. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 86a, where n is 1 and R5 is in position 4 (or the para position), in relation to the connection of the nitroanilino ring to the rest of formula 1. Embodiment 88. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 86a, where n is 1 and R5 is in position 6 (or ortho position), in relation to the connection of the nitroanilino ring with the rest of Formula 1. Embodiment 89. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 86a, where n is 2 and an R5 is in position 4 (or para position), and the other is in position 6 (or ortho position), relative to the connection of the nitroanilino ring to the rest of Formula 1. Embodiment 90. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 86a, where n is 1 and R5 is in position 4 (or position for); or n is 1 and R5 is in position 6 (or ortho position); or n is 2 and one R5 is in position 4 (or para position), and the other is in position 6 (or ortho position), relative to the connection of the nitroanilino ring to the rest of Formula 1. Embodiment 91. The composition comprising components (a) and (b) described in the Summary of the Invention where in Formula 1, or any one of Embodiments 1 to 90, where m and n are each 1 and R4 is in position 4 (or para position), and R5 is in position 6 (or ortho position); or m is 1 and R4 is in position 4 (or para position), and n is 2 and one R5 is in position 4 (or para position) and the other is in position 6 (or ortho position); or m and n are each 1 and R4 is in position 4 (or position for), and R5 is in position 4 (or position for); o m is 2 and one R4 is in position 4 (or para position) and the other is in position 6 (or ortho position), and n is 1 and R5 is in position 6 (or ortho position), relative to the connection of the phenyl and nitroanilino rings with the rest of Formula 1. Embodiment 92. The composition of Embodiment 91 wherein m and n are each 1 and R4 is in position 4 (or para position) and R5 is in position 6 (or ortho position); or month 1 and R4 is in position 4 (or para position), and n is 2 and one R5 is in position 4 (or para position) and the other is in position 6 (or ortho position); m is 2 and one R4 is in position 4 (or position para) and the other is in position 6 (or ortho position), and n is 1 and R5 is in position 6 (or position M A / ortho), in relation to the connection of the phenyl and nitroanilino rings with the rest of Formula 1. Embodiment 93. The composition of Embodiment 92 wherein m and n are each 1 and R4 is in position 4 (or para position) and R5 is in position 6 (or ortho position); or month 1 and R4 is in position 4 (or para position), and n is 2 and one R5 is in position 4 (or para position) and the other is in position 6 (or ortho position), relative to the connection of the phenyl and nitroanilino rings to the rest of Formula 1. Embodiment 94. The composition of Embodiment 93 wherein m and n are each 1 and R4 is in position 4 (or para position) and R5 is in position 6 (or ortho position). Embodiment 95. The composition of Embodiment 93 wherein m is 1 and R4 is at position 4 (or position for), and n is 2 and one R5 is at position 4 (or position for) and the other is at position 6 ( or ortho position). Embodiment 96. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 95, wherein component (a) does not comprise a ΛΖ-oxide of a compound of Formula 1. Embodiment 97. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 95, wherein component (a) comprises a compound selected from the group consisting of 4-(2-bromo-4,6-difluorophenyl)- / V-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazole-5-amine (Compound 1) , 3-chloro-4-[5-[(2-chloro-4-fluoro-6-nitrophenyl)amino]-1,3-dimethyl-1 / - / -pyrazol-4-yl]benzon trilo (Compound 18), A / -(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine (Compound 19), 4-(2-chloro-6-fluorophenyl)- / \ / -(2-fluoro-4-methoxy-6-nitrophenyl)-1,3- dimethyl-1 / 7-pyrazole-5-amine (Compound 23), 4-(2,4-difluorophenyl)- / \ / -(2-fluoro-4-methoxy¡-6-nitrophen¡l)-1 ,3-dimethyl-1 / 7-pyrazole-5-amine (Compound 57), 4-(2-bromo-4-fluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3- dimethyl-1 / - / -pyrazole-5-amine (Compound 60), 4-(2-chloro-4,6-difluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl- 1 / 7-pyrazole-5-amine (Compound 68), 4-(2-chloro-4-fluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-3-ethyl-1-methyl-1 / - / -pyrazole-5-amine (Compound 72), A / -(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-methoxyphenyl)-1,3 -dimethyl-1 / - / -pyrazole-5-amine (Compound 73), 4-(2-chloro-4-fluorophenyl)-A / -(2-fluoro-4-methyl-6-nitrophen) l)-1,3-dimethyl-1 / - / -pyrazole-5-amine (Compound 93), 4-(2-chloro-4-fluorophenyl)-A / -(4-fluoro-2-nitrophen) l)-1,3-dimethi 1-1 / - / -pyrazole-5-amine (Compound 111), 4-(2-chloro-4-fluorophenyl)- / \ / -(2-fluoro-6-nitrophen) l)-1,3-dimethi 1-1 / - / -pyrazole-5-amine (Compound 112), 4-(2,4-difluorophenyl)- / \ / -(2-fluoro-6-nitrophenyl) -1,3-dimethyl-1 / - / -pyrazole-5-amine (Compound 118), A / -(4-chloro-2-fluoro-6-nitrophenyl)-4-(2-chloro-4- fluorophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine (Compound 121) and 3-chloro-4-[5-[(2-fluoro-4-methyl-6-nitrophenyl)amino]-1,3-dimethyl-1 / - / -pyrazol-4-yl]benzonitrile (Compound 127) . Embodiment 98. The composition of Embodiment 97 wherein component (a) comprises a compound selected from the group consisting of Compounds 1,19, 57, 60, 68, 72, 93, 112, 121 and 127. Embodiment 99. The composition of Embodiment 98 wherein component (a) comprises a compound selected from the group consisting of Compounds 68, 72 and 112. Embodiment 100. The composition of Embodiment 99 wherein component (a) comprises Compound 68. Embodiment 101. The composition of Embodiment 99 wherein component (a) comprises Compound 72. Embodiment 102. The composition of Embodiment 99 wherein component (a) comprises Compound 112. Embodiment 103. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 99 wherein component (a) is 4-(2-chloro-4,6 -difluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl 1-1 H-pyrazole-5-amine. Embodiment 104. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 99 wherein component (a) is 4-(2-chloro-4-fluorophen ¡l)- / V-(2-fluoro-6-nitrophen¡l)-3-ethyl-1-methyl-1 / 7-pyrazole-5-amine. Embodiment 105. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 to 99 wherein component (a) is 4-(2-chloro-4-fluorophen ¡l)- / V-(2-fluoro-6-nitrophen¡l)-1,3-dimethyl-1 / 7-pyrazole-5-amine. Embodiment 106. The composition of Embodiments 1 to 105, wherein component (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of two fungicidal compounds, wherein one of the fungicidal compounds is cyproconazole, difenoconazole, epoxiconazole, flutriafol, metconazole, prothioconazole or tebuconazole, then the other fungicidal compound is other than azoxystrobin, benzovindiflupyr, bixaphene, boscalide, fluopyram, fluindapir, fluxapyroxad, isopyrazam, cresoximmethyl, penthiopyrad, picoxystrobin, proquinazid, pyracloestrobin, quinoxy pheno , sedaxane or trifloxystrobin. Embodiment 107. The composition of Embodiment 106, wherein component (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of two fungicidal compounds, wherein one of the fungicidal compounds is cyproconazole , difenoconazole, epoxiconazole, flutriafol, prothioconazole or tebuconazole, then the other fungicidal compound is other than azoxystrobin, benzovindiflupyr, bixaphene, fluindapir, fluxapyroxad, isopyrazam, picoxystrobin, pyracloestrobin or trifloxystrobin. Embodiment 108. The composition of Embodiment 107, wherein (b) comprises at least two fungicidal compounds, and when component (b) consists of a binary combination of two fungicidal compounds, wherein one of the fungicidal compounds is cyproconazole, difenoconazole , epoxiconazole, flutriafol, prothioconazole or tebuconazole, then the other fungicide compound is other than azoxystrobin, benzovindiflupyr, bixaphene, fluindapir, fluxapyroxad, picoxystrobin, pyracloestrobin or trifloxiestrobin. ΜΛ / í MA / Embodiments of the present invention, including Embodiments 1-108 above as well as any other embodiments described herein, may be combined in any manner, and the descriptions of variables in the embodiments relate not only to compositions comprising compounds of Formula 1 with at least one other fungicide compound, but also to compositions comprising compounds of Formula 1 with at least one invertebrate pest control compound or agent, and also to compounds of Formula 1 and their compositions, and also to starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. Furthermore, embodiments of the present invention, including Embodiments 1-108 above, as well as any other embodiments described herein, and any combination thereof , belong to the methods of the present invention. Therefore, it is worth highlighting as an additional embodiment the composition disclosed above that comprises (a) at least one compound selected from the compounds of Formula 1 described above, / V-oxides and salts thereof; and at least one invertebrate pest control compound or agent. Combinations of Embodiments 1-108 are illustrated by: Embodiment A. The composition comprising components (a) and (b) described in the Summary of the Invention, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein in Formula 1, R1 is methyl; R2 is cyano, halogen or C1-C2 alkyl; R3 is halogen; each R4 is independently halogen, cyano, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy or C2-C4 cyanoalkoxy; each R5 is independently halogen, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy or C2-C4 cyanoalkoxy; R6is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R6a; or S(=O)UR7u OR9; R6a is cyano, Cs-Ce cycloalkyl or C1-C3 alkoxy; R7 is methyl or halomethyl; R9is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R9a; and R9a is cyano, C3-C6 cycloalkyl or C1-C3 alkoxy. Embodiment B. The composition of Embodiment B wherein in Formula 1, R2 is methyl or ethyl; R3is Br, Cl or F; each R4 is independently halogen, cyano, methyl or methoxy; m is 1 and R4 is in position 4 (or position para); or m is 1 and R4 is in position 6 (or ortho position); or m is 2 and one R4 is in position 4 (or para position), and the other is in position 6 (or ortho position); each R5 is independently halogen, methyl or methoxy; n is 1 and R5 is in position 4 (or position para); or n is 1 and R5 is in position 6 (or ortho position); or n is 2 and one R5 is in position 4 (or para position), and the other is in position 6 (or ortho position); and R6is H or methyl. Embodiment C. The composition of Embodiment B, where in Formula 1, R2 is methyl; each R4 is independently Br, Cl, F, cyano or methoxy; each R5 is independently Br, Cl, F, methyl or methoxy; and R6es H. Embodiment D. The composition of Embodiment C wherein in Formula 1, each R4 is independently Br, Cl or F; each R5 is independently Br, Cl, F or methoxy; and m and n are each 1 and R4 is in position 4 (or para position) and R5 is in position 6 (or ortho position); or m is 1 and R4 is in position 4 (or para position), and n is 2 and one R5 is in position 4 (or para position) and the other is in position 6 (or ortho position); o m is 2 and one R4 is in position 4 (or para position) and the other is in position 6 (or ortho position), and n is 1 and R5 is in position 6 (or ortho position). Embodiment E. The composition of Embodiment D, where in Formula 1, R4is Cl or F; each R5 is independently Cl, F or methoxy; and m and n are each 1 and R4 is in position 4 (or para position) and R5 is in position 6 (or ortho position); o m is 1 and R4 is in position 4 (or para position), and n is 2 and one R5 is in position 4 (or para position) and the other is in position 6 (or ortho position). Embodiment F. The composition comprising components (a) and (b) described in the Summary of the Invention, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein in Formula 1, R1 is C1-C2 alkyl; R2 is cyano, halogen, C1-C2 alkyl or C1-C2 haloalkyl; R3 is halogen or methyl; each R4 is independently halogen, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy, C2-C6 alkoxyalkyl or C2-C6 alkoxyalkoxy; each R5 is independently halogen, C1-C3 alkyl, C2-C6 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy or C2-C6 alkoxyalkoxy, provided that at least one R5se select halogen; m and n are each independently 1,2 or 3; M A / t / ZUZZ / U / 4ZÓU R6is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents independently selected from R6a; or amino, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, CH(=O), S(=O)2OM, S(=O)UR7, (C=W)R8u OR9; each R6a is independently cyano, C3-C6 cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 alkylsulfinyl or C1-C3 alkylsulfonyl; M is K or Na; u is 0, 1 or 2; R7 is C1-C3 alkyl or C1-C3 haloalkyl; W is O or S; R8 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-O6 dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio or C2-C4 alkylthioalkyl; R9is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents independently selected from R9a; or CH(=O), C3-C6 cycloalkyl, S(=O)2OM or (C=W)R10; and each R9a is independently cyano, Cs-Cs cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-alkylthio C3, C1-C3 alkylsulfinylO C1-C3 alkylsulfonyl; and R10 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio or C2-C4 alkylthioalkyl; provided that the Formula 1 compound is not: A / -(2-bromo-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine; either 3-chloro-4-(2-chloro-4-fluorophenyl)-A / -(2,4-difluoro-6-nitrophenyl)-1 -methyl-1 / - / -pyrazole-5-amine; Embodiment G. The composition of Embodiment F, where in Formula 1, R1 is methyl; R2 is cyano, halogen or C1-C2 alkyl; R3 is halogen; each R4 is independently halogen, cyano, methyl, C1-C2 alkoxy or C1-C2 haloalkoxy; m is 1 and R4 is in position 4 (or position para); or m is 1 and R4 is in position 6 (or ortho position); or m is 2 and one R4 is in position 4 (or para position), and the other is in position 6 (or ortho position); each R5 is independently halogen, methyl, methoxy, halomethyl, C2-C4 alkenyloxy or C2-C4 cyanoalkoxy; n is 1 and R5 is in position 4 (or position para); or n is 1 and R5 is in position 6 (or ortho position); or n is 2 and one R5 is in position 4 (or para position), and the other is in position 6 (or ortho position); and R6is H or methyl. Embodiment H. The composition of Embodiment G, where in Formula 1, R2 is methyl; ΜΛ / í M A / each R4 is independently Br, Cl, F, cyano or methoxy; each R5 is independently Br, Cl, F, methyl or methoxy; and R6es H. Embodiment I. The composition of Embodiment H, wherein in Formula 1, R4is Br, Cl or F; each R5 is independently Br, Cl, F or methoxy; and m and n are each 1 and R4 is at position 4 and R5 is at position 6; or m is 1 and R4 is at position 4, and n is 2 and one R5 is at position 4 and the other is at position 6. Embodiment J. The composition of Embodiment I where R4is Cl or F; and each R5 is independently Cl, F or methoxy. Embodiment K. The composition of any one of Embodiments A to J wherein component (a) comprises a compound selected from the group consisting of: Compound 1, Compound 18, Compound 19, Compound 23, Compound 57, Compound 60, Compound 68, Compound 72, Compound 73, Compound 93, Compound 111, Compound 112, Compound 121 and Compound 127. Embodiment L. The composition of Embodiment K wherein component (a) comprises a compound selected from the group consisting of: Compound 68, Compound 72 and Compound 112. Embodiment M. The composition of Embodiment L wherein component (a) comprises Compound 112. Realization B1. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M) wherein component (b) includes at least one compound selected from (b1) fungicides of methylbenzimidazole carbamate such as benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate and thiophanate-methyl. Realization B2. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M) wherein component (b) includes at least one compound selected from (b2) fungicides of dicarboximide such as clozolinate, dimethaclone, iprodione, procymidone and vinclozolin. Realization B3. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M) wherein component (b) includes at least one compound selected from (b3) fungicides demethylation inhibitors such as triforine, butiobate, pyrifenox, pyrisoxazole fenarimol, nuarimol, triarimol econazole, imazalil, oxpoconazole, pefurazoate, prochloraz, triflumizoleazaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole , fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, ipfentrifluconazole, quinconazole, simeconazole, tebuconazole, tetraconazole triadimefon, triadimenol, triticonazole, uniconazole and uniconazol-P. Realization B4. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b4) phenylamide fungicides such as metalaxyl, metalaxyl-M, benalaxyl, benalaxyl-M, furalaxyl, ofurace and oxadixyl. Implementation B5. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b5) amine / morpholine fungicides such as aldimorph, dodemorph, fenpropimorph, tridemorph, trimorfamide, fenpropidine, piperaline and spiroxamine. Embodiment B6. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b6) fungicides that inhibit phospholipid biosynthesis such as edifenphos, iprobenphos, pyrazophos and isoprothiolane. Embodiment B7. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b7) succinate dehydrogenase inhibitor fungicides such as benodanil, flutolanil, mepronil, isofetamide, fluopyram, fenfuram, carboxin, oxycarboxin, tifluzamide, benzovindiflupyr, bixafen, fluindapir, fluxapiroxad, furametpir, inpirfluxam, isopyrazam, penflufen, penthiopyrad, pyrapropoin, sedaxane, flubeneteram , isoflucipram, pidiflumethofen, boscalide and pyraziflumid. Embodiment B8. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b8) hydroxyl (2-amino-)pyrimidine fungicides such as bupirimate, dimethimol and etirimol. Embodiment B9. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b9) anilinopyrimidine fungicides such as cyprodinil, mepanipyrim and pyrimethanil. Realization B10. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b10) N-phenyl carbamate fungicides such as dietofencarb. Embodiment B11. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b11) Quinone exterior inhibitory fungicides such as azoxystrobin, cumoxystrobin, enoxastrobin, fluphenoxystrobin, picoxystrobin, pyroxystrobin, mandestrobin, pyraclostrobin, pyrametostrobin, triclopiricarb, kresoxim-methyl, trifloxiestrobin, dimoxystrobin, phenaminestrobin, metominostrobin, orisastrobin, fluoxaestrobin, famoxadone, fenamidone and piribencarb . Realization B12. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) MA / t / ZUZZ / U / 4ZÓU includes at least one compound selected from (b12) phenylpyrrole fungicidal compound such as fenpiclonyl and fludioxonyl. Embodiment B13. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M) wherein component (b) includes at least one compound selected from (b13) fungicides of azanaphthalene such as quinoxifene and proquinazid. Implementation B14. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b14) fungicides that inhibit cellular peroxidation such as biphenyl, chloroneb, dichlorane, quintazene, technazene, tolclofos-methyl and etridiazole. Implementation B15. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b15) fungicides that inhibit melanin-reductase biosynthesis such as phthalide, pyroquilone and tricyclazole. Embodiment B16a. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b16a) melanin-dehydratase biosynthesis-inhibiting fungicides such as carpropamid, diclocimet and fenoxanil. Embodiment B16b. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b16b) melanin-polyketide synthase biosynthesis-inhibiting fungicides such as tolprocarb. Embodiment B17. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b17) keto reductase inhibitor fungicides such as fenhexamid, fenpyrazamine, quinofumeline and ipflufenoquine. Embodiment B18. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b18) squaleneepoxidase inhibitor fungicides such as pyributicarb, naftifine and terbinafine. Embodiment B19. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b19) polyoxin fungicides such as polyoxin. Realization B20. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b20) phenylurea fungicides such as pencicuron. Implementation B21. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) M A / t / ZUZZ / U / 4ZÓU M A / includes at least one compound selected from (b21) quinone interior inhibitory fungicides such as cyazofamid, amisulbrom and fenpicoxamide (Registration Number 517875-34-2). Realization B22. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b22) benzamide and thiazole carboxamide fungicides such as zoxamide and etaboxam. Realization B23. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b23) enopyranuronic acid antibiotic fungicides such as blasticidin-S. Realization B24. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b24) hexopyranosyl antibiotic fungicides such as kasugamycin. Realization B25. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b25) glucopyranosyl antibiotic fungicides: protein synthesis such as streptomycin. Implementation B26. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b26) glucopyranosyl antibiotic fungicides: trehalose and inositol biosynthesis such as validamycin. Implementation B27. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b27) cyanoacetylamidoxime fungicides such as cymoxanil. Implementation B28. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b28) carbamate fungicides such as propamacarb, prothiocarb and iodocarb. Realization B29. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b29) oxidative phosphorylation uncoupling fungicides such as fluazinam, binapacryl, meptyldinocap and dinocap. Realization B30. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b30) organotin fungicides such as fentin acetate, fentin chloride and fentin hydroxide. M A / Implementation B31. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b31) carboxylic acid fungicides such as oxolinic acid. Realization B32. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b32) heteroaromatic fungicides such as himexazole and octylinone. Realization B33. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b33) phosphonate fungicides such as phosphorous acid and its various salts, including fosetyl-aluminum. Realization B34. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b34) phthalamic acid fungicides such as teclofthalam. Realization B35. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b35) benzotriazine fungicides such as triazoxide. Realization B36. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b36) benzene-sulfonamide fungicides such as flusulfamide. Realization B37. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b37) pyridazinone fungicides such as diclomezine. Realization B38. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b38) thiophene-carboxamide fungicides such as silthiofam. Realization B39. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b39) NADH oxidoreductase complex I inhibitor fungicides such as diflumetorim, tolfenpyrad and fenazaquin. Realization B40. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b40) carboxylic acid amide fungicides such as dimethomorph, bentiavalicarb, bentiavalicarb-isopropyl, iprovalicarb, valifenalate, mandipropamid, flumorf, dimethomorph, flumorf, pirimorf, bentiavalicarb, bentiavalicarb-isopropyl, iprovalicarb, tolprocarb, valifenalate and mandipropamid. Implementation B41. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b41) tetracycline antibiotic fungicides such as oxytetracycline. Realization B42. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b42) thiocarbamate fungicides such as metasulfocarb. Realization B43. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b43) benzamide fungicides such as fluopicolide and fluopimomide. Realization B44. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b44) microbial fungicides such as Bacillus amyloliquefaciens strains QST713, FZB24, MB1600, D747, F727, TJ100 (also called BE strain 1; known from EP2962568) and the fungicidal lipopeptides they produce. Realization B45. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b45) quinone exterior and stigmatellin binding inhibitor fungicides such as ametoctradine. Implementation B46. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b46) fungicides from plant extracts such as Melaleuca alternifolia, eugenol, geraniol and thymol. Realization B47. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b47) cyanoacrylate fungicides such as fenamacryl. Realization B48. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b48) polyene fungicides such as natamycin. Implementation B49. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) M A / t / ZUZZ / U / 4ZÓU MA / includes at least one compound selected from (b49) oxysterol binding protein inhibitor fungicides such as oxathiapiproline and fluoxapiproline. Realization B50. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b50) aryl-phenyl-ketone fungicides such as metrafenone and pyrifenone. Embodiment B51. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b51) host plant defense induction fungicides such as acibenzolar-S-methyl, probenazole, thiadinil, isotianyl, laminarin, Reynoutria sachalinensis extract and isolate J of Bacillus mycoides and cell walls of Saccharomyces cerevisiae strain LAS117. Realization B52. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b52) multi-site fungicides such as copper oxychloride, copper sulfate, copper hydroxide, Bordeaux composition (tribasic copper sulfide), elemental sulfur, ferbam, mancozeb, maneb, metiram, propineb, thiram, zinc thiazole, zineb , ziram, folpet, capitan, capitafol, chlorothalonil, dichlofluanid, tolifuanide, guazatine, iminoctadine albesylate, iminoctadine triacetate, anylazine, dithianon, quinomethionate and fluoroimide. Embodiment B53. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b53) biological fungicides with multiple modes of action such as extract from the cotyledons of lupine seedlings. Embodiment B54. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b54) fungicides other than fungicides of component (a) and components (b1) to (b53), such as cyflufenamide, bethoxazine, neo-asozine, pyrrolnitrin, tebufloquine, dodine, flutianil, ferimzone, picarbutrazox, diclobenthiazox (Registration Number 957144-77- 3), dipimethitrone (Registration Number 16114-35-5), flomethoquine, tolnifanide (Registration Number 304911-98-6), / V-[4-[4-chloro-3-(trifluoromethyl)phenoxy¡] -2,5-dimethylphenyl]-A / -ethyl- / \ / methylmetanimidamide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamide and 4-fluorophenyl N-[1 -[[[1 -(4cyanophen¡l)ethyl]sulfon¡l]methyl]propyl]carbamate (XR-539). Realization B55. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes / \ / -[[3-( (1 S)-2,2-bis(4-fluorophenyl)-1 methylethyl acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]-L-alaninate (provisional common name florylpicoxamid). Embodiment B56. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes 1 -[2-[[[1 -(4-chlorophenyl)-1 H-pyrazol-3-¡ l]oxy]methyl]-3-methylphenyl]-1,4-dihydro-4-methyl-5 / - / -tetrazol-5one (provisional common name methyltetraprol). Realization B57. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes 3-chloro-4-(2, 6-difluorophenyl)-6-methyl-5-phenylpridazine (provisional common name pyridaclomethyl). Embodiment B58. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes 2-amino-6-methyl-p (4-phenoxyphenyl)methyl iridine-3-carboxylate (provisional common name aminopyrifene). Implementation B59. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b54. 11) (i.e. Formula b54.11) ΜΛ / t / ZUZZ / U / 4ZÓU Component (b54.11) refers to a compound of Formula b54.11 H3C where Rbiy ró3 are cac|a independently halogen; and Rb2es H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl. Realization B60. The composition of Embodiment B59 wherein component (b) includes at least one fungicidal compound selected from the group consisting of Λ / -[[5-[1 (2,6-difluoro-4-formylphenyl)-1 Hpyrazole-3 Methyl -yl]-2-methylphen¡l]methyl]carbamate, Λ / -[[5-[1 -(4-cyclopropyl-2,6-dichlorophenyl)-1 / - / -pyrazole-3 Methyl l]-2-methylphenyl]methyl]carbamate, N-[[5-[1 - (4-chloro-2,6-dif I uorophenyl)-1 H-pi razol-3-i l]-2methylphenyl Methyl ]methyl]carbamate, Λ / -[[5-[1 -(4-cyclopropyl-2,6-difluorophenyl)-1 / - / -pyrazol-3-yl]-2methylphenyl]methyl]carbamate methyl, Λ / -[[5-[1 -[2,6-difluoro-4-(1 -methylethyl)phenyl]-1 / 7-pyrazol-3-yl]-2methylphenyl]methyl]carbamate methyl and methyl Λ / -[[5-[1 -[2,6-difluoro-4-(trifluoromethyl)phenyl]-1 / 7-pyrazol-3-yl]-2methylphenyl]methyl]carbamate. Embodiment B60b. The composition of Embodiment B60 wherein component (b) includes at least one fungicidal compound selected from the group consisting of Λ / -[[5-[1 -(4-cyclopropyl-2,6-dichlorophenyl)1 / +p Methyl razazol-3-yl]-2-methylphenyl]methyl]carbamate, A / -[[5-[1 -(4-chloro-2,6-difluorophenyl)-1 / - / -pyrazole Methyl -3¡l]-2-methylphenyl]methyl]carbamate, Λ / -[[5-[1 -[2,6-difluoro-4-(1 -methylethyl)pheniI]-1 / - / - methyl pyrazole-3-¡l]-2methylphenyl]methyl]carbamate and Λ / -[[5-[1 -[2,6-difluoro-4-(trifluoromethyl)phenyl]-1 / 7-pyrazole-3 Methyl -yl]-2methylphenyl]methyl]carbamate. Embodiment B61. The composition described in the Summary of the Invention (including, but not limited to, the MA / composition of any one of Embodiments 1 to 108 and A to M), wherein component (b) includes at least one compound selected from (b54.12) (i.e., Formula b54.12) Component (b54.12) refers to a compound of Formula b54.12 Rb5 b54.12 where Rb4es N— Rb6 EITHER Rb6 Rb6 is C2-C4 alkoxycarbonyl or C2-C4 haloalkylaminocarbonyl; L is CH2 or CH2O, where the atom on the right is connected to the phenyl ring in Formula b54.12; Rb5es Rb7 is C1-C3 alkyl, where the wavy bond indicates the (Z) or (E) configuration of the adjacent double bond or a mixture of these. Embodiment B62. The composition of Embodiment B61 wherein component (b) includes at least one fungicidal compound selected from the group consisting of / V-(2,2,2-trifluoroethyl)-2-[[4-[5(trif luoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolcarboxamide, 1 -[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-¡l]phenoxy ]methyl]-1 / - / -pyrazole-4-carboxylate ethyl, 1 -[[4-[[(1 Z)-2-ethoxy-3,3,3-trifluoro-1 propen-1 -yl ]oxy]phenyl] methi I]-1 / - / -pyrazole-4-carboxylate and 1 -[[4-[[2-(trif I uoro methyl)-1,3-dioxolan-2yl]methoxy¡]phen Ethyl l]methyl]-1 H-pyrazole-4-carboxylate. Embodiment B62b. The composition of Embodiment B62 wherein component (b) includes at least one fungicidal compound selected from the group consisting of / V-(2,2,2-trifluoroethyl)-2-[[4-[5(trif luoromethyl) -1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolcarboxamide and 1 -[[4-[[( 1 Z)-2-ethoxy¡-3,3,3trifIuoro- Ethyl 1-propen-1-yl]oxy]phenyl]methyl]-1 H-pyrazole-4-carboxylate. Embodiment B63. The composition described in the Summary of the Invention (including, but not limited to, the composition of any one of Embodiments 1 to 108 and A to M) wherein component (b) includes at least one fungicidal compound (fungicide) selected from group consisting of azoxystrobin, benzovindiflupyr, boscalide (nicobifen), bixafen, bromuconazole, carbendazim, chlorothalonil, copper hydroxide, cyflufenamide, cyproconazole, difenoconazole, dimoxystrobin, epoxiconazole, famoxadone, fenbuconazole, fenpropidine, fenpropimorph, fluindapyr, flusilazole, flutriafol, fluxapirox ad , hexaconazole, ipconazole kresoxim-methyl, manzate, metconazole, metominoestrobin, metrafenone, myclobutanil, penconazole, penthiopyrad, picoxystrobin, prochloraz, propiconazole, proquinazid, prothioconazole, pidiflumethofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriophenone quinoxifene, tebuconazole, tri floxystrobin, triticonazole, A Methyl / -[[5-[1 -(4-cyclopropyl-2,6dichlorophenyl)-1 H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, Λ / -[[5-[1 Methyl -(4-chloro-2,6-difluorophenyl)1 / 7-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, Λ / -[[5-[1 -[2,6-difluoro- Methyl 4-(1 -methylethyl l)phen i I]-1 Hpyrazole-3-¡l]-2-methylphen¡l]methyl]carbamate, Λ / -[[5-[1 -[2 ,6-dif I uoro-4-(trif luoromethi l)fe η i I]-1Hpyrazole-3-¡l]-2-methyllfen¡l]methyl¡l]carbamate methyl, A / -(2, 2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethi)-1,2,4oxadiazol-3- ¡l]phenyl]methyl]-4-oxazolcarboxamide and 1 -[[4-[[ Ethyl (1 Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1 / 7-pyrazole-4-carboxylate. Embodiment B64. The composition of Embodiment B63 wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixaphene, chlorothalonil, copper hydroxide, cyflufenamide, cyproconazole, difenoconazole, dimoxystrobin, epoxiconazole, famoxadone, fenpropidine, fenpropimorph, fluindapir, flusilazol, flutriafol, fluxapiroxad, kresoxim-methyl, manzate, metconazole, metominostrobin, metrafenone, myclobutanil, penthiopyrad, picoxystrobin, propiconazole, proquinazid, prothioconazole, pidiflumethofen, pyraclostrobin, pyrametostrobin, pyraoxyestrobin, pyriofenone quinoxy pheno, tebuconazole, trifloxiestrobin, triticonazole , Λ / -[[5-[1 -(4-cyclopropyl-2,6-dichloroph en i I) -1 H-pyrazol-3-¡l]-2-methylphen¡l]rnet¡l]carbamate methyl, methyl A / -[[5-[1-(4-chloro-2,6-difluorophenyl)-1 H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, Λ Methyl / -[[5[1 -[2,6-difluoro-4-(1 -methylethyl)phenyl]-1 / 7-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, Λ / -[ Methyl [5-[ 1 -[2,6dif luoro-4-(trif luoromethyl)phenyl]-1 / 7-pyrazol-3-¡l]-2-methylphen¡l]methyl]carbamate, Λ / -(2,2,2trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- l]phenyl]methyl]-4-oxazolecarboxam da and 1-[[4-[[(1Z)2-ethoxy¡-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1 H-pyrazole-4- ethyl carboxylate. Realization B65. The composition of Embodiment B64 wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixaphene, chlorothalonil, copper hydroxide, cyproconazole, difenoconazole, epoxiconazole, fenpropidine, fenpropimorph, fluindapyr, flutriafol, fluxapyroxad, manzate, metominostrobin, picoxystrobin, prothioconazole, pidiflumethofen, pyraclostrobin, tebuconazole, trifloxiestrobin, / V-[[5-[1 -(4-cyclopropyl2,6-dichlorophenyl)-1 / 7-pyrazole-3-yl]-2 Methyl -methylphenyl]methyl]carbamate, A / -[[5-[1-(4-chloro-2,6dif I uorophenyl) -1 / 7-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate Methyl Methyl methyl]carbamate, A / -[[5-[1-[2,6-difluoro-4(trifluoromethyl)phenyl]-1 / - / -plrazol-3-yl]-2-methylphenyl] methyl]carbamate, A / -(2,2,2-trifluoroethyl)-2-[[4[5-(trifIuoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4- oxazolecarboxamide and 1 -[[4-[[(1 Z)-2-ethoxy-3,3,3trifluoro-1 -propen-1 -yl]oxy]phenyl]methyl]-1 / 7-pyrazole-4- ethyl carboxylate. Embodiment B66. The composition of Embodiment B65, wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixaphene, M A / chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, fenpropidine, fenpropimorph, fluindapir, flutriafol, fluxapyroxad, manzato, metominostrobin, picoxystrobin, prothioconazole, pidiflumethofen, pyraclostrobin, tebuconazole, trifloxiestrobin. Noteworthy is the composition of any one of the embodiments described herein, including any Embodiments 1 to 108, A to M, and B1 to B66, wherein reference to Formula 1 includes the salts thereof, but not the / V-oxides thereof; therefore, the term a compound of Formula 1 may be replaced by the term a compound of Formula 1 or a salt thereof. It should be noted in the present composition, component (a) comprises a compound of Formula 1 or a salt thereof. Also notable as embodiments are fungicidal compositions of the present invention comprising a fungicide-effective amount of a composition of Embodiments 1 to 108, A to M, and B1 to B66, and at least one additional component selected from the group consisting of surfactants. , solid diluents and liquid diluents. Embodiments of the invention further include methods for controlling plant diseases caused by fungal phytopathogens comprising applying to the plant or a portion thereof, or to the seed of the plant or seedling, a fungicide-effective amount of a composition of a any of Embodiments 1 to 108, A to M and B1 to B66 (e.g., as a composition including formulation ingredients as described herein). Embodiments of the invention also include methods of protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying a fungicide-effective amount of a composition of any one of Embodiments 1 to 108, A to M, and B1 to B66 to the plant or seed of the plant. Some embodiments of the invention involve controlling a plant disease or protecting against a plant disease that primarily affects the foliage of the plant and / or applying the composition of the invention to the foliage of the plant (i.e. , plants instead of seeds). Preferred methods of use include those involving the above preferred compositions; and diseases controlled with particular effectiveness include plant diseases caused by fungal phytopathogens. Combinations of fungicides used in accordance with the present invention can facilitate disease control and delay the development of resistance. Embodiments of the method further include: Embodiment 01. A method for protecting a plant from a disease selected from rust, powdery mildew and Septoria diseases comprising applying to the plant a fungicide effective amount of the composition comprising components (a) and ( b) described in the Summary of the Invention or any one of Embodiments 1 to 108. Realization C2. The method of Embodiment C1, wherein the disease is a rust disease and component (b) of the composition includes at least one fungicide compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b5) fungicides of ΜΛ / amine / morpholine, (b7) succinate dehydrogenase inhibitory fungicides, (b11) quinone exterior (Qol) inhibitory fungicides, (b13) methylbenzimidazole carbamate fungicides and (b52) fungicides with multisite activity. Realization C3. The method of Embodiment C2, wherein component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b7) succinate dehydrogenase inhibitor fungicides and (b11) quinone exterior inhibitor fungicides (Qol). Realization C4. The method of Embodiment C3, wherein component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b7) succinate dehydrogenase inhibitor fungicides and (b11) quinone exterior inhibitor fungicides (Qol). Embodiment 05. The method of any one of Embodiments C1 to C4, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixaphene, cyproconazole, difenoconazole, epoxiconazole, fenpropimorph , florilpicoxamid, fluindapir, flutriafol, fluxapiroxad, inpirfluxam, isoflucipram, mefentrifluconazole, metominostrobin, picoxystrobin, prothioconazole, pidiflumethofen, pyraclostrobin, tebuconazole and trifloxiestrobin. Embodiment 06. The method of Embodiment C5, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, benzovindiflupyr, cyproconazole, epoxiconazole, fluindapir, fluxapyroxad, metominostrobin, picoxystrobin, prothioconazole, pyraclostrobin, tebuconazole and trifloxiestrobin. Implementation C7. The method of any one of Embodiments C2 to C6, wherein the disease is Asian soybean rust caused by Phakopsora pachyrhizi. Implementation C8. The method of any one of Embodiments C2 to C6, wherein the disease is wheat leaf rust caused by Puccinia recondita. Implementation C9. The method of Embodiment C1, wherein the disease is a powdery mildew disease and component (b) of the composition includes at least one fungicide compound selected from (b3) demethylation inhibitor fungicides (DMI), (b11) inhibitor fungicides of quinone exterior (Qol), (b13) azanaphthalene fungicides and (b52) fungicides with multi-site activity. Realization C10. The method of Embodiment C9, wherein component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor fungicides (DMI), (b11) quinone exterior inhibitor fungicides (Qol) and (b52) fungicides with multi-site activity. Embodiment C11. The method of Embodiments C9 and C10, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, chlorothalonil, copper sulfate, cyproconazole, difenoconazole, epoxiconazole, M A / fenpropimorph, florilpicoxamid, flutriafol, mancozeb, mefentrifluconazole, metominostrobin, picoxystrobin, prothioconazole, pyraclostrobin, tebuconazole and trifloxiestrobin. Realization C12. The method of Embodiment C11, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of cyproconazole, difenoconazole, epoxiconazole, prothioconazole and tebuconazole. Implementation C13. The method of Embodiment C10, wherein component (b) of the composition includes at least one fungicide compound selected from (b3) DMI fungicides. Implementation C14. The method of Embodiment C13, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of cyproconazole, difenoconazole and prothioconazole. Realization C15. The method of Embodiment C10, wherein component (b) of the composition includes at least one fungicide compound selected from (b11) Qol fungicides. Implementation C16. The method of Embodiment C15, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, picoxystrobin and pyraclostrobin. Implementation C17. The method of any one of Embodiments C9 to C16, wherein the disease is wheat powdery mildew caused by Erysiphe graminis. Realization C18. The method of Embodiment C1, wherein the disease is a disease caused by Septoria and component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, and (b11) quinone exterior inhibitor fungicides (Qol). Realization C19. The method of Embodiment C18, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, cyproconazole, difenoconazole, epoxiconazole, fenpropimorph, florylpicoxamid, flutriafol, mefentrifluconazole, metominostrobin, picoxystrobin, prothioconazole , pyraclostrobin, tebuconazole and trifloxiestrobin. Realization C20. The method of Embodiment C19, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of epoxiconazole and fenpropimorph. Realization C21. The method of any one of Embodiments 018 to C20, wherein the disease is wheat leaf spot caused by Zymoseptoria tritici. Embodiment 022. The method of Embodiment 01, wherein the disease is a disease caused by Botrytis and component (b) of the composition includes at least one fungicide compound selected from (b11) quinone exterior inhibitor fungicides (Qol) and (b52) fungicides with multi-site activity. Embodiment 023. The method of Embodiment C22, wherein component (b) of the composition includes at least one fungicide compound selected from the group consisting of M A / azoxystrobin, chlorothalonil, florylpicoxamid, mancozeb, metominostrobin, picoxystrobin, pyraclostrobin and trifloxiestrobin. Realization C24. The method of Embodiment C23, wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin and chlorothalonil. Realization C25. The method of any one of Embodiments C1 to C24, wherein components (a) and (b) are applied in synergistically effective amounts (and in a synergistic relationship with each other). It is worth highlighting the embodiments that are homologous to Embodiments C1 to C25 relating to a method for controlling plant diseases caused by fungal phytopathogens that comprises applying to the plant or a portion thereof, a fungicide-effective amount of a fungicide composition of the invention. As noted in the Summary of the Invention, the present invention also relates to a compound of Formula 1, or to a ZV-oxide or a salt thereof. It is also noted that embodiments of the present invention, including Embodiments 1-108, also relate to compounds of Formula 1. The present invention provides a fungicide composition comprising a compound of Formula 1 (including all stereoisomers, ΛΖ-oxides and salts thereof) and at least one other fungicide. Noteworthy as embodiments of said compositions are compositions that comprise a compound that corresponds to any of the embodiments of compounds described above. The present invention provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, ZV-oxides and salts thereof) (i.e., in an amount effective as a fungicide) and at least one additional component selected from the group consisting in surfactants, solid diluents and liquid diluents. Noteworthy as embodiments of said compositions are compositions that comprise a compound that corresponds to any of the embodiments of compounds described above. The present invention provides a method for controlling plant diseases caused by fungal phytopathogens comprising applying to the plant or portion thereof, or to the seed of the plant, a fungicide-effective amount of a compound of Formula 1 (including all stereoisomers, ZV-oxides and salts thereof). Noteworthy as embodiments of such methods are methods that comprise applying a fungicide-effective amount of a compound corresponding to any of the embodiments of compounds described above. Of particular note are embodiments where the compounds are applied as compositions of the present invention. The compounds of formula 1 stand out, which are compounds of Formula 1A (including all geometric and stereoisomers), ZV-oxides, hydrates and salts thereof, and the agricultural compositions that contain them and their use as fungicides: ΜΛ / í ΙΑ where R2 is cyano, halogen or C1-C2 alkyl; R3 is halogen; R4a and R4b are each independently H or halogen, provided that at least one is halogen; and R5a and R5b are each independently H, halogen, methyl or methoxy, provided that at least one is halogen; provided that when R3 is Cl, R4 is F and R4 is H, then R5 is H, Br, Cl, I, methyl or methoxy. Embodiment A1. A compound of Formula 1 A, where R2 is methyl or ethyl; R3is Br, Cl or F; R4a and R4b are each independently H, Br, Cl or F; and R5a and R5b are independently H, Br, Cl, F or methyl. Realization B1. A compound of Embodiment A1 wherein R2 is methyl; R4aes Cl or F; R4bes H, Cl or F; and R5ais H, Cl, F or methyl; and R5bes H or F. Also noteworthy is a fungicide composition comprising a fungicide-effective amount of a compound of Formula 1A (including all geometric and stereoisomers, A / -oxides and salts thereof) or any one of the equivalent embodiments that are equivalent to the embodiment a Embodiments 1 to 107 and Embodiments A to M and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Additionally, it is worth highlighting a method for controlling plant diseases caused by fungal phytopathogens that comprises applying to the plant or portion thereof, or to the seed of the plant, a fungicide-effective amount of a compound of Formula 1A (including all the geometric and stereoisomers, Noxides and salts thereof) or any one of said equivalent embodiments. It is worth highlighting in MA / particularly the embodiments where the compounds of Formula 1a are applied as compositions of the present invention. One or more of the following methods and variations as described in Schemes 1-12 may be used to prepare the compounds of Formula 1. The definitions of R1, R2, R3, R4, R5, m, n and R6 in the compounds of Formulas 1-21 below are as defined above in the Summary of the Invention, unless otherwise indicated. Formulas 1a and 1b are subsets of Formula 1. The Substituents for the subset formulas are as defined for their parent formula, unless otherwise indicated. As shown in Scheme 1, compounds of Formula 1 can be prepared by reaction of 5-aminopyrazoles of Formula 2 with nitrophenyl compounds of Formula 3 wherein L1 is a leaving group such as halogen (e.g., F, Cl , Br, I) or sulfonate (e.g., mesylate, triflate or p-toluenesulfonate), optionally in the presence of a metal catalyst, and generally in the presence of a base such as potassium tert-butoxide, triethylamine or carbonate of potassium and a solvent such as tetrahydrofuran, N,Ndimethylformamide, 1,4-dioxane, toluene, ethanol, methanol or dimethyl sulfoxide. In certain cases, the use of a metal catalyst in amounts ranging from catalytic to superstoichiometric can facilitate the desired reaction. Typical reaction conditions include, for example, carrying out the reaction in the presence of a metal catalyst, such as copper salt complexes (e.g., Cul with Λ / , / Vdimethylethylenediamine, proline or bipyridyl), palladium (e.g., tris(dibenzylideneacetone)dipalladium(0)) or palladium salts (e.g., palladium acetate) with ligands such as 4,5-bis( diphenylphosphino)-9,9dimethylxanthene, 2-dicyclohexylphosphino-21,4,,6'-triisopropylbiphenyl or 2,2'-bis(diphenylphosphino)1,1'-binaphthalene, with a base such as potassium carbonate, cesium carbonate , potassium phosphate, sodium phenoxide or sodium tertbutoxide and a solvent such as N,N-dimethylform amide, 1,2-dimethoxyethane, dimethyl sulfoxide, 1,4dioxane or toluene, optionally containing an alcohol such as ethanol. For relevant references, see PCT Patent Publications WO 2013 / 126283, Synthesis Example 1, Step C; and WO 2010 / 020363, Example 2A. Furthermore, the method of Scheme 1 is illustrated in this Example 1, Step C; Example 5, Step C; and Example 3. Compounds of Formula 3 are commercially available or their preparation is known in the art. Scheme 1 Useful general methods for preparing 5-aminopyrazoles of Formula 2 are well known in the art; see, for example, Journal für Praktische Chemie (Leipzig) 1911, 83, 171 and J. Am. Chem. Soc. 1954, 76, 501. One such method is illustrated in Scheme 2 below, where the 5-aminopyrazoles of Formula 2 are prepared by condensing compounds of Formula 4 with a hydrazine of Formula 5 (e.g., methylhydrazine or ethylhydrazine) in a solvent such as ethanol or methanol and optionally in the presence of an acid such as acetic acid, according to the general procedures known in the art; see, for example, PCT Patent Publication WO 2012 / 031061 Synthesis Example 1, Step A; and Synthesis Example 2, Step C. Additionally, the method of Scheme 2 is illustrated in this Example 1, Step B. Scheme 2 M A / t / ZUZZ / U / 4ZÓU Alternatively, as shown in Scheme 3, 5-aminopyrazoles of Formula 2 can also be prepared by reacting 4-bromo or 4-iodo pyrazoles of Formula 6 with boronic acid compounds of Formula 7 using cross-coupling reaction conditions. catalyzed by well-known transition metals. Scheme 3 General methods useful for preparing compounds of Formula 6 are known in the art. Compounds of Formula 1a (i.e., Formula 1 where Rses H) can be prepared as shown in Scheme 4. In this method, compounds of Formula 8 are condensed with a hydrazine of Formula 5 (e.g., methylhydrazine or ethylhydrazine) in a solvent such as ethanol or methanol and optionally in the presence of an acidic or basic catalyst such as acetic acid, piperidine or sodium methoxide, according to general procedures known in the art. For reaction conditions, see PCT Patent Publication WO 2013 / 116251, Synthesis Example 1, Step C and Example 2, Step B. Furthermore, the method of Scheme 4 using a compound of Formula 8 where Raes methyl, is illustrated in Example 2, Step C of the present invention. Scheme 4 M A / t / ZUZZ / U / 4ZÓU where Raes H or lower alkyl (e.g. CH3. CH2CH3or(CH2)2CH3) As shown in Scheme 5, compounds of Formula 8 can be prepared by reacting ketene dithioacetal derivatives of Formula 9 with compounds of Formula 10 optionally in the presence of a base, such as sodium hydride or ethylmagnesium chloride, in solvents such such as toluene, tetrahydrofuran or dimethoxymethane, at temperatures ranging from approximately -10 °C to the boiling point of the solvent. For a related reference see, for example, J. Heterocycl. Chem. 1975, 72(1), 139. General methods useful for preparing compounds of Formula 9 are known in the art. Scheme 5 Furthermore, as shown in Scheme 6, compounds of Formula 8 where Raes lower alkyl (e.g., methyl, ethyl, n-propyl) and Formula 8a (i.e., tautomer of Formula 8 when Raes H) are They can be prepared by a condensation reaction of isothiocyanate compounds of Formula 11 with carbonyl compounds of Formula 12 to give intermediate compounds of Formula 13, which are salts of the thioamides of Formula 8a. The intermediate compounds of Formula 13 can be used in situ (as illustrated in WO 2013 / 116251, Synthesis Example 1, Step C; and this Example 2, Step C) or isolated (as illustrated in WO 2013 / 116251, Example 2, Step A). Useful bases for preparing compounds of Formula 13 include sodium or potassium hydrides, alkoxides, hydroxides or carbonates, such as sodium hydride, potassium erc-butoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide or potassium carbonate. Amine bases (e.g., triethylamine or Λ / , / V-diisopropylethylamine) can also be used to effect the condensation of the compounds of Formulas 11 and 12 with the ΜΛ / Formula 13. A variety of solvents are useful, such as tetrahydrofuran, diethyl ether, toluene, A / ,A / -dimethylformamide, alcohols (e.g., ethanol), esters (e.g., sodium acetate). ethyl or isopropyl acetate), or mixtures thereof. Solvents are chosen for their compatibility with the base, as understood by those skilled in the art. Reaction temperatures can vary from -78 °C to the boiling point of the solvent. A useful mixture of base and solvent combination is potassium tert-butoxide or potassium tert-pentoxide in tetrahydrofuran, to which may be added a solution of an isothiocyanate of Formula 11 and a carbonyl compound of Formula 12, which is They are combined in a solution or added separately, preferably by the addition of the carbonyl compound followed by the addition of the isothiocyanate. Typically, this reaction takes place between -70 and 0 °C. The salt of Formula 13 can be acidified to form the ketothioamide compound of Formula 8a or alkylated with RaX1 (Formula 14) where Ra is lower alkyl (e.g., methyl, ethyl, n-propyl) and X1 is a nucleofuge (es i.e. a nucleophilic reaction leaving group such as Br, I, OS(O)2CH3) to form the corresponding compound of Formula 8. This general method is known in the chemical literature; see, for example, Zhurnal Organicheskoi Khimii 1982, 78(12), 2501. The method of Scheme 6 for preparing a compound of Formula 8 wherein Raes methyl from an intermediate compound of Formula 13, which is not isolated, is illustrated in PCT Patent Publication WO 2013 / 116251 Synthesis Example 1, Step C. Additionally, this Example 2, Step C illustrates the preparation of a compound of Formula 8. Scheme 6 NO-, The ketothioamides of Formula 8a can also be prepared by allowing the corresponding ketoamides to react with sulfurizing agents such as Lawesson's reagent or P2S5; see, for example, Helv. Chim. Act. 1998, 87(7), 1207. ΜΛ / As shown in Scheme 7, compounds of Formula 1 can also be prepared by reacting 1 / - / -pyrazole compounds of Formula 15 with methylating agents of Formula R1-L2 where R1 is methyl or ethyl and L2 is a leaving group such as halogen (e.g., Cl, Br, I), sulfonate (e.g., mesylate, triflate or p-toluenesulfonate) or phosphate (e.g., dimethyl phosphate), preferably in the presence of a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene, potassium carbonate or potassium hydroxide, and a solvent such as Λ / , / V-dimethylformamide, tetrahydrofuran, toluene or water. General procedures for methylations of this type are well known in the art and can be easily adapted to prepare the compounds of the present invention. Particularly useful methylation agents include diazomethane and iodomethane using general procedures known in the art, such as those described in Cañada Journal of Chemistry 1986, 64, 2211-2219 and Heterocycles 2000, 53(12), 2775-2780. Scheme 7 1 Compounds of Formula 15 can be prepared by condensing compounds of Formula 8 with hydrazine, analogous to the method of Scheme 4. This method is described in Chemistry of Heterocyclic Compounds 2005, 41(1), 105-110. In an alternative method, as shown in Scheme 8, compounds of Formula 1 can be prepared by reaction of 4-bromo or 4-iodopyrazoles of Formula 16 with organometallic compounds of Formula 17 under metal-catalyzed cross-coupling reaction conditions. transition, in the presence of a suitable palladium, copper or nickel catalyst. In this method, the compounds of Formula 17 are organoboronic acids (e.g., M1es B(OH)2), organoboronic esters (e.g., M1es B(-OC(CH2)3O-), organotrifluoroborates (e.g. e.g. M1es BF3K), organotin reagents (e.g. M1es Sn(n-Bu)s, Sn(Me)3), Grignard reagents (e.g. M1es MgBr or MgCl) or organozinc reagents (e.g., M1es ZnBr or ZnCl). Suitable metal catalysts include, but are not limited to: palladium(II) acetate, palladium(II) chloride, tetrakis(triphenylphosphine)palladium(0), bis(II) dichloride. triphenylphosphine)palladium (II), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II), bis(triphenylphosphine)dichloronickel(II) and copper (I) salts (e.g. copper (I) iodide, copper (I) bromide, copper (I) chloride, copper (I) cyanide or copper (I) triflate). The optimal conditions will depend on the catalyst used and the counterion incorporated into the reagent. coupling (i.e., M1), as will be understood by one skilled in the art. In some cases, the addition of a ligand such as a substituted phosphine or a substituted bisphosphinoalkane stimulates reactivity. Likewise, the presence of a base such as an alkali carbonate, tertiary amine or alkali fluoride may be necessary for some reactions involving organoboron reagents of Formula 17. For Scheme 11 ΜΛ / t / ZUZZ / U / 4ZÓU L3 is a leaving group such as halogen or sulfonate Id Analogous to the method of Scheme 11, compounds of Formula 20 can be treated with potassium (trifluoromethyl)trimethoxyborate to provide trifluoromethyl analogues of Formula 1b. In another example, as shown in Scheme 12, compounds of Formula 1 where R6 is other than H can be prepared from the corresponding compounds of Formula 1 where R6 is H by reaction with an electrophile comprising R6 (i.e. , Formula 21). Typically, the reaction is carried out in the presence of a base such as sodium hydride and a polar solvent such as N,Ndimethylformamide. In this context the term electrophile comprising R6 means a chemical compound capable of transferring an R6 moiety to a nucleophile (i.e. the nitrogen atom in Formula 1 when R6 is H). Often, electrophiles comprising R6 have the formula R6X2 where X2 is a nucleofuge (i.e. leaving group in nucleophilic reactions). Typical nucleofuges include halide (e.g., Br, Cl, I) or sulfonate (e.g., mesylate, triflate, p-toluenesulfonate). However, some electrophiles that comprise R6 do not comprise a nucleofuge; An example is sulfur trioxide (SO3), which after deprotonation (such as by a base of the formula M+H~ where M+ is a cation) of the nitrogen atom in Formula 1 when R6 is H, can attach to the nitrogen atom as a -SO3M substituent. Scheme 12 It is recognized that some reagents and reaction conditions described above for the preparation of compounds of Formula 1 may not be compatible with certain functional groups present in the intermediates. In these cases, the incorporation of protection / deprotection sequences or interconversions of the functional groups in the synthesis will help to obtain the desired products. He M A / use and choice of protecting groups will be apparent to one skilled in chemical synthesis (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, following the introduction of a given reagent as represented in any individual scheme, it may be necessary to perform additional routine synthesis steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that suggested in the particular sequence presented to prepare the compounds of Formula 1. One skilled in the art will also recognize that the compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation and reduction reactions to add substituents or modify existing substituents. Without further details, it is believed that one skilled in the art using the above description can utilize the present invention to its full extent. Therefore, the following Examples are to be interpreted as merely illustrative and not limiting the disclosure in any way. The steps in the following Examples illustrate a procedure for each step in an overall synthesis transformation and the starting material for each step may not necessarily have been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight, except for chromatographic solvent mixtures or when otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise noted. 1H NMR spectra are presented in ppm from tetramethylsilane; s means singlet, d means doublet, t means triplet, m means multiplet, s a means wide singlet and dd means doublet of doublets. EXAMPLE 1 Preparation of 4-(2-chloro-4-fluorophenyl)- / V-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 H-pyrazole-5-amine (Compound 112) Step A: Preparation of a-acetyl-2-chloro-4-fluorobenzeneacetonitrile A mixture of a solution of sodium methoxide (30% in methanol, 85 ml, 0.47 mol) in toluene (400 ml) was heated to 120 °C with the use of a Dean-Stark trap for the azeotropic removal of methanol. After cooling to 90 °C, 2-chloro-4fluorobenzeneacetonitrile (40.0 g, 0.24 mol) in ethyl acetate (200 ml) was added dropwise to the reaction mixture. The reaction mixture was stirred for 1 hour at 90 °C and then hydrochloric acid (1 N, 30 ml) was added. The resulting mixture was extracted with ethyl acetate (3 x 250 ml) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with ethyl acetate-petroleum ether 3:7) to provide the title compound as a white solid (35 g). 1H NMR (CDCh): Ó7.49 (dd, 1H), 7.24 (dd, 1H), 7.14-7.09 (m, 1H), 5.13 (s, 1H), 2.36 (s, 3H). Step B: Preparation of 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / 7-pyrazole-5-amine To a mixture of α-acetyl-2-chloro-4-fluorobenzeneacetonitrile (i.e., the product from Step A) (28 g, 0.13 mol) in ethanol (400 ml) was added methylhydrazine sulfate (28.6 g, 0.20 mol ) and sodium acetate (21.7 g, 0.27 mol). The reaction mixture was heated at 120 °C for 12 h and then concentrated under reduced pressure to remove the solvent. The resulting mixture was poured into ice water (500 ml) and filtered, collecting a white solid. The solid was rinsed with water and pentane, then dried to give the title compound as an off-white solid (24 g). 1H NMR (CDCh): 57.45 (dd, 1H), 7.27 (t, 1H), 7.23-7.12 (m, 1H), 4.89 (s, 2H), 3.49 (s, 3H). Step C: Preparation of 4-(2-chloro-4-fluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazole-5amine To a mixture of 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / 7-pyrazole-5-amine (i.e., the product of Step B) (1.2 g, 5.0 mmol) in tetrahydrofuran (40 ml) at 0 °C potassium tert-butoxide (1 M in THF, 10 ml, 10 mmol) was added portionwise. The reaction mixture was stirred for 1 h at 0 °C and then 1,2-difluoro-3-nitrobenzene (0.85 g, 5.3 mmol) was added dropwise. After 30 minutes at 0°C, saturated aqueous ammonium chloride was added to the reaction mixture and the resulting mixture was extracted with ethyl acetate (100 mL). The aqueous layer was further extracted with ethyl acetate (2 x 40 ml) and the combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 40% ethyl acetate in petroleum ether) to provide the title compound, a compound of the present invention, as a yellow solid (1.1 g). Ή NMR (CDCh): δ8.59 (s, 1H), 7.59 (d, 1H), 7.31 (d, 1H), 7.2 (d, 1H), 7.09 (t, 1H), 7.04-7.01 (m, 1H ), 6.826.86 (m, 1H), 3.74 (s, 3H), 1.97 (s, 3H). EXAMPLE 2 Preparation of 3-chloro-4-[5-[(2-fluoro-6-nitrophenyl)amino]-1,3-dimethyl-1 / 7-pyrazol-4-yl]benzonitrich (Compound 113 ) Step A: Preparation of 3-chloro-4-(2-oxopropyl)benzonitrile To a mixture of 4-amino-3-chlorobenzonite (50.0 g, 0.33 mol) in diethyl ether (500 ml) at -10 °C was added boron trifluoride diethyl etherate (61 ml, 0.50 mol). The reaction mixture was stirred at -10 °C for 10 minutes and then tere-butyl nitrite (48 ml, 0.4 mol) was added. After 20 minutes at -10 °C, the reaction mixture was allowed to warm to room temperature, stirred for 2 h and then filtered, collecting a white solid. The white solid was triturated with diethyl ether and pentane (1:1,300 ml), filtered and dried to give the intermediate 2-chloro4-cyanobenzene diazonium tetrafluoroborate salt as an off-white solid (72 g). To a mixture of diazonium tetrafluoroborate salt of 2-chloro-4-cyanobenzene (72 g, 0.33 mol) in dimethylformamide (500 ml) at -10 °C was added isopropenyl acetate (354 ml, 3.2 mol). The reaction mixture was stirred for 20 minutes at -10°C and then 4-aminomorpholine (1.0 ml) in dimethyl sulfoxide (40 ml) was added. After 1 h, ice water (1000 ml) was added and the resulting mixture was extracted with ethyl acetate (3 x 250 ml). The combined organic extracts were dried over sodium sulfate. ΜΛ / í sodium, were filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 1:4 ethyl acetate-petroleum ether) to provide the title compound as a solid (52 g). 1H NMR (CDCh): δ 7.69 (s, 1H), 7.53 (d, 1H), 7.32 (d, 1H), 3.93 (s, 2H), 2.28 (s, 3H). Step B: Preparation of 1-fluoro-2-isothiocyanato-3-nitrobenzene To a mixture of 2-fluoro-6-nitrobenzenamine (1.0 g, 6.4 mmol) in 1,2-dichlorobenzene (10 ml) at 0 °C, 2 drops of dimethylformamide were added followed by thiophosgene (1.46 ml, 19 mmol). The reaction mixture was heated to 160 °C for 1 h, cooled to room temperature, and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 1:9 ethyl acetate-petroleum ether) to provide the title compound as an oil (0.91 g). 1H NMR (CDCh) δ 7.88 (d, 1H), 7.46 (t, 1H), 7.36 (m,1H). Step C: Preparation of 3-chloro-4-[5-[(2-fluoro-6-nitrophenyl)amino]-1,3-dimethyl-1 / - / -pyrazol-4yl]benzonitrile To a mixture of 3-chloro-4-(2-oxopropyl)benzonitrile (i.e., the product from Step A) (1.0 g, 5.2 mmol) in tetrahydrofuran (20 ml) at -10 °C was added tert -potassium butoxide (0.7 g, 6.2 mmol). After 30 minutes at -10°C, 1-fluoro-2-isothiocyanate-3-nitrobenzene (i.e., the product from Step B) (0.99 g, 5.0 mmol) in tetrahydrofuran ( 10 ml) and continued stirring for approximately 15 minutes to provide a reaction mixture containing the intermediate compound 4-[1-[[(2-chloro-6-nitrophenyl)amino]mercaptomethylene]-2-oxoprop ¡l]-3-chloro-benzonítrilo potassium salt, which is the potassium salt of a-acetyl-A / -(2-chloro-6-nitrophenyl)-2-chloro-4-c ¡ano-benzeneethanethioam¡da. Iodomethane (1.2 ml, 19 mmol) was added to the reaction mixture. After 20 minutes at −10 °C, the reaction temperature was brought to 0 °C and acetic acid (5.0 ml) and methylhydrazine (85% in water, 0.5 g, 10 mmol) were added. The reaction mixture was allowed to warm to room temperature, refluxed for 2 h and then poured into ice water (30 mL) and ethyl acetate (20 mL). The organic layers were separated and the aqueous layer was extracted with ethyl acetate (2x10 ml). The combined organic extracts were washed with saturated sodium chloride solution (20 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 2:3 ethyl acetate-petroleum ether) to provide the title compound, a compound of the present invention, as a pale yellow solid ( 0.850 g). 1H NMR (CDCh) δ 8.71 (d, 1H), 7.85 (d, 1H), 7.64-7.58 (m, 2H), 7.34-7.25 (m, 2H), 6.87-6.81 (m, 1H), 3.75 (s , 3H), 1.99 (s, 3H). EXAMPLE 3 Preparation of A / -(4-bromo-2-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-d imethyl-1 / 7-pyrazole-5- amine (Compound 61) To a mixture of 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-5-amine (i.e., the product of Example 1, Step B) (0.5 g, 2.1 mmol) in tetrahydrofuran (30 ml) at 0 °C, tert-butoxide was added in portions. M A / t / ZUZZ / U / 4ZÓU M A / potassium (1 M in THF, 4.2 ml, 4.2 mmol). The reaction mixture was stirred for 1 h at 0 °C and then 5-bromo-1,2-difluoro-3-nitrobenzene (0.54 g, 2.3 mmol) was added dropwise. After 30 minutes at 0°C, saturated aqueous ammonium chloride was added to the reaction mixture and the resulting mixture was extracted with ethyl acetate (100 mL). The aqueous layer was further extracted with ethyl acetate (2 x 40 ml) and the combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 40% ethyl acetate in petroleum ether) to provide the title compound, a compound of the present invention, as a yellow solid (0.45 g). 1H NMR (CDCh): δ 8.69 (s a, 1H), 7.77 (t, 1H), 7.66 (dd, 1 H), 7.27 (dd, 2.0 Hz, 1H), 7.09-7.06 (m, 2H), 3.73 ( s, 3H), 1.97 (s, 3H). EXAMPLE 4 Preparation of 4-(2-chloro-4-fluorophenyl)- / \ / -(2-f luoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1 / - / - pyrazole-5-amine (Compound 93) Step A: Preparation of A / -(4-bromo-2-fluoro-6-nitrophenyl)-A / -[4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 Hpyrazol-5 1,1-dimethylethyl -l]carbamate To a mixture of / V-(4-bromo-2-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / 7-pyrazole-5amine (i.e., the product of Example 3) (1 g, 2.2 mmol) and triethylamine (1.24 mi, 8.9 mmol) in dichloromethane (20 mi) at 0 ° C, tere-butyl dicarbonate (1.46 g, 6.7 mmol) was added. . The reaction mixture was allowed to warm to room temperature and stirred overnight and then diluted with water (20 mL) and extracted with dichloromethane (2 x 20 mL). The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 40% ethyl acetate in petroleum ether) to provide the title compound as a yellow solid (750 g). 1H NMR (CDCh): δ 7.85 (s, 1H), 7.78 (s, 1H), 7.52-7.47 (m, 1H), 7.17-7.19 (m, 1H), 6.97-6.88 (m, 1H), 3.8 ( s, 3H), 1.96 (s, 3H), 1.49 (s, 9H). Step B: Preparation of 4-(2-chloro-4-fluorophenyl)-A / -(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1Hpyrazole-5-amine A mixture of A / -(4-bromo-2-fluoro-6-nitrophenyl)-A / -[4-(2-chloro-4-fluorophenyl)-1,3-dimethi 1-1 / 7 1,1-dimethylethyl -pyrazol5-íl]carbamate (i.e., the product of Step A) (600 mg, 1.07 mmol), potassium carbonate (372 mg, 2.7 mmol), dichloro[1,1' complex -bis(diphenylphosphino)ferrocene]palladium(III) and dichloromethane (1:1) (40 mg, 0.05 mmol) and trimethylboroxine (0.54 ml, 3.9 mmol) in 1,4-dioxane (20 ml) were heated to reflux. for 3 hours. The reaction mixture was diluted with water (15 ml) and extracted with ethyl acetate (2x10 ml). The combined organic extracts were washed with saturated aqueous sodium chloride solution (3 x 5 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was dissolved in dichloromethane and trifluoroacetic acid (3:1; 4 ml) and stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure and the resulting material was dissolved in M A / dichloromethane (5 ml) and washed with a saturated aqueous sodium bicarbonate solution (2 ml). The aqueous layer was further extracted with dichloromethane (3x10 ml). The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 40% ethyl acetate in petroleum ether) to provide the title compound, a compound of the present invention, as a yellow solid (210 g). 1H NMR (CDCh) δ 8.41 (s, 1H), 7.45 (s, 1H), 7.24-7.15 (m, 2H), 7.1-7.01 (m, 2H), 3.72 (s, 3H), 2.15 (s, 3H ), 1.95 (s, 3H). EXAMPLE 5 Alternative preparation of 3-chloro-4-[5-[(2-fluoro-6-nitrophenyl)amino]-1,3-dimethyl-1 / - / -pyrazole-4-íl]benzonitr (Compound 113) Step A: Preparation of 1-methyl-hydrazinecarbonitrile A solution of cyanogen bromide (13.5 g, 127.5 mmol) and dichloromethane (250 ml) was cooled to 0 °C and then a mixture of methylhydrazine (85% aqueous solution, 6.0 g, 127.5 mmol) was added dropwise with vigorous stirring. mmol), sodium carbonate (7.5 g, 63.9 mmol) and water (60 mi). After visible signs of gas evolution ceased, the aqueous layer was separated and extracted with dichloromethane (3x). The combined organic layers were dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure to provide the title compound as an oil (6.0 g). Step B: Preparation of 4-(5-amino-1,3-dimethyl-1 / - / -pyrazol-4-íl)-3-chlorobenzonitol A mixture of 3-chloro-4-(2-oxopropyl)benzonitrile (13.7 g, 71.4 mmol) and 1-methylhydrazinecarbonitrile (i.e., the product from Step A) (6.0 g, 86 mmol) was heated to 60 °C with agitation. After 48 h, the reaction mixture was dissolved in dichloromethane (100 ml) and water (100 ml), the layers were separated and the aqueous layer was extracted with dichloromethane (3x). The combined organic layers were dried over magnesium sulfate, filtered and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 60% ethyl acetate in petroleum ether) to provide the title compound as a light yellow solid (8.1 g). LCMS: 247 (M+1) Step C: Preparation of 3-chloro-4-[5-[(2-fluoro-6-nitrophenyl)amino]-1,3-dimethyl-1 / 7-pyrazol-4yl]benzonitrile To a mixture of 4-(5-amino-1,3-dimethyl-1 / 7-pyrazol-4-yl)-3-chlorobenzonitrich (i.e., the product of Step B) ( 1.2 g, 4.8 mol) in tetrahydrofuran (40 ml) at 0 °C potassium tert-butoxide (9.7 ml, 1 M in tetrahydrofuran) was added dropwise. The reaction mixture was stirred at 0 °C for 1 hour and then 1,2-difluoro-3-nitrobenzene (0.85 g, 5.3 mmol) was added dropwise and stirring was continued for a further 30 minutes at 0 °C. The reaction mixture was diluted with saturated aqueous ammonium chloride and ethyl acetate (100 mL) and the layers were separated. The aqueous layer was extracted with ethyl acetate (40 ml x 2) and the combined organic extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 40% ethyl acetate in petroleum ether) to provide a yellow solid. The yellow solid crystallized from ethanol to provide the title compound, a compound of the present invention, as a light yellow solid (560 mg). 1H NMR (CDCh) δ 8.71 (d, 1H), 7.85 (d, 1H), 7.63-7.58 (m, 2H), 7.33-7.25 (m, 2H), 6.86-6.82 (m, 1H), 3.75 (s , 3H), 1.99 (s, 3H). LCMS: 386 (M+1)Q By the procedures described herein together with methods known in the art, the compounds disclosed in the following Tables can be prepared. The following abbreviations are used in the Tables below: Me means methyl, MeO means methoxy, EtO means ethoxy and CN means cyano. TABLE 1 ΜΛ / í R2 is CH3, R3 is Cl and (R4)m is 4-F. R2 is CH3, R3 is Cl and (R4)m is 4-F. (R5)n (R5)n 6-F 4-CI, 6-Br 4,6-di-F 4-I, 6-Br 4-CI, 6-F 4-Me, 6-Br 4-Br, 6-F 4-MeO, 6-Br 4-I, 6-F 4-EtO, 6-Br 4-Me, 6-F 6-I 4-MeO, 6-F 4,6-di-l 4- EtO, 6-F 4-F, 6-I 6-CI 4-CI, 6-I 4,6-di-CI 4-Br, 6-I 4-F, 6-CI 4-Me, 6-I 4-Br, 6-CI 4-MeO, 6-I 4-I, 6-CI 4-EtO, 6-I 4-Me, 6-CI 4-Me 4-MeO, 6-CI 4-MeO 4- EtO, 6-CI 4-EtO 6-Br 6-Me R2 is CH3, R3 is Cl and (R4)m is 4-F. R2 is CH3, R3 is Cl and (R4)m is 4-F. (R5)n (R5)n 4,6-di-Br 6-MeO 4-F, 6-Br 6-EtO ΜΛ / t / ZUZZ / U / The present disclosure also includes Tables 1A to 46A, each of which is constructed the same as Table 1 above, except that the row heading in Table 1 (i.e., R2 is CH3, R3 is Cl and (R4)m is 4-F is replaced with the respective row headings shown below. Table Row Header Table Row Header 1A R2 is CH3, R3 is F, and (R4)m is 4-F. 24A R2 is Et, R3 is F and (R> is 4-F. 2A R2 is CH3, R3 is Br and (R4)m is 4-F. 25A R2 is Et, R3 is Br and (R4)m is 4 -F. 3A R2 is CH3, R3 is Me and (R4)m is 4-F. 26A R2 is Et, R3 is Me and (R4)m is 4-F. 4A R2 is CH3, R3 is Cl and (R4 )m is 4-MeO. 27A R2 is Et, R3 is Cl and (R4)m is 4-MeO. 5A R2 is CH3, R3 is F and (R4)m is 4-MeO. 28A R2 is Et, R3 is F and (R4)m is 4-MeO. 6A R2 is CH3, R3 is Br and (R4)m is 4-MeO. 29A R2 is Et, R3 is Br and (R4)m is 4-MeO. 7A R2 is CH3, R3 is Me and (R4)m is 4-MeO. 30A R2 is Et, R3 is Me and (R4)m is 4-MeO. 8A R2 is CH3, R3 is Cl and (R4)m is 4-CN . 31A R2 is Et, R3 is Cl and (R> is 4-CN. 9A R2 is CH3, R3 is F and (R4)m is 4-CN. 32A R2 is Et, R3 is F and (R> is 4 -CN.10A R2 is CH3, R3 is Br and (R4)m is 4-CN 33A R2 is Et, R3 is Br and (R4)m is 4-CN 11A R2 is CH3, R3 is Me and (R4)m is 4-CN. 34A R2 is Et, R3 is Me and (R4)m is 4-CN. 12A R2 is CH3, R3 is Cl and (R4)m is 4,6-di-F. 35A R2 is Et, R3 is Cl and (R4)m is 4,6-di-F. 13A R2 is CH3, R3 is F and (R4)m is 4,6-di-F. 36A R2 is Et, R3 is F and (R4 )m is 4.6-di-F. 14A R2 is CH3, R3 is Br and (R4)m is 4.6-di-F. 37A R2 is Et, R3 is Br and (R4)m is 4.6-di-F. 15A R2 is CH3, R3 is Me and (R4)m is 4.6-di-F. 38A R2 is Et, R3 is Me and (R4)m is 4.6-di-F. 16A R2 is CH3, R3 is Cl and (R4)m is 4-CI, 6-F. 39A R2 is Et, R3 is Cl and (R4)m is 4-CI, 6-F. 17A R2 is CH3, R3 is F and (R4)m is 4-CI, 6-F. 40A R2 is Et, R3 is F and (R4)m is 4-CI, 6-F. 18A R2 is CH3, R3 is Br and (R4)m is 4-CI, 6-F. 41A R2 is Et, R3 is Br and (R4)m is 4-CI, 6-F. 19A R2 is CH3, R3 is Me and (R4)m is 4-CI, 6-F. 42A R2 is Et, R3 is Me and (R4)m is 4-CI, 6-F. 20A R2 is CH3, R3 is Cl and (R4)m is 4-MeO, 6-F. 43A R2 is Et, R3 is Cl and (R4)m is 4-MeO, 6-F. 21A R2 is CH3, R3 is F and (R4)m is 4-MeO, 6-F. 44A R2 is Et, R3 is F and (R4)m is 4-MeO, 6-F. 22A R2 is CH3, R3 is Br and (R4)m is 4-MeO, 6-F. 45A R2 is Et, R3 is Br and (R4)m is 4-MeO, 6-F. 23A R2 is CH3, R3 is Me and (R4)m is 4-MeO, 6-F. 46A R2 is Et, R3 is Me and (R4)m is 4-MeO, 6F. TABLE 2 M A / í R2 is CH3 and R3 is Cl. R2 is CH3, R3 is Cl and (R4)m is 4-F. (R4)m (R4)m 6-F 4-I, 6-Br 4,6-di-F 4-Me, 6-Br 4-CI, 6-F 4-MeO, 6-Br 4-Br, 6-F 4-EtO, 6-Br 4-I, 6-F 4-CN, 6-Br 4-Me, 6-F 6-I 4-MeO, 6-F 4,6-di-l 4- EtO, 6-F 4-F, 6-I 4-CN, 6-F 4-CI, 6-I 6-CI 4-Br, 6-I 4,6-di-CI 4-Me, 6-I 4-F, 6-CI 4-MeO, 6-I 4-Br, 6-CI 4-EtO, 6-I 4-I, 6-CI 4-CN, 6-I 4-Me, 6-CI 4 -Me 4-MeO, 6-CI 4-MeO 4-EtO, 6-CI 4-EtO 4-CN, 6-CI 4-CN 6-Br 6-Me 4,6-di-Br 6-MeO 4- F, 6-Br 6-EtO 4-CI, 6-Br 6-CN Formulation / Utility A compound of Formula 1 of this invention (including A / -oxides and salts thereof), or a mixture (i.e., a composition) comprising the compound with at least one additional fungicidal compound as described in the Summary of the Invention, it will generally be used as a fungicide active ingredient in a composition, that is, a formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which act M A / as a vehicle. The ingredients of the composition or formulation are selected to match the physical properties of the active ingredient, the mode of application and environmental factors such as soil type, humidity and temperature. Mixtures of component (a) (i.e., at least one compound of Formula 1, / V-oxides or salts thereof) with component (b) (e.g., selected from (b1) to (b54) and salts thereof as described above) and / or one or more other biologically active compound or agent (i.e., insecticides, other fungicides, nematicides, acaricides, herbicides and other biological agents) can be formulated in a number of ways, including: (i) component (a), component (b) and / or one or more other biologically active compounds or agents may be formulated separately and applied separately or applied simultaneously in an appropriate weight ratio, for example, as a tank mix; or (II) component (a), component (b) and / or one or more other biologically active compounds or agents may be formulated together in the appropriate weight ratio. Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in-water emulsions, fluid concentrates and / or suspoemulsions) and the like, which may optionally be thickened to form gels. General types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil-in-water emulsion, flowable concentrate and suspoemulsion. General types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate, and oil dispersion. General types of solid compositions are fine powders, powders, granules, microgranules, beads, tablets, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (wettable) or water-soluble. Films and coatings formed from film-forming solutions or fluid suspensions are particularly useful for seed treatment. The active ingredient can be (micro)encapsulated and also formed into a suspension or solid formulation; Alternatively, the entire active ingredient formulation may be encapsulated (or overcoated). Encapsulation can control or delay the release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High concentration compositions are mainly used as intermediates for further formulation. It is worth highlighting one embodiment of the composition, where granules of a solid composition comprising a compound of Formula 1 (or a / V-oxide or a salt thereof) are mixed with granules of a solid composition comprising component (b). These mixtures may be additionally mixed with granules comprising additional agricultural protectants. Alternatively, two or more agricultural safeners (e.g., a component (a) compound (Formula 1), a component (b) compound, an agricultural safener other than component (a) or (b)) may be combined in the solid composition of a set of granules, which is then mixed with one or more sets of granules of solid compositions comprising one or more additional agricultural protectants. These granule mixtures may be in accordance with the general disclosure of granule mixtures of PCT Patent Publication WO 94 / 24861 or, more preferably, with the teaching of homogeneous granule mixtures of US Patent 6,022,552. Sprayable formulations are normally spread on a suitable medium before spraying. Such liquid and solid formulations are formulated to be easily diluted in the spray medium, usually water, but occasionally another suitable medium such as an aromatic or paraffinic hydrocarbon or vegetable oil. Spray volumes can vary from about one to several thousand liters per hectare, but are most often in the range of about ten to several hundred liters per hectare. Spray formulations can be mixed in a tank with water or other suitable medium for foliar treatment by aerial or terrestrial application, or for application in the plant's growth medium. Liquid and dry formulations can be administered directly to drip irrigation systems or administered into the furrow during planting. Liquid and solid formulations can be applied to crop seeds and other desired vegetation as seed treatments prior to planting to protect developing roots and other underground plant parts and / or foliage through systemic adsorption. The formulations will normally contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges totaling up to 100 weight percent. ΜΛ / f Weight percentage Active ingredient Diluent Surfactant Granules, tablets and powders dispersible in water and hydrosoluble. 0.001-90 0-99.999 0-15 Dispersions, suspensions, emulsions and oil solutions (including emulsifiable concentrates) 1-50 40-99 0-50 Fine powders 1-25 70-99 0-5 Granules and microgranules 0.001-95 5 -99,999 0-15 Concentration compositions 90-99 0-10 0-2 elevated Solid diluents include, for example, clays such as dentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica. , diatomaceous earth, urea, calcium cardonate, sodium cardonate and dicardonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey. Liquid diluents include, for example, water, A / ,A / -dimethylalkanamides (e.g., N,Ndimethylformamide), limonene, dimethyl sulfoxide, M-alkylpyrrolidones (e.g., / V-methylpyrrolidinone), phosphates alkyl (e.g. triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g. white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerin, glycerol triacetate, sorbitol, dearomatized aliphatic, aromatic hydrocarbons, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and γ-butyrolactone, and alcohols, which They can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, nhexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C6-C22), such as vegetable seed and fruit oils (e.g., olive, castor, linseed, sesame, corn, peanut, sunflower oils). , grape seed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish) and mixtures of these. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) where the fatty acids can be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950. The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as surface-active agents) generally modify and, most often, reduce the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants may be useful as wetting agents, dispersants, emulsifiers, or antifoaming agents. Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the compositions herein include, but are not limited to: alcohol alkoxylates, such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and oxide of ethylene, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides, such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates, such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonylphenol ethoxylates and dodecylphenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers in which the end blocks are prepared from propylene oxide; acids M A / t / ZUZZ / U / 4ZÓU ethoxylated fatty acids; esters and ethoxylated fatty oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, PEG (polyethylene glycol) alkyl resins, graft or comb polymers and star polymers; polyethylene glycols (PEG); esters of fatty acids with polyethylene glycol; silicone surfactants; and sugar derivatives such as sucrose esters, alkyl polyglucosides and alkylpolysaccharides. Useful anionic surfactants include, but are not limited to: alkylarylsulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sultanates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sultanates of oils and fatty acids; ethoxylated alkylphenol sulfates and sultanates; alcohol sulphates; sulfates of ethoxylated alcohols; amine and amide sultanates such as N,A / -alkyltaurates; benzene, eumene, toluene, xylene and dodecyl sultanates and tridecylbenzenes; condensed naphthalene sultanates; naphthalene and alkyl naphthalene sultanates; fractionated petroleum sultanates; sulfosuccinates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts. Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as / V-alkylpropanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides. Also useful for the compositions herein are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon's Emulsifiers and Detergents, American and International Annual Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987. The compositions of this invention may also contain formulation aids and additives, known to those skilled in the art as formulation aids. Such formulation aids and additives can control: pH (buffers), foaming during processing (antifoams such as polyorganosiloxanes (e.g. Rhodorsil® 416), sedimentation of the Sea ΜΛ / active ingredients (suspending agents), viscosity (thixotropic thickeners), microbial growth in the container (antimicrobials), product freezing (antifreezes), color (dyes / pigment dispersions (e.g. Pro- lzed® Red dye), removal with washing (film formers or adhesives), evaporation (evaporation retardants) and other formulation attributes. Film formers include, for example, polyvinyl acetates, acetate copolymers of polyvinyl, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, American and International Annual Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03 / 024222. The compound of Formula 1 and any other active ingredients are normally incorporated into the compositions herein by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared simply by mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsified concentrate is immiscible in water, an emulsifier is normally added to emulsify the solvent containing the active ingredient by diluting it with water. Thick suspensions of active ingredients, with particle diameters up to 2000 pm, can be wet milled using media mills to obtain particles with average diameters less than 3 pm. Aqueous slurries can be converted to finished slurry concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations generally require dry milling processes, which produce average particle diameters in the range of 2 to 10 pm. Fine powders and powders can be prepared by mixing and, typically, grinding (such as with a hammer mill or fluid power mill). The granules and microgranules can be prepared by spraying the active material into preformed granular vehicles or by agglomeration techniques. See Browning, Agglomeration, Chemical Engineering, December 4, 1967, pp. 147-48, Perry's Chemical Engineer's Handbook, 4th ed., McGraw-Hill, New York, 1963, pp. 8-57 et seq., and document WO 91 / 13546. The microgranules can be prepared as described in U.S. Pat. 4,172,714. The water-dispersible and hydrosoluble granules can be prepared as taught in U.S. documents. 4,144,050, U.S. 3,920,442 and DE 3,246,493. The tablets can be prepared as taught in U.S. documents. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. The films can be prepared as taught in GB 2,095,558 and U.S. documents. 3,299,566. One embodiment of the present invention relates to a method of controlling fungal pathogens, comprising diluting the fungicidal composition of the present invention (a compound of Formula 1 formulated with surfactants, solid diluents and liquid diluents or a formulated mixture of a compound of Formula 1 and at least one different fungicide) with water and optionally adding an adjuvant to form a dilute composition, and contacting the fungal pathogen or its environment with an effective amount of said diluted composition. MA / Although a spray composition formed by diluting a sufficient concentration of the fungicidal composition herein with water can provide sufficient efficacy to control fungal pathogens, separately formulated adjuvant products can also be added to the spray tank mixtures. These additional adjuvants are commonly known as spray adjuvants or tank mix adjuvants, and include any substance mixed in a spray tank to improve the performance of a pesticide or alter the physical properties of the spray mixture. Adjuvants may be anionic or nonionic surfactants, emulsifying agents, crop oils from petroleum, seed oils from crops, acidifiers, buffers, thickeners or antifoaming agents. Adjuvants are used to enhance efficacy (e.g., biological availability, adhesion, penetration, uniformity of coverage, and durability of protection), or minimize or eliminate spray application problems associated with incompatibility. , foaming, entrainment, evaporation, volatilization and degradation. For optimal performance, adjuvants are selected taking into account the properties of the active ingredient, formulation and target (e.g. crops, insect pests). The amount of adjuvants added to spray mixtures is generally in the range of about 2.5% to 0.1% by volume. Application rates of adjuvants added to spray mixtures are typically between approximately 1 and 5 I per hectare. Representative examples of spray adjuvants include: 47% methylated rapeseed oil in Adigor® liquid hydrocarbons (Syngenta), Silwet® polyalkylene oxide modified heptamethyltrisiloxane (Helena Chemical Company) and 17% surfactant blend in mineral oil a Assist® 83% paraffin base (BASF). One method of treating seeds is by spraying or dusting the seed with a compound of the invention (i.e., as a formulated composition) before sowing the seeds. Compositions formulated for seed treatment generally comprise an adhesive or film-forming agent. Therefore, typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1 and a film former or adhesive agent. Seeds can be coated by spraying a flowable suspension concentrate directly into a seed turning bed and then drying the seeds. Alternatively, other types of formulation such as wet powders, solutions, suspoemulsions, emulsifiable concentrates and water emulsions can be sprayed on the seed. This process is particularly useful for applying film coatings to seeds. An expert in the field has various coating machines and processes. Suitable processes include those listed in P. Kosters et al., Seed Treatment: Progress and Prospecta, BCPC Monograph N.s57 of 1994, and the references listed therein. For more information on the formulation technique, see T. S. Woods, The Formulator's Toolbox-Product Forms for Modern Agriculture in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Ed., 9th Congress proceedings International Conference on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. document 3,235,361, Col. 6, line 16 to Col. 7, line 19 and Examples 10-41; the U.S. document 3,309,192, from Col. 5, line 43 to Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; the U.S. document 2,891,855, Col. 3, line 66 to Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc, New York, 1961, pp. 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, United Kingdom, 2000. In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Tables A-B. Without going into further details, it is believed that one skilled in the art using the above description can take full advantage of the present invention. Therefore, the following Examples are to be interpreted as merely illustrative and not limiting the disclosure in any way. Example A High Concentration Concentrate MA / t / ZUZZ / U / 4ZÓU Compound 60 98.5% silica airgel 0.5% synthetic amorphous fine silica 1.0% Example B Wettable powder Compound 68 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0% Example C Granule Compound 72 10.0% attapulgite granules (low volatile matter, 0.71 / 0.30 mm; 90.0% U.S.S. N.s25-50 sieves) Example D Extruded Microgranule Compound 93 25.0% anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0% calcium / magnesium bentonite 59.0% M A / Example E Emulsifiable concentrate Compound 112 polyoxyethylene sorbitol hexoleate fatty acid methyl ester Ce-Cio 10.0% 20.0% 70.0% Example F Microemulsion Compound 118 5.0% polyvinylpyrrolidone-vinyl acetate copolymer 30.0% alkylpolyglycoside 30.0% glyceryl monooleate 15.0% water 20. 0% Example G Seed Treatment Compound 60 20.00% polyvinylpyrrolidone-vinyl acetate copolymer 5.00% montanic acid wax 5.00% calcium ligninsulfonate 1.00% polyoxyethylene / polyoxypropylene block copolymers 1.00% stearyl alcohol (POE 20) 2.00% polyorganosilane 0.20% red dye dye 0.05% water 65.75% Example H Fertilizer stick Compound 68 2.50% pyrrolidone-styrene copolymer 4.80% tristyrylphenyl 16-ethoxylate 2.30% talc 0.80% corn starch 5.00% slow release fertilizer 36.00% kaolin 38.00% water 10.60% Example I Concentrate in suspension Compound 72 butylpolyoxyethylene / polypropylene block copolymer stearic acid / polyethylene glycol copolymer 35% 4.0% 1.0% styrene acrylic polymer / polypropylene 4.0% stearic acid copolymer / polyethylene glycol 1.0% styrene acrylic polymer 1.0% 20.0 water Example K 58.7% 20 Oil dispersion Compound 112 25% polyoxyethylene sorbitol hexaoleate 15% organically modified bentonite clay 2.5% fatty acid methyl ester 57.5% 25 Example L Suspoemulsion Compound 118 10.0% midacloprid 5.0% butylpolyoxyethylene block copolymer / polypropylene 4.0% 30 stearic acid copolymer / polyethylene glycol 1.0% styrene acrylic polymer 1.0% oil 20.0% water 53.7% MA / Water-soluble and water-dispersible formulations are normally diluted with water to form aqueous compositions before application. Aqueous compositions for direct applications to the plant or a portion thereof (e.g., spray tank compositions) typically contain at least about 1 ppm or more (e.g., 1 ppm to 100 ppm) of the compound(s). the present invention. Seeds are typically treated at a rate of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (i.e., about 0.0001 to 1% by weight of seed before treatment). A fluid suspension formulated for seed treatment typically comprises from about 0.5 to about 70% of the active ingredient, from about 0.5 to about 30% of the film-forming adhesive, from about 0.5 to about 20% of the film-forming agent. dispersant, 0 to approximately 5% of the thickener, 0 to approximately 5% of the pigment and / or colorant, 0 to approximately 2% of the antifoam agent, 0 to approximately 1% of the preservative and 0 to approximately approximately 75% of the volatile liquid diluent. The compounds of the present invention are useful as agents for controlling plant diseases. Therefore, the present invention further comprises a method for controlling plant diseases caused by fungal phytopathogens which comprises applying to the plant or portion thereof to be protected, or to the seed of the plant to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and / or compositions of this invention provide control of diseases caused by a broad spectrum of fungal phytopathogens in the phyla Ascomycota, Basidiomycota, Zygomycota and the fungal-like class Oomycota. They are effective in controlling a wide spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal and fruit crops. These pathogens include, but are not limited to, those listed in Table 1-1. For ascomycetes and basidiomycetes, names for the sexual / teleomorphic / perfect stage as well as names for the asexual / anamorphic / imperfect stage are listed (in parentheses) when known. Synonymous names for pathogens are indicated with an equal sign. For example, the name of the sexual / teleomorphic / perfect stage Phaeosphaeria nodorum is followed by the corresponding name of the asexual / anamorphous / imperfect stage Stagnospora nodorum and the former synonymous name Septoria nodorum. Table 1-1 Ascomycetes of the order Pleosporales including Alternaria solani, A. alternata and A. brassicae, Guignardia bidwellii, Venturia inaequalis, Pyrenophora tritici-repentis (Dreschlera tritici-repentis = Helminthosporium tritici-repentis) and Pyrenophora teres (Dreschlera teres = Helminthosporium teres), Corynespora cassiicola, Phaeosphaeria nodorum (Stagonospora nodorum = Septoria nodorum), Cochliobolus carbonum and C. heterostrophus, Leptosphaeria biglobosa and L. maculans; ΜΛ / Ascomycetes of the order Mycosphaerellales which include Mycosphaerella graminicola (Zymoseptoria tritici = Septoria tritici), M. berkeleyi (Cercosporidium personatum), M. arachidis (Cercospora arachidicola), Passalora sojina (Cercospora sojina), Cercospora zeae-maydis and C. beticola; Ascomycetes of the order Erysiphales (the powdery mildews) such as Blumeria graminis f.sp. tritici and Blumeria graminis f.sp. hordei, Erysiphe polygoni, E. necator (= Uncinula necator), Podosphaera fuliginea (= Sphaerotheca fuliginea), and Podosphaera leucotricha (= Sphaerotheca fuliginea), Ascomycetes of the order Helotiales such as Botryotinia fuckeliana (Botrytis cinerea), Oculimacula yallundae (= Tapesia yallundae; anamorph Helgardia herpotrichoides = Pseudocercosporella herpetrichoides), Monilinia fructicola, Sclerotinia sclerotiorum, Sclerotinia minor, and Sclerotinia homoeocarpa; Ascomycetes of the order Hypocreales such as Giberella zeae (Fusarium graminearum), G. monoliformis (Fusarium moniliforme), Fusarium sotaní and Verticillium dahliae; Ascomycetes of the order Eurotiales such as Aspergillus flavus and A. parasiticus; Ascomycetes of the order Diaporthales such as Cryptosphorella vitícola (= Phomopsis vitícola), Phomopsis longicolla, and Diaporthe phaseolorum; Other Ascomycete pathogens including Magnaporthe grisea, Gaeumannomyces graminis, Rhynchosporium secalis, and anthracnose pathogens such as Glomerella acutata (Colletotrichum acutatum), G. graminicola (C. graminicola) and G. lagenaria (C. orbicuiare); Basidiomycetes of the order Urediniales (the rusts) including Puccinia recondita, P. striiformis, Puccinia hordei, P. graminis and P. arachidis), Hemileia vastatrix and Phakopsora pachyrhizi; Basidiomycetes of the order Ceratobasidiales such as Thanatophorum cucumeris (Rhizoctonia solani) and Ceratobasidium oryzae-sativae (Rhizoctonia oryzae); Basidiomycetes of the order Polyporales such as Athelia rolfsii (Sclerotium rolfsii); Basidiomycetes of the order Ustilaginales such as Ustilago maydis; Zygomycetes of the order Mucorales such as Rhizopus stolonifer, Oomycetes of the order Pythiales, including Phytophthora infestans, P. megasperma, P. parasitica, P. sojae, P. cinnamomi and P. capsici, and pathogenic Pythium such as Pythium aphanidermatum, P. graminicola, P. irregulare, P. ultimum and P. dissoticum; Oomycetes of the order Peronosporales such as Plasmopara viticola, P. halstedii, Peronospora hyoscyami (=Peronospora tabacina), P. manshurica, Hyaloperonospora parasitica (=Peronospora parasitica), Pseudoperonospora cubensis and Bremia lactucae; and other genera and species closely related to all the above pathogens. In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae and other related species. By controlling harmful microorganisms, the compounds of the invention are useful for improving (i.e., increasing) the ratio of beneficial to harmful microorganisms in contact with crop plants or their propagules (e.g., seeds, corms, bulbs). , tubers, cuttings) or in the agronomic environment of the crop plants or their propagules. M A / The compounds of the invention are useful in the treatment of all plants, plant parts and seeds. Varieties and cultivars of seeds and plants can be obtained through conventional propagation and breeding methods or through genetic engineering methods. Genetically modified plants or seeds (transgenic plants or seeds) are those in which a heterologous gene (transgene) has been stably integrated into the genome of the plant or seed. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event. Cultivars of genetically modified plants that can be treated according to the invention include those that are resistant against one or more biotic insults (pests such as nematodes, insects, mites, fungi, etc.) or abiotic insults (drought, cold temperatures, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits such as herbicide tolerance, insect resistance, modified oil profiles or drought tolerance. Treatment of genetically modified plants and seeds with compounds of the invention may result in superadditive or enhanced effects. For example, the reduction of application rates, the broadening of the spectrum of activity, the increase in tolerance to biotic / abiotic aggressions or the enhancement of storage stability may be greater than what is expected from simple effects alone. additives from the application of the compounds of the invention on genetically modified plants and seeds. The compounds and compositions of the present invention are useful in seed treatments to protect seeds from plant diseases. In the context of the present disclosure and claims, treating a seed means contacting the seed with a biologically effective amount of a compound of the present invention, which is typically formulated as a composition of the invention. This seed treatment protects the seed from soil-borne pathogens and can also generally protect the roots and other soil-contact parts of the plant from the seedling that develops from the germinated seed. Seed treatment may also provide foliage protection by translocating the compound of the present invention or a second active ingredient into the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants genetically transformed to express specialized traits will germinate. Representative examples include those that express proteins toxic to invertebrate pests, such as Bacillus thuringiensis toxin, or those that express herbicide resistance, such as glyphosate acetyltransferase, which provides resistance to glyphosate. Seed treatments with compounds of the present invention can also increase the vigor of plants grown from seed. The compounds of the present invention and their compositions, both alone and in combination with other fungicides, nematicides and insecticides, are particularly useful in the treatment of seeds for crops including, but not limited to, corn, soybeans, cotton, cereals (e.g., wheat, oats, barley, rye and rice), potatoes, vegetables and rapeseed. M A / Furthermore, the compounds of this invention are useful in the treatment of post-harvest diseases of fruits and vegetables caused by fungi and bacteria. These infections can occur before, during and after harvest. For example, infections may occur before harvest and then remain latent until some time during ripening (e.g., the host begins to change tissues so that the infection can progress); Infections may also arise from superficial wounds created by mechanical or insect injuries. In this sense, the compounds of the present invention can reduce losses (i.e., losses as a result of quantity and quality) due to post-harvest diseases that can occur at any time from harvest to consumption. Treatment of post-harvest diseases with compounds of the invention can increase the period of time during which perishable edible parts of plants (e.g., fruits, seeds, foliage, stems, bulbs, tubers) can be stored refrigerated. or unrefrigerated after harvest, and remain edible and without degradation or noticeable or harmful contamination by fungi or other microorganisms. Treatment of edible parts of the plant before or after harvest with compounds of the invention can also decrease the formation of toxic metabolites from fungi or other microorganisms, for example, mycotoxins such as aflatoxins. Control of plant diseases is typically achieved by applying an effective amount of a compound of the present invention, either before or after infection, to the portion of the plant to be protected, such as roots, stems, , the foliage, fruits, seeds, tubers or bulbs, or the medium (soil or sand) in which the plants to be protected grow. The compounds can also be applied to seeds to protect the seeds and the seedlings that develop from the seeds. The compounds can also be applied through irrigation water to treat plants. Control of post-harvest pathogens that infect produce before harvest is typically achieved by field application of a compound of the present invention, and in cases where infection occurs post-harvest, The compounds can be applied to the harvested crop as dips, sprays, fumigants, treated wrappers, and box linings. The compounds can also be applied using an unmanned aerial vehicle (UAV) for dispersion of the compositions disclosed herein over a planted surface. In some embodiments, the planted area is an area containing crops. In some embodiments, the crop is selected from a monocot or a dicot. In some embodiments, the crop is selected from rice, corn, barley, soybeans, wheat, vegetables, tobacco, tea tree, fruit tree and sugar cane. In some embodiments, the compositions disclosed herein are formulated for ultra-low volume spraying. Drone-applied products can use water or oil as the spray vehicle. Typical spray volume (including product) used for global scale drone applications. 5.0 liters / ha - 100 liters / ha (approximately 0.510 gpa). This includes the range from ultra-low volume (ULV) spray to low volume (LV) spray. Although it is not common, there may be ΜΛ / situations where even lower spray volumes of as little as 1.0 liter / ha (0.1 gpa) could be used. The appropriate application rates (e.g., fungicide effective amounts) of component (a) (i.e., at least one compound selected from the compounds of Formula 1, A / -oxides and salts thereof), as well as Appropriate application rates (e.g., biologically effective amounts, fungicide-effective amounts, or insecticidal-effective amounts) for mixtures and compositions comprising component (a) according to the present invention may be influenced by factors such as diseases. of the plants to be controlled, the plant species to be protected, the population structure of the pathogen to be controlled, the ambient humidity and temperature and must be determined under actual conditions of use. One skilled in the art can easily determine, through simple experimentation, the fungicide-effective amount necessary for the desired level of plant disease control. Foliage can normally be protected when treated at a rate of less than about 1 g / ha to about 5000 g / ha of active ingredient. Seed and seedlings can normally be protected when the seed is treated at a rate of about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed. A person skilled in the art can easily determine, through simple experimentation, the application rates of component (a), and mixtures and compositions thereof, containing particular combinations of active ingredients according to the present invention, necessary to provide the desired spectrum of plant protection and control of plant diseases and, optionally, other plant pests. The compounds and compositions of the present invention may also be useful in increasing the vigor of a crop plant. This method comprises contacting the crop plant (for example, foliage, flowers, fruits or roots) or the seed from which the crop plant is grown with compositions comprising a compound of Formula 1 in sufficient amount to achieve the desired plant vigor effect (i.e., a biologically effective amount). Typically, the compound of Formula 1 is applied in a formulated composition. Although the compound of Formula 1 is usually applied directly to the crop plant or its seed, it can also be applied to the site of the crop plant, that is, the environment of the crop plant, in particular the portion of the environment sufficiently next to allow the Formula 1 compound to migrate to the crop plant. The relevant location for this method most typically comprises the growth medium (i.e. the medium that provides nutrients to the plant), usually the soil in which the plant is grown. Treatment of a crop plant to increase the vigor of the crop plant therefore comprises contacting the crop plant, the seed from which the crop plant grows or the location of the crop plant with a biologically effective amount of a Formula 1 compound. Increased crop vigor may result in one or more of the following observed effects: (a) optimal crop establishment, as demonstrated by excellent seed germination, crop emergence, and crop seedling density; (b) enhanced crop growth, such as M A / is demonstrated by rapid and robust leaf growth (e.g., measured by leaf area index), plant height, number of canes (e.g., for rice), root mass, and total dry weight of the vegetative mass of the crop; (c) improved crop yields, as demonstrated by time to flowering, duration of flowering, number of flowers, total biomass accumulation (i.e. yield quantity) and / or marketability of the grade of the fruit or grain of the product (i.e., the quality of the yield); (d) enhanced ability of the crop to resist or prevent infections by plant diseases and infestations by arthropod, nematode or mollusk pests; and (e) greater capacity of the crop to resist environmental aggressions such as exposure to extreme temperatures, suboptimal humidity or phytotoxic chemical compounds. The compounds and compositions of the present invention can increase the vigor of treated plants compared to untreated plants, preventing and / or curing plant diseases caused by fungal phytopathogens in the plant environment. In the absence of such plant disease control, diseases reduce plant vigor by consuming plant tissues or sap, or transmitting phytopathogens such as viruses. Even in the absence of fungal phytopathogens, the compounds of the invention can increase plant vigor by modifying plant metabolism. Generally, the vigor of a crop plant will be increased more significantly by treating the plant with a compound of the invention if the plant is grown in a non-ideal environment, that is, an environment that comprises one or more aspects adverse for the plant to achieve the full genetic potential that it would present in an ideal environment. Noteworthy is a method of increasing the vigor of a crop plant where the crop plant is grown in an environment comprising plant diseases caused by fungal phytopathogens. Also noteworthy is a method of increasing the vigor of a crop plant where the crop plant is grown in an environment that does not comprise plant diseases caused by fungal phytopathogens. Also noteworthy is a method of increasing the vigor of a crop plant wherein the crop plant is grown in an environment comprising less than an ideal amount of humidity to stimulate growth of the crop plant. The compounds and compositions of the present invention may also be mixed with one or more different biologically active compounds or agents, including fungicides, insecticides, nematicides, bactericides, acaricides, herbicides, herbicide protectants, growth regulators such as shedding inhibitors. insects and rooting stimulants, chemosterilizers, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, viruses or fungi to form a multicomponent pesticide that provides an even broader spectrum of agricultural protection . Therefore, the present invention also relates to a composition comprising a compound of Formula 1 (in a fungicide effective amount) and at least one compound or agent with additional biological activity (in a biologically effective amount) and may further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other compounds or agents with biological activity can be formulated in compositions comprising at least one of a surfactant and a ΜΛ / solid or liquid diluent. For the mixtures of the present invention, one or more different compounds or biologically active agents may be formulated together with a compound of Formula 1 to form a premix, or one or more different compounds or biologically active agents may be formulated separately. of the compound of Formula 1, and combine the formulations with each other before application (for example, in a spray tank) or, alternatively, apply them successively. As mentioned in the Summary of the Invention, one aspect of the present invention is a fungicidal composition comprising (i.e., a mixture or combination of) a compound of Formula 1, an A / -oxide or a salt thereof (i.e. i.e. component a), and at least one other fungicide (i.e. component b). It is worth highlighting a combination of this type where the other fungicide active ingredient has a different site of action than the compound of Formula 1. In certain cases, a combination with at least one different fungicide active ingredient will be particularly advantageous for resistance management. that has a similar spectrum of control but a different site of action. Therefore, a composition of the present invention may further comprise a fungicide-effective amount of at least one additional fungicide active ingredient having a similar control spectrum but a different site of action. Examples of fungicides of component (b) include acibenzolar-S-methyl, aldimorf, ametoctradine, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl-M), benodanil, benomyl, bentiavalicarb (including bentiavalicarb-isopropyl), benzovindiflupyr, betoxazine, binapacryl, biphenyl, bitertanol, bixaphene, blasticidin-S, boscalide, bromuconazole, bupirimate, butiobate, captafol, capitan, carbendazim, carboxin, carpropamid, chloroneb, chlorothalonil, clozolinate, clotrimazole, copper hydroxide, copper oxychloride, sulfate Copper, cumoxiestrobin, ciazofamid, kflufenamide, decent, cyproconazole, cypodinyl, diclofluanid, diclocimet, diclomecin, diclorean, dietofencarb, difenoconazole, difflumetorim, sleeping, dimetomorf, dimoxiestrobine, dynamonazole (including M), Dinocap, ditianón, ditiolanós, dodemorf, dodine, dipimethrone, econazole, edifenphos, enoxaestrobin (also known as enestroburin), epoxiconazole, etaconazole, etaboxam, etirimol, etridiazole, famoxadone, fenamidone, fenarimol, phenaminestrobin, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidine, fenpropimor f, fenpyrazamine, fentine acetate, fentine chloride, fentine hydroxide, ferbam, ferimzone, flomethoquine, florilpicoxamid, fluazinam, fludioxonil, fluphenoxystrobin, fluindapir, flumorph, fluopicolide, fluopimomide, fluopyram, flouroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, phthalide, fuberidazole, furalaxil, furametpir, guazatine, hexaconazole, himexazole, imazalil, imibenconazole, iminoctadine albesylate, iminoctadine triacetate, iodocarb, ipconazole, ipfentrifluconazole, iprobenphos, iprodione, iprovalicarb, isoconazole, isof etamide, isoprothiolane, isoflucipram, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandepropamid, mandestrobin, maneb, mepanipirim, mepronil, meptyldinocap, metalaxyl (including metalaxyl-M / mefenoxam), mefentrifluconazole, metconazole, metasulfocarb, metiram, metominoestrobin, metrafenone, miconazole, myclobutanil, naftifine, neo-asozine, nuarimol, octylinone, ofurace, orisastrobin, oxadixil, oxathiapiproline, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, pefurazoate, penconazole, pencicuron, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g. fosetyl-aluminum), picarbutrazox, picoxystrobin, piperaline, polyoxin, probenazole, prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, piribencarb, piributicarb, pirifenox, pyrimethanil, pyrio phenone, pyrisoxazole , piroquilon, pyrolnitrin, biweekly, quinofumelin (registration number 861647-84-9) Quinometionate, quinoxycene, fifth, silkaxan, siltiofam, simheconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquina, telloftalam, technozen aconazole, tiabendazole, tifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclophos-methyl, tolnifanide, tolprocarb, tolifluanid, triadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole, triclopiricarb, tridemorph, trifloxiestrobin, triflumizole, triforin, trimorf amide , uniconazole, uniconazol-P, validamicin, valifenalate (also known as valifenal), vinclozolin, zineb, ziram, zoxamide, Λ / -[2-(1 S,2ñ)-[1,1 '-bicycloprop¡l]-2 -¡ líen i l]-3-(d if I uoromethyl) -1 -methyl-1 Z7-pyrazole-4-carboxamide, a(1-chlorocycloprop¡l)-a-[2-(2,2-dichlorocycloprop ¡l)ethyl¡l]-1 / 7-1,2,4-triazol-1-ethanol, (aS)-[3-(4-chloro-2-fluorophenyl)5-(2,4-difluorophenyl)- 4-isoxazolyl]-3-pyridinomethanol, relC -[[(2fi,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2oxiranyl]methyl]-1 / 7- 1,2,4-triazole, re / -2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2dihydro -3 / 7-1,2,4-triazol-3-thione, re / -1-[[(2F?,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl) -2-oxiraníl]methyl]-5-(2propen-1 -ylthio)-1 / 7-1,2,4-triazole, Z\ / -[2-[4-[[3-(4-chlorophen ¡l)-2-prop¡n-1-¡l]ox¡]-3-methoxy¡phen¡l]ethyl]-3-met¡l-2[(methylsulfonyl)amino]butanamide , / V-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1 -yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2[(ethylsulfonyl)amino]butanam ¡da, / V-[4-[4-chloro-3-(trifluoromethyl)phenoxy¡]-2,5-dimethylphen¡l]- / \ / -ethyl¡l- / \ / methylmetanimidamide, Z \Z-[[(cycloprop¡lmethox¡)am¡no][6-(d¡fluoromethox¡)-2,3difluorophenyl]methylene]benzeneacetam¡de, Z\ / -[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1 / 7-pyrazole-4-carboxamide, / V-(3',4'-difluoro[ 1,1'-biphenyl]-2-yl)-3-(trifluoromethyl)-2-pyrazinecarboxamide, 3-(difluoromethyl)-A / -(2,3-dihydro-1,1,3-trimethyl-1 / 7-inden-4-I)-1 -methyl-1 / 7-pyrazole-4-carboxamide, 5,8-difluoro / V-[2-[3-methoxy¡-4-[[4-(tnfluoromethyl) -2-pyridínl]oxy]phenyl]ethyl]-4-quinazolinamine, 1-[4-[4-[5 / 7-[(2,6difluorophenoxy)methyl]-4, 5-dihydro-3-isoxazolíl]-2-thiazolyl]-1 -piperdiníl]-2-[5-methyl-3-(trifluoromethyl)-1 / 7-pyrazole-1 yljetanone, Λ / -[1 -[[[1 -(4-cyanophen¡l)ethyl]sulfon¡l]methyl]propyl]carbamate 4-fluorophenyl, 5-fluoro-2-[(4fluorophen¡l)methoxy]-4- p¡nmid¡nam¡ne, a-(methoxy¡mino)-A / -methyl-2-[[[1-[3(trifluoromethyl)phenyl]ethoxy¡]im¡no]methyl]benzeneacetam¡ da and [[4-methoxy¡-2[[[(3S,7 / ?,8F?,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-2-methylpropanoate dioxo-7-(phenylmethyl)-1,5-dioxonan-3yl]amino]carbonyl]-3-pyridinyl]oxy]methyl. Therefore, it is worth highlighting a fungicide composition that comprises as component (a) a compound of Formula 1 (or a Z\Z-oxide or a salt thereof) and as component (b) at least one fungicide selected from the previous list. ., Particularly noteworthy are combinations of compounds of Formula 1 (or a ΛΖ-oxide or a salt thereof) (i.e., Component (a) in the compositions) with compounds of component (b) selected from aminopyrifene (Registration Number 1531626- 08-0) , dimethomorph, epoxiconazole, etaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapir, fluopyram, flusilazol, flutianil, flutriafol, fluxapiroxad, folpet, ipflufenoquine (Registration Number MA / 1314008-27-9), prodione, isofetamide, isoflucipram, isopyrazam, kresoxim-methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M / mefenoxam), mefentrifluconazole, metconazole, metrafenone, methyltetraprol (Registration Number 1472649-01 -6), myclobutanil, oxathiapiproline, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g. fosetylaluminum), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyridaclomethyl (Registration Number 1358061 -55-8), pyraclostrobin, pyrapropoin (Registration Number 1803108-03-3), pyrimethanil, sedaxane spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxiestrobin, zoxamide, a-(1-chlorocyclopropyl)-a-[2(2,2-dichlorocyclopropyl)ethyl]- 1 / 7-1,2,4-triazol-1-ethanol, 2-[2-(1 -chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2h hydroxybutyl]-1,2-dih id ro-3 H-1,2,4-triazol-3-thione, A / -[2-(2,4-dichlorophenyl)-2-methoxy¡-1 -methyl letyl]-3(difluoromethyl)-1 -methyl-1 / 7-pyrazole-4-carboxamide, 3-(difluoromethyl)-A / -(2,3-dihydro-1,1,3-trimethyl-1 / 7-inden-4yl)-1 -methyl-1 / 7-pyrazole-4-carboxamide, 1 -[4-[4-[5 / 7-(2,6-d¡fluorophenyl)-4,5-di¡ h id ro-3-isoxazolyl]-2-thiazole i I]-1 piperidin yl]-2-[5-methyl-3-(trifluoromethi l)-1 / 7-pyrazol-1 -yl]ethanone, A / -[6-[[[[( 1 1,1-Dimethylethyl-methyl-1 / 7-tetrazol-5yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, dipimethitrone, 5-fluoro-2-[( 4fluorophenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[ (4-methylphenyl)methoxy]-4-pyrimidinamine, (aS)-[3-(4 -chloro-2fluorophenyl)-5-(2,4-difluorophenyl)-4-soxazolyl]-3-pyridinmethanol, re / -1-[[(2F?,3S)-3-(2 -chlorophenyl)-2-(2,4difluorophenyl)-2-ox¡ran¡l]met¡l]-1 HA ,2,4-triazole, re / -2-[[(2 / :?,3S)- 3-(2-chlorophenyl)-2-(2.4-difluorophenyl)-2oxiranyl]methyl]-1,2-dihydro-3 / 7-1,2,4-triazole-3-thione, and relA - [[(2fi,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2oxiranyl]methyl]-5-(2-propen-1 -ylthio)-1 / 7-1,2 ,4-triazole (i.e., as Component (b) in the compositions). Particularly noteworthy are combinations of compounds of Formula 1 (or a / V-oxide or a salt thereof) (i.e., Component (a) in the compositions) with the compounds of component (b) selected from aminopyrifene (Registration Number 1531626-08-0) , difenoconazole, dimethomorph, dipimethitrone, epoxiconazole, etaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapir, fluopyram, flusilazol, flutian¡lo, flutriafol, fluxapiroxad, folpet, ipflufenoquine (Registration Number 1314008-27-9), prodione, isofetamide, isoflucipram, isopyrazam, kresoxim-methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M / mefenoxam), mefentrifluconazole, metconazole, metrafenone, methyltetraprol (Registration Number 1472649-01-6), myclobutanil, oxathiapiproline, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g. fosetylaluminium), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyridaclomethyl (Registration Number 1358061-55-8), pyraclostrobin, pyrapropoin (Registration Number 1803108-03-3) , pyrimethanil, sedaxane spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, a-(1-chlorocyclopropyl)-a-[2(2,2-dichlorocyclopropyl)ethyl]-1 / 7-1,2, 4-triazol-1-ethanol, A / -[2-(2,4-dichlorophenyl)-2-methoxy¡-1-methylethyl]-3(difluoromethyl)-1-methyl-1 / 7-pyrazole-4-carboxamide , 3-(difluoromethyl)-A / -(2,3-dihydro-1,1,3-trimethyl-1 / 7-ynden-4yl)-1-methyl-1 / 7-pyrazole -4-carboxamide, 1 -[4-[4-[5 / 7-(2,6-difluorophenyl)-4,5-di h id ro-3-isoxazol yl]-2-thiazol i I]-1 piperidine yl]-2-[5-methyl-3-(trif luorometi I)-1 / 7-pyrazol-1 -yljetanone, W-[6-[[[[(1 -methyl-1 / 7-tetrazol-5yl) 1,1-Dimethylethyl phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4pyrimidinamine, (cS)-[3- (4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolíl]-3-pyridinomethanol, relAΜΛ / [[(2fi,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiraníl]methyl]-1 H-1,2,4-triazole, re / -2-[[(2ñ,3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole- 3-thione and re / -1-[[(2fi,3S)-3-(2chlorophen i I)-2-(2,4-dif luorophen i l)-2-ox iranyl] methyl]-5-(2- propen-1 -ylthio)-1 H-1,2,4-triazole (i.e. as Component (b) in the compositions). Generally, for better c Generally, for better control of plant diseases caused by fungal phytopathogens (e.g., lower use rate or broader spectrum of controlled phytopathogens) or resistance management, mixtures of a compound of Formula 1, an A / -oxide or a salt thereof, with a fungicidal compound selected from the group: amisulbrom, azoxystrobin, benzovindiflupyr, bixaphene, boscalide, carbendazim, carboxin, chlorothalonllo, copper hydroxide, cymoxanil, cyproconazole, difenoconazole, dimethomorph, dimoxystrobin, epoxiconazole, fenpropidine , fenpropimorph, florilpicoxamid, fluazinam, fludioxonil, fluphenoxystrobin, fluindapir, fluquinconazole, fluopicol ida, fluoxaestrobin, flutriafol, fluxapiroxad, ipconazole, ipfentrifluconazole, iprodione, kresoxim-methyl, mancozeb, metalaxyl, mefenoxam, mefentrifluconazole, metconazole, metominoestro bina, myclobutanil, paclobutrazol , penflufen, picoxystrobin, prothioconazole, pidiflumethofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriophenone, sedaxane, siltiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole. In the fungicidal compositions of the present invention, component (a) (i.e., at least one compound selected from compounds of Formula 1, A / -oxides and salts thereof) and component (b) are present in effective amounts as a fungicide. The weight ratio of component (b) (i.e., one or more additional fungicidal compounds) to component (a) is generally between about 1:3000 and about 3000:1 and more typically from about 1:500 to about 500:1. . Noteworthy are the compositions where the weight ratio of component (a) to component (b) is from approximately 125:1 to approximately 1:125. Noteworthy are compositions where the weight ratio of component (a) to component (b) is from about 25:1 to about 1:25, or from about 5:1 to about 1:5. One skilled in the art can determine, through simple experimentation, the weight ratios and application rates of the fungicide compounds necessary for the desired spectrum of fungicide protection and control. It will be apparent that the inclusion of additional fungicidal compounds in component (b) may broaden the spectrum of plant diseases controlled beyond the spectrum controlled by component (a) alone. Additionally, examples of weight ratios for combinations of fungicidal compounds of the present invention are provided below in Tables A1-A15 and C1-C15. Table B1 below lists the typical, most typical and most typical ranges of ratios involving particular fungicidal compounds of component (b). Table A1 discloses specific mixtures of a compound of component (a) with a compound of component (b). Compounds in component (a) are identified by their compound number; see Index Tables A-B for a description of the compounds. Entries headed Illustrative Ratios disclose three specific weight ratios of Component (a) to Component (b) for the disclosed mixture. For example, the first line of Table A1 discloses a mixture of Compound 1 of the present invention with acibenzolar-S-methyl, with weight ratios of Compound 1 to acibenzolar-S-methyl of 1:1, 1:4 or 1:18. M A / t / ZUZZ / U / 4ZÓU Component Component (b) Illustrative relations 5 (a)]*) Compound 1 acibenzolar-S-methyl 1:1 1:4 1:18 Compound 1 aldimorph 7:1 3:1 1:1 Compound 1 ametoctradine 3:1 1: 1 1:3 Compound 1 amisulbrom 1:1 1:2 1:6 10 Compound 1 anylazine 22:1 8:1 4:1 Compound 1 azaconazole 2:1 1:2 1:4 Compound 1 azoxystrobin 3:1 1:1 1:3 Compound 1 benalaxyl 1:1 1:2 1:6 Compound 1 benalaxyl-M 1:1 1:3 1:8 15 Compound 1 benodanyl 4:1 2:1 1:2 Compound 1 benomyl 11:1 4: 1 1:1 Compound 1 bentiavalicarb 1:1 1:4 1:12 Compound 1 bentiavalicarb-isopropyl 1:1 1:4 1:12 Compound 1 bethoxazine 15:1 5:1 2:1 20 Compound 1 binapacryl 15:1 5 :1 2:1 Compound 1 biphenyl 15:1 5:1 2:1 Compound 1 bitertanol 3:1 1:1 1:2 Compound 1 bixaphene 2:1 1:1 1:3 Compound 1 blasticidin-S 1:4 1 :12 1:30 25 Compound 1 Bordeaux mixture (tribasic copper sulfate) 45:1 15:1 5:1 Compound 1 boscalide 4:1 2:1 1:2 Compound 1 bromuconazole 3:1 1:1 1:3 Compound 1 Bupirimate 1:3 1:10 1:30 Compound 1 Captafol 15:1 5:1 2:1 30 Compound 1 Captan 15:1 5:1 2:1 Compound 1 Carbendazim 11:1 4:1 2:1 Compound 1 carboxine 4:1 2:1 1:2 Compound 1 carpropamid 3:1 1:1 1:3 Compound 1 chloroneb 100:1 35:1 14:1 35 Compound 1 chlorothalonyl 15:1 5:1 2:1 Compound 1 clozolinate 11:1 4:1 2:1 Compound 1 clotrimazole 3:1 1:1 1:3 Compound 1 copper hydroxide 45:1 15:1 5:1 Component Component (b) Illustrative relations (a) (*) Compound 1 copper oxychloride 45:1 15:1 5 1 Compound 1 cyazofamid 1:1 1:2 1 6 5 Compound 1 cyflufenamide 1:2 1:6 1 24 Compound 1 cymoxanil 1:1 1:2 1 5 Compound 1 cyproconazole 1:1 1:2 1 6 Compound 1 cyprodinil 4:1 2:1 1 2 Compound 1 dichlofluanid 15:1 5:1 2 1 10 Compound 1 diclocimet 15:1 5:1 2 1 Compound 1 diclomezine 3:1 1:1 1 3 Compound 1 dichlorane 15:1 5:1 2 1 Compound 1 dietofencarb 7:1 2:1 1 2 Compound 1 difenoconazole 1:1 1:3 1 12 15 Compound 1 diflumetorim 15:1 5:1 2 1 Compound 1 dimethirimol 1:3 1:8 1 30 Compound 1 dimethomorph 3:1 1:1 1 2 Compound 1 dimoxystrobin 2:1 1:1 1 4 Compound 1 diniconazole 1:1 1:3 1 8 20 Compound 1 diniconazol-M 1:1 1:3 1 12 Compound 1 dinocap 2:1 1:1 1 3 Compound 1 dithianon 5:1 2:1 1 2 Compound 1 dodemorph 7:1 3:1 1 1 Compound 1 dodine 10:1 4:1 2 1 25 Compound 1 edifenphos 3:1 1:1 1 3 Compound 1 enstroburin 2:1 1:1 1 4 Compound 1 epoxiconazole 1:1 1:3 1 7 Compound 1 etaconazole 1:1 1:3 1 7 Compound 1 etaboxam 2:1 1:1 1 3 30 Compound 1 ethirimol 7:1 3:1 1 1 Compound 1 etridiazole 7:1 2:1 1 2 Compound 1 famoxadone 2:1 1: 1 1 4 Compound 1 phenamidone 2:1 1:1 1 4 Compound 1 phenaminestrobin 3:1 1:1 1 3 35 Compound 1 fenarimol 1:2 1:7 1 24 Compound 1 fenbuconazole 1:1 1:3 1 10 Compound 1 fenfuram 4:1 1:1 1 2 Compound 1 fenhexamid 10:1 4:1 2 1 Component (a) Component (b) Illustrative relationships(*) fenoxanyl fenpiclonyl Compound 1 Compound 1 15:1 15:1 4:1 5:1 1:1 2:1 5 Compound 1 fenpropidine 7:1 2:1 1:1 Compound 1 fenpropimorph 7:1 2:1 1:1 Compound 1 fenpyrazamine 3:1 1:1 1:3 Compound 1 fentin salt such as fentin acetate, fentin chloride or fentin hydroxide 3:1 1:1 1: 3 10 Compound 1 ferbam 30:1 10:1 4:1 Compound 1 ferimzone 7:1 2:1 1:2 Compound 1 fluazinam 3:1 1:1 1:2 Compound 1 fludioxonil 2:1 1:1 1:4 Compound 1 flumetover 3:1 1:1 1:2 15 Compound 1 flumorph 3:1 1:1 1:3 Compound 1 fluopicolide 1:1 1:2 1:6 Compound 1 fluopyram 3:1 1:1 1:3 Compound 1 fluoroimide 37:1 14:1 5:1 Compound 1 fluoxastrobin 1:1 1:2 1:6 20 Compound 1 fluquinconazole 1:1 1:2 1:4 Compound 1 flusilazole 3:1 1:1 1:3 Compound 1 flusulfamide 15:1 5:1 2:1 Compound 1 flutianil 1:1 1:2 1:6 Compound 1 flutolanil 4:1 1:1 1:2 25 Compound 1 flutriafol 1:1 1:2 1:4 Compound 1 fluxapyroxad 2:1 1:1 1:3 Compound 1 folpet 15:1 5:1 2:1 Compound 1 fosetyl-aluminum 30:1 12:1 5:1 Compound 1 fuberidazole 11:1 4:1 2:1 30 Compound 1 furalaxyl 1:1 1:2 1:6 Compound 1 furametpyr 15:1 5:1 2:1 Compound 1 guazatine 15:1 5:1 2:1 Compound 1 hexaconazole 1:1 1:2 1:5 Compound 1 himexazol 75 :1 25:1 9:1 35 Compound 1 imazalyl 1:1 1:2 1:5 Compound 1 imibenconazole 1:1 1:2 1:5 Compound 1 iminoctadine 15:1 4:1 1:1 Compound 1 iodocarb 15: 1 5:1 2:1 ΜΛ / 1 / ¿ U¿ ¿ / U / 4ZÓU Component Component (b) Illustrative relations (a) (*) Compound 1 ipconazole 1:1 1:2 1 5 Compound 1 iprobenphos 15:1 5:1 2 1 5 Compound 1 iprodione 15:1 5:1 2 1 Compound 1 iprovalicarb 2:1 1:1 1 3 Compound 1 isoprothiolane 45:1 15:1 5 1 Compound 1 isopyrazam 2:1 1:1 1 3 Compound 1 isotianyl 2:1 1:1 1 3 10 Compound 1 kasugamycin 1:2 1: 7 1 24 Compound 1 kresoxim-methyl 2:1 1:1 1 4 Compound 1 mancozeb 22:1 7:1 3 1 Compound 1 mandipropamid 2:1 1:1 1 4 Compound 1 maneb 22:1 7:1 3 1 15 Compound 1 mepanipyrim 6:1 2:1 1 1 Compound 1 mepronyl 1:1 1:2 1 6 Compound 1 meptyldinocap 2:1 1:1 1 3 Compound 1 metalaxyl 1:1 1:2 1 6 Compound 1 metalaxyl-M 1 :1 1:4 1 12 20 Compound 1 metconazole 1:1 1:2 1 6 Compound 1 metasulfocarb 15:1 5:1 2 1 Compound 1 methiram 15:1 5:1 2 1 Compound 1 metominostrobin 3:1 1:1 1 3 Compound 1 metrafenone 2:1 1:1 1 4 25 Compound 1 myclobutanyl 1:1 1:3 1 8 Compound 1 naphthifine 15:1 5:1 2 1 Compound 1 neo-asozine (ferric methanoarsonate) 15:1 5: 1 2 1 Compound 1 nuarimol 3:1 1:1 1 3 Compound 1 octylinone 15:1 4:1 1 1 30 Compound 1 ofu race 1:1 1:2 1 6 Compound 1 orisastrobin 3:1 1:1 1 3 Compound 1 oxadixyl 1:1 1:2 1 6 Compound 1 oxolinic acid 7:1 2:1 1 2 Compound 1 oxpoconazole 1:1 1:2 1 5 35 Compound 1 oxycarboxine 4:1 1:1 1 2 Compound 1 oxytetracycline 3: 1 1:1 1 3 Compound 1 pefurazoate 15:1 5:1 2 1 Compound 1 penconazole 1:2 1:6 1 15 Component Component (b) Illustrative relations (a) (*) Compound 1 pencicuron 11:1 4:1 2:1 Compound 1 penflufen 2:1 1:1 1:3 5 Compound 1 penthiopyrad 2:1 1:1 1:3 Compound 1 phosphorous acid or a salt thereof 15:1 6:1 2:1 Compound 1 phthalide 15:1 6:1 2:1 Compound 1 picoxystrobin 1:1 1:2 1:5 Compound 1 piperaline 3:1 1: 1 1:3 10 Compound 1 polyoxin 3:1 1:1 1:3 Compound 1 probenazole 3:1 1:1 1:3 Compound 1 prochloraz 7:1 2:1 1:2 Compound 1 procymidone 11:1 4:1 2:1 Compound 1 propamocarb or propamocarb hydrochloride 10:1 4:1 2:1 15 Compound 1 propiconazole 1:1 1:2 1:5 Compound 1 propineb 11:1 4:1 2:1 Compound 1 proquinazid 1:1 1:3 1:12 Compound 1 prothiocarb 3:1 1:1 1:3 Compound 1 prothioconazole 1:1 1:2 1:5 20 Compound 1 pyraclostrobin 2:1 1:1 1:4 Compound 1 pyrametostrobin 2:1 1 :1 1:4 Compound 1 pyroxystrobin 2:1 1:1 1:4 Compound 1 pyrazophos 15:1 4:1 1:1 Compound 1 pyribencarb 4:1 1:1 1:2 25 Compound 1 pyributicarb 15:1 4: 1 1:1 Compound 1 pyrifenox 3:1 1:1 1:3 Compound 1 pyrimethanyl 3:1 1:1 1:2 Compound 1 pyriophenone 2:1 1:1 1:4 Compound 1 pyrisoxazole 3:1 1:1 1 :3 30 Compound 1 pyroquilone 3:1 1:1 1:3 Compound 1 pyrrolnitrin 15:1 5:1 2:1 Compound 1 quinconazole 1:1 1:2 1:4 Compound 1 quinomethionate 15:1 5:1 2: 1 Compound 1 quinoxifene 1:1 1:2 1:6 35 Compound 1 quintazene 15:1 5:1 2:1 Compound 1 silthiopham 2:1 1:1 1:4 Compound 1 simeconazole 1:1 1:2 1:5 Compound 1 spiroxamine 5:1 2:1 1:2 MA / t / ¿ U / Component Component (b) Illustrative relations (a) (*) Compound 1 streptomycin 3:1 1:1 1 3 Compound 1 sulfur 75:1 25:1 9 1 5 Compound 1 tebuconazole 1:1 1:2 1 5 Compound 1 tebufloquine 3:1 1:1 1 3 Compound 1 teclofthalam 15:1 5:1 2 1 Compound 1 technazene 15:1 5:1 2 1 Compound 1 terbinafine 15:1 5:1 2 1 10 Compound 1 tetraconazole 1:1 1: 2 1 5 Compound 1 thiabendazole 11:1 4:1 2 1 Compound 1 tifluzamide 3:1 1:1 1 3 Compound 1 thiophanate 11:1 4:1 2 1 Compound 1 thiophanate-methyl 11:1 4:1 2 1 15 Compound 1 thiram 37:1 14:1 5 1 Compound 1 thiadinyl 2:1 1:1 1 3 Compound 1 tolclophos-methyl 37:1 14:1 5 1 Compound 1 tolnifanide 3:1 1:1 1 3 Compound 1 tolylfluanide 15 :1 5:1 2 1 20 Compound 1 triadimefon 1:1 1:2 1 5 Compound 1 triadimenol 1:1 1:2 1 5 Compound 1 triarimol 1:2 1:7 1 24 Compound 1 triazoxide 15:1 5:1 2 1 Compound 1 tricyclazole 3:1 1:1 1 3 25 Compound 1 tridemorph 7:1 2:1 1 1 Compound 1 trifloxiestrobin 2:1 1:1 1 4 Compound 1 triflumizole 3:1 1:1 1 3 Compound 1 triforin 3:1 1:1 1 3 Compound 1 trimorphoamide 7:1 2:1 1 2 30 Compound 1 triticonazole 1:1 1:2 1 5 Compound 1 uniconazole 1:1 1:2 1 5 Compound 1 validamycin 3:1 1: 1 1 3 Compound 1 valifenalate 2:1 1:1 1 4 Compound 1 vinclozolin 15:1 6:1 2 1 35 Compound 1 zineb 37:1 14:1 5 1 Compound 1 ziram 37:1 14:1 5 1 Compound 1 zoxamide 2:1 1:1 1 4 ΜΛ / Component Component (b) Illustrative relations (a) (*) Compound 1 5-chloro-6-(2,4,6-trifluorophen¡l)-7-(4-methylp¡perídin-1 il )[1,2,4]triazolo[1,5-a]pyrimídine (DPX-BAS600F) 1:1 1:2 1:6 Compound 1 / V-[2-[4-[[3- (4-chlorophenyl)-2-prop¡n-1-¡l]ox¡]-3- methoxyphenyl]ethyl]-3-methyl-2- [(methylsulfonyl)amino]butanamide 2:1 1:1 1 :4 Compound 1 A / -[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-¡l]ox¡]-3- methoxyphenyl]ethyl]-3-methyl-2- [ (ethylsulfonyl)amino]butanamide 2:1 1:1 1:4 Compound 1 Λ / -[1 -[[[1 -(4-cyanophen¡l)et¡l]sulfon¡l]methyl 4-fluorophenyl ]prop¡l]carbamate 2:1 1:1 1:4 Compound 1 a-[methoxy¡mino]-A / -methyl-2-[[[1-[3- (trifluoromet ¡l)phenyl]ethoxy]imino]methyl]benzeneacetam¡de 3:1 1:1 1:3 Compound 1 / V-[4-[4-chloro-3-(trifluoromet¡l)phenoxy¡]-2 ,5-dimethylphenyl]-A / ethyl-AZ-methylmetanimidamide 3:1 1:1 1:3 (*) Ratios of Component (b) with respect to Component (a) by weight. Tables A2 to A15 are each constructed the same as Table A1 above except that the entries under the Component (a) column heading are replaced by the respective entry in the Component (a) column shown below. Thus, for example, in Table A2, the entries under the column heading Component (a) all list Compound 18. Therefore, the first entry in Table A2 specifically discloses a mixture of Compound 18 with acibenzolar- S-methyl. Tables A3 to A15 are constructed similarly. Column Entry Number Column Entry Number table Component (a) table Component (a) A2 Compound 18 A9 Compound 73 A3 Compound 19 A10 Compound 93 A4 Compound 23 A11 Compound 111 A5 Compound 57 A12 Compound 112 A6 Compound 60 A13 Compound 118 A7 Compound 68 A14 Compound 121 A8 Compound 72 A15 Compound 127 Table B1 lists combinations of a compound of Component (b) with a compound of Component (a) illustrative of the mixtures, compositions and methods of the present invention. The first column of Table B1 lists the specific Component (b) compound (e.g., acibenzolarS-methyl is the first entry). Listed in the second, third, and fourth columns of Table B1 are ranges of weight ratios for the rates at which the compound of Component (a) is typically applied to a field-grown crop relative to Component (b). Therefore, for For example, the first line of Table B1 discloses that the combination of a compound of Component (a) with acibenzolar-S-methyl is typically applied at a weight ratio of Component (a) to Component (b) of between 2 :1 to 1:180, most typically between 1:1 to 1:60, and most typically between 1:1 to 1:18. The remaining lines of Table B1 are to be interpreted in a similar way. Noteworthy is a composition comprising a mixture of any one of the compounds listed in Embodiment 97 as Component (a) with a compound listed in the Component (b) column of Table B1 according to the weight ratios disclosed in the Table B1. Table B1 therefore complements the specific ratios disclosed in Tables A1 to A15 with ranges of ratios for these combinations. Table B1 Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio acibenzolar-S-methyl from 2:1 to 1:180 from 1:1 to 1:60 from 1:1 to 1:18 aldimorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 ametoctradine 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 amisulbrom 6:1 to 1:18 2:1 to 1:6 1:1 to 1:6 anylazine 90:1 to 2:1 30:1 to 4:1 22:1 to 4:1 azaconazole 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 azoxystrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 benalaxyl 4:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1:6 benalaxyl-M from 4:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:8 benodanyl from 18:1 to 1:6 from 6:1 to 1:2 from 4:1 to 1:2 benomyl from 45:1 to 1:4 from 15:1 to 1:1 from 11:1 to 1:1 bentiavalicarb or bentiavalicarb-isopropyl from 2:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:12 bethoxazine from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 binapacryl from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 biphenyl from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 bitertanol from 15:1 to 1:5 from 5:1 to 1:2 from 3:1 to 1:2 bixafen from 12:1 to 1:9 from 4:1 to 1:3 from 2:1 a 1:3 blasticidin-S from 3:1 to 1:90 from 1:1 to 1:30 from 1:4 to 1:30 boscalide from 18:1 to 1:6 from 6:1 to 1:2 from 4 :1 to 1:2 bromuconazole from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 bupirimate from 3:1 to 1:90 from 1:1 to 1:30 from 1 :3 to 1:30 Captafol from 90:1 to 1:4 from 30:1 to 1:2 from 15:1 to 2:1 Captano from 90:1 to 1:4 from 30:1 to 1:2 from 15 :1 to 2:1 Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio carbendazim from 45:1 to 1:4 from 15:1 to 1:2 from 11:1 to 2:1 carboxine from 18:1 to 1:6 from 6:1 to 1:2 from 4:1 to 1:2 carpropamid from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 chloroneb from 300:1 to 2:1 from 100:1 to 4:1 from 100:1 to 14:1 chlorothalonyl from 90:1 to 1:4 from 30:1 to 1:2 from 15:1 to 2:1 clozolinate from 45:1 to 1 :2 from 15:1 to 2:1 from 11:1 to 2:1 clotrimazole from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 copper salts such as the mixture Bordeaux (tribasic copper sulphate), copper oxychloride, copper sulphate and copper hydroxide from 450:1 to 1:1 from 150:1 to 4:1 from 45:1 to 5:1 ciazofamid from 4:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1:6 cyflufenamide from 1:1 to 1:90 from 1:2 to 1:30 from 1:2 to 1:24 cymoxanil from 6:1 to 1:18 from 2:1 to 1:6 from 1:1 to 1:5 cyproconazole from 4:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1:6 cyprodinil from 22:1 to 1:9 from 7:1 to 1:3 from 4:1 to 1:2 diclofluanid from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 diclocimet from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 diclomezine from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 dichlorane from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 dietofencarb from 22:1 to 1:9 from 7:1 to 1:3 from 7:1 to 1:2 difenoconazole from 4:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:12 diflumetorim from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 dimethimol from 3:1 to 1:90 from 1:1 to 1:30 from 1:3 to 1:30 dimethomorph from 9:1 to 1:6 from 3:1 to 1:2 from 3:1 to 1:2 dimoxystrobin from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 diniconazole from 3:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:8 diniconazole M from 3:1 to 1:90 from 1:1 to 1:30 from 1:1 to 1:12 dinocap from 7:1 to 1:9 from 2:1 to 1:3 from 2:1 to 1:3 ditianon from 15:1 to 1:4 from 5:1 to 1:2 from 5:1 to 1:2 dodemorph from 30:1 to 1:3 from 10:1 to 1:1 from 7:1 to 1:1 dodina from 30:1 to 1:2 from 10:1 to 2:1 from 10:1 to 2:1 edifenfós from 30:1 to 1:9 from 10:1 to 1:3 from 3:1 to 1:3 Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio enstroburin from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 epoxiconazole from 3:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:7 etaconazole from 3:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:7 etaboxam from 7:1 to 1:9 from 2:1 to 1:3 from 2:1 to 1:3 etirimol from 30:1 to 1:3 from 10:1 to 1:1 from 7:1 to 1:1 etridiazole from 30:1 to 1:9 from 10:1 to 1:3 from 7:1 to 1:2 famoxadone from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 fenamidone from 6:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 phenaminestrobin from 9:1 to 1:18 from 3:1 to 1:6 from 3:1 to 1:3 fenarimol from 3:1 to 1:90 from 1:1 to 1:30 from 1:2 to 1:24 fenbuconazole from 3:1 to 1:30 from 1:1 to 1:10 from 1:1 to 1:10 fenfuram from 18:1 to 1:6 from 6:1 to 1:2 from 4:1 to 1:2 fenhexamid from 30:1 to 1:2 from 10:1 to 2:1 from 10:1 to 2:1 fenoxanyl from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 1:1 fenpiclonil from 75:1 to 1:9 from 25:1 to 1:3 from 15:1 to 2:1 fenpropidine from 30:1 to 1:3 from 10:1 to 1:1 from 7:1 to 1:1 fenpropimorph from 30:1 to 1:3 from 10:1 to 1:1 from 7:1 to 1:1 fenpyrazamine from 100:1 to 1:100 from 10:1 to 1:10 from 3:1 to 1:3 fentine salt such as acetate, chloride or hydroxide from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 ferbam from 300:1 to 1:2 from 100:1 to 2:1 from 30:1 to 4:1 ferimzona from 30:1 to 1:5 from 10:1 to 1:2 from 7:1 to 1:2 fluazinam from 22:1 to 1:5 from 7:1 to 1:2 from 3:1 to 1:2 fludioxonil from 7:1 to 1:12 from 2:1 to 1:4 from 2:1 to 1:4 flumetover from 9:1 to 1:6 from 3:1 to 1:2 from 3:1 to 1:2 flumorph from 9:1 to 1:18 from 3:1 to 1:6 from 3:1 to 1:3 fluopicolide from 3:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1:6 fluopyram from 15:1 to 1:90 from 5:1 to 1:30 from 3:1 to 1:3 fluoromide 150:1 to 2:1 50:1 to 4:1 37:1 to 5:1 fluoxastrobin 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 fluquinconazole from 4:1 to 1:12 from 1:1 to 1:4 from 1:1 to 1:4 flusilazol from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 flusulfamide from 90:1 to 1:2 from 30:1 to 2:1 from 15:1 to 2:1 MA / t / ZUZZ / U / 4ZÓU Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio flutianyl from 7:1 to 1:36 from 2:1 to 1:12 from 1:1 to 1:6 flutolanyl from 18:1 to 1:6 from 6:1 to 1:2 from 4:1 to 1:2 flutriafol from 4:1 to 1:12 from 1:1 to 1:4 from 1:1 to 1:4 fluxapiroxad from 12:1 to 1:9 from 4:1 to 1:3 from 2:1 to 1:3 folpet from 90:1 to 1:4 from 30:1 to 1:2 from 15:1 to 2:1 fosetyl-aluminum of 225: 1 to 2:1 from 75:1 to 5:1 from 30:1 to 5:1 fuberidazole from 45:1 to 1:4 from 15:1 to 1:2 from 11:1 to 2:1 furalaxil from 15: 1 to 1:45 from 5:1 to 1:15 from 1:1 to 1:6 furametpyr from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 guazatine or iminoctadine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 hexaconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 himexazole 225:1 to 2:1 75:1 to 4:1 75:1 to 9:1 imazalyl 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 imibenconazole 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 iodocarb from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 ipconazole 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 iprobenphos from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 iprodione 120:1 to 1:2 40:1 to 2:1 15:1 to 2:1 iprovalicarb 9:1 to 1:9 3:1 to 1:3 2:1 to 1:3 isoprothiolane 150:1 to 2:1 50:1 to 4:1 45:1 to 5:1 isopyrazam 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 isotianyl 12:1 to 1:9 from 4:1 to 1:3 from 2:1 to 1:3 kasugamycin from 7:1 to 1:90 from 2:1 to 1:30 from 1:2 to 1:24 kresoxim- methyl from 7:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 mancozeb from 180:1 to 1:3 from 60:1 to 2:1 from 22:1 to 3:1 mandipropamid from 6:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 maneb from 180:1 to 1:3 from 60:1 to 2:1 from 22:1 to 3:1 mepanipirime from 18:1 to 1:3 from 6:1 to 1:1 from 6:1 to 1:1 mepronil from 7:1 to 1:36 from 2:1 to 1:12 from 1:1 to 1:6 meptyldinocap from 7:1 to 1:9 from 2:1 to 1:3 from 2:1 to 1:3 metalaxyl from 15:1 to 1:45 from 5:1 to 1:15 from 1:1 to 1:6 metalaxyl-M from 7:1 to 1:90 from 2:1 to 1:30 from 1:1 to 1:12 metconazole from 3:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1 :6 Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio metasulfocarb from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 1:1 metiram from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 1:1 methominostrobin from 9:1 to 1:12 from 3:1 to 1:4 from 3:1 to 1:3 metrafenone from 6:1 to 1:12 from 2:1 to 1:4 from 2:1 to 1:4 myclobutanyl from 5:1 to 1:26 from 1:1 to 1:9 from 1:1 to 1:8 naphthifine from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 neo-asozine (ferric methanoarsonate) from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 nuarimol from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 octylinone from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 1:1 ofu race from 15:1 to 1:45 from 5:1 to 1:15 from 1:1 to 1:6 orisastrobin from 9:1 to 1:12 from 3:1 to 1:4 from 3:1 to 1: 3 oxadixyl from 15:1 to 1:45 from 5:1 to 1:15 from 1:1 to 1:6 oxolinic acid from 30:1 to 1:9 from 10:1 to 1:3 from 7:1 to 1 :2 oxpoconazole from 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 oxycarboxin from 18:1 to 1:6 from 6:1 to 1:2 from 4:1 to 1 :2 oxytetracycline from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 pefurazoate from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2 :1 penconazole from 1:1 to 1:45 from 1:2 to 1:15 from 1:2 to 1:15 pencicuron from 150:1 to 1:2 from 50:1 to 2:1 from 11:1 to 2 :1 penflufen from 12:1 to 1:9 from 4:1 to 1:3 from 2:1 to 1:3 penthiopyrad from 12:1 to 1:9 from 4:1 to 1:3 from 2:1 to 1 :3 phosphorous acid and salts thereof from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 phthalide from 150:1 to 1:36 from 50:1 to 1:12 15:1 to 2:1 picoxystrobin 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 piperaline 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 polyoxin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 probenazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 prochloraz 22:1 to 1:4 7:1 to 1:1 7:1 to 1:2 procymidone 45:1 to 1:3 15:1 to 1:1 11:1 to 2:1 propamocarb or propamocarb hydrochloride 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 propiconazole 4:1 to 1:18 1:1 to 1:6 from 1:1 to 1:5 propineb from 45:1 to 1:2 from 15:1 to 2:1 from 11:1 to 2:1 Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio proquinazid from 3:1 to 1:36 from 1:1 to 1:12 from 1:1 to 1:12 prothiocarb from 9:1 to 1:18 from 3:1 to 1:6 from 3:1 to 1:3 prothioconazole from 6:1 to 1:18 from 2:1 to 1:6 from 1:1 to 1:5 pyraclostrobin from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 pyrametostrobin from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 pyraoxystrobin from 9:1 to 1:18 from 3:1 to 1:6 from 2:1 to 1:4 pyrazophos from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 1:1 pyribencarb from 15:1 to 1:6 from 5:1 to 1:2 from 4:1 to 1:2 pyrifenox from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 pyrimethanyl from 30:1 to 1:6 from 10:1 to 1:2 from 3:1 to 1:2 pyriophenone from 6:1 to 1:12 from 2:1 to 1:4 from 2:1 to 1:4 pyrisoxazole from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 pyroquilone from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 pyrrolnitrin from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 quinconazole from 4:1 to 1:12 from 1:1 to 1:4 from 1:1 to 1:4 quinmethionate from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 quinoxifene from 4:1 to 1:18 from 1:1 to 1:6 from 1:1 to 1:6 quintazene from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 silthiofam from 7:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 simeconazole from 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 spiroxamine from 22:1 to 1:4 from 7:1 to 1:2 from 5:1 to 1:2 streptomycin from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 sulfur from 300:1 to 3:1 from 100:1 to 9:1 from 75:1 to 9:1 tebuconazole from 7:1 to 1:18 from 2:1 to 1:6 from 1:1 to 1:5 tebufloquine from 100:1 to 1:100 from 10:1 to 1:10 from 3:1 to 1:3 teclofthalam from 150:1 to 1 :36 from 50:1 to 1:12 from 15:1 to 2:1 technazene from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 terbinafine from 150:1 to 1 :36 from 50:1 to 1:12 from 15:1 to 2:1 tetraconazole from 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 thiabendazole from 45:1 to 1 :4 from 15:1 to 1:2 from 11:1 to 2:1 tifluzamide from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 thiophanate from 45:1 to 1 :3 from 15:1 to 2:1 from 11:1 to 2:1 thiophanate-methyl from 45:1 to 1:3 from 15:1 to 2:1 from 11:1 to 2:1 MA / t / ¿ U / Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio thyram 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 thiadinyl 12:1 to 1:9 from 4:1 to 1:3 from 2:1 to 1:3 tolclophos-methyl from 150:1 to 1:2 from 50:1 to 2:1 from 37:1 to 5:1 tolnifanide from 15: 1 to 1:18 from 5:1 to 1:6 from 3:1 to 1:3 tolylfluanid from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 triadimefon from 15: 1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 triadimenol from 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 triarimol from 3: 1 to 1:90 from 1:1 to 1:30 from 1:2 to 1:24 triazoxide from 150:1 to 1:36 from 50:1 to 1:12 from 15:1 to 2:1 tricyclazole from 15: 1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 tridemorph from 30:1 to 1:3 from 10:1 to 1:1 from 7:1 to 1:1 trifloxystrobin from 6: 1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 triflumizole from 15:1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 triforine from 15: 1 to 1:9 from 5:1 to 1:3 from 3:1 to 1:3 trimorphoamide from 45:1 to 1:9 from 15:1 to 1:3 from 7:1 to 1:2 triticonazole from 15: 1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 uniconazole from 15:1 to 1:36 from 5:1 to 1:12 from 1:1 to 1:5 validamicin from 150: 1 to 1:36 from 50:1 to 1:12 from 3:1 to 1:3 valifenalate from 6:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 vinclozolin from 120: 1 to 1:2 from 40:1 to 2:1 from 15:1 to 2:1 zineb from 150:1 to 1:2 from 50:1 to 2:1 from 37:1 to 5:1 ziram from 150: 1 to 1:2 from 50:1 to 2:1 from 37:1 to 5:1 zoxamide from 6:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 5-chloro- 6-(2,4,6-trifluorophenyl)-7-(4methi Ipiperidin -1 -yl)[1,2,4]triazolo[1,5a]pyrimidine (DPX-BAS600F) from 15:1 to 1:36 5:1 to 1:12 1:1 to 1:6 A / -[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl ]-3-methyl-2[(methylsulfonyl)amino]butanamide from 6:1 to 1:18 from 2:1 to 1:6 from 2:1 to 1:4 A / -[2-[4-[[3 -(4-chlorophenyl)-2-propyl-1yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2[(ethylsulfonyl)amino]butanamide 6:1 to 1 :18 from 2:1 to 1:6 from 2:1 to 1:4 MA / t / ZUZZ / U / 4ZÓU Component (b) Typical weight ratio Most typical weight ratio Most typical weight ratio / V-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4- t¡ad¡ azol-5-yl]ox¡]-2,5-dimethylphen¡l]- / V-ethyl / V-methylmetanimidamide from 20:1 to 1:20 from 8:1 to 1:8 from 3: 1 to 1:3 Λ / -[1-[[[1-(4-cyanophen¡l)ethyl]sulfonyl]methyl]prop¡l]carbamate 4-fluorophenyl from 6:1 to 1: 18 from 2:1 to 1:6 from 2:1 to 1:4 / V-[[(cyclopropylmethoxy)amino][6- (difluoromethoxy)-2,3- difluorophenyl]methylene]benzeneacetamide of 1 :1 to 1:90 1:2 to 1:30 1:2 to 1:24 a-[methoxyamino]-A / -methyl-2-[[[1 -[3(trifluoromethyl )phenyl]ethoxy¡]¡m¡no]methyl]benc enoacetamide from 9:1 to 1:18 from 3:1 to 1:6 from 3:1 to 1:3 / V-[4-[4-chloro- 3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]- / \ / -ethyl- / \ / methylmetanimidamide from 15:1 to 1:18 from 5:1 to 1:6 from 3:1 to 1: 3 A / -[4-[[[[( 1 -methyl-1 H-tetrazol-5yl)phenylmethylene]amino]oxy]methyl]-2thiazolyl]pentyl carbamate from 9:1 to 1:18 from 3:1 to 1:6 3:1 to 1:3 A / -[6-[[[[(1 -methyl-1 / 7-tetrazol-5yl)phenylmethylene]amino]oxy]methyl]-2pyridinyl]pentyl carbamate of 9 :1 to 1:18 from 3:1 to 1:6 from 3:1 to 1:3 2-[(3-bromo-6-quinolini l)oxy]-A / -( 1,1 - dimethyl- 2-butyn-1-yl)-2-(methylthio)acetamide from 5:1 to 1:22 from 2:1 to 1:8 from 2:1 to 1:4 2-[(3-ethin ¡l-6-quinolinyl)oxy]- / V-[1 (hydroxy methyl) -1 -methyl-2-propyn-1 -yl]-2(methylthio)acetamide from 5:1 to 1:22 of 2 :1 to 1:8 from 2:1 to 1:4 / V-(1,1 -dimethyl-2-butyn-1 -yl)-2-[(3-ethynyl-6-quinolin¡l) oxy]-2-(methylthio)acetamide from 5:1 to 1:22 from 2:1 to 1:8 from 2:1 to 1:4 ΜΛ / t / ZUZZ / U / 4ZÓU As already noted, the present invention includes embodiments, wherein the composition comprising components (a) and (b), wherein component (b) comprises at least one fungicidal compound from each of the two selected groups from (b1) to (b54). Table C1 lists specific mixtures to illustrate embodiments wherein component (b) includes at least one fungicidal compound from each of the two groups selected from (b1) to (b54). Table C1 discloses a mixture of Compound 1 of the present invention with at least two compounds of Component (b). Entries headed Illustrative Ratios disclose three specific weight ratios of Component (a) to each compound of Component (b). For example, the first line discloses a mixture of Compound 1 with cyproconazole and azoxystrobin and lists weight ratios of Compound 1 to cyproconazole to azoxystrobin of 1:1:1,2:1:1 or 3:1:1. M A / í Table C1 Component (a) Component (b) Illustrative relationships (*) Compound 1 cyproconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole kresoxim-methyl 1:1:1 2:1:1 3: 1:1 Compound 1 cyproconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole pyrametrostrobin 1:1:1 2:1:1 3:1:1 na Compound 1 cyproconazole pyroxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole trifloxiestrobin 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole bixaphene 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole boscalide 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole cyflufenamide 1:2:1 2:2: 1 3:2:1 Compound 1 cyproconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole metrafenone 1: 1:2 2:1:2 3:1:2 Compound 1 cyproconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole proquinazid 1:1:1 2:1:1 3:1: 1 Compound 1 cyproconazole pyriophenone 1:1:2 2:1:2 3:1:2 Compound 1 cyproconazole quinoxifene 1:1:1 2:1:1 3:1:1 Compound 1 cyproconazole sedaxane 1:1:2 2: 1:2 3:1:2 Compound 1 cyproconazole picoxystrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 cyproconazole trifloxiestrobin proquinazi d 1:1:1:1 2: 1:1:1 3:1:1: 1 Compound 1 diphenconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole kresoxim-methyl 1:1:1 2:1:1 3:1 :1 Compound 1 diphenconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole pyrametostrobin 1:1:1 2 :1:1 3:1:1 na Compound 1 difenoconazole pyroxystrobin 1:1:1 2:1:1 3:1:1 Component (a) Component (b) Illustrative relations(*) Compound 1 diphenconazole trifloxiestrobin 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole bixaphene 1:1:2 2:1:2 3:1 :2 Compound 1 diphenconazole boscalide 1:1:2 2:1:2 3:1:2 Compound 1 diphenconazole cyflufenamide 1:2:1 2:2:1 3:2:1 Compound 1 diphenconazole fluopyram 1:1:2 2 :1:2 3:1:2 Compound 1 diphenconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 diphenconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 diphenconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 1 diphenconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole pyriophenone 1:1:2 2:1:2 3 :1:2 Compound 1 diphenconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 1 diphenconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 1 diphenconazole picoxystrobin proquinazi d 1: 1:1:1 2:1:1:1 3:1:1: 1 Compound 1 diphenconazole trifloxiestrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 epoxiconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole pyraoxystrobin 1: 1:1 2:1:1 3:1:1 Compound 1 epoxiconazole trifloxiestrobin 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole bixaphene 1:1:2 2:1:2 3:1: 2 Compound 1 epoxiconazole boscalide 1:1:2 2:1:2 3:1:2 Compound 1 epoxiconazole cyflufenamide 1:2:1 2:2:1 3:2:1 Compound 1 epoxiconazole fluopyram 1:1:2 2: 1:2 3:1:2 Compound 1 epoxiconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 epoxiconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 epoxiconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 1 epoxiconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole pyriophenone 1:1:2 2:1:2 3: 1:2 Compound 1 epoxiconazole quinoxifene 1:1:1 2:1:1 3:1:1 Compound 1 epoxiconazole sedaxane 1:1:2 2:1:2 3:1:2 100 Component (a) Component (b) Illustrative relations(*) Compound 1 epoxiconazole picoxystrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 epoxiconazole trifloxiestrobin proquinazi d 1:1 :1:1 2:1:1:1 3:1:1: 1 Compound 1 metconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 metconazole kresoxim-methyl 1:1:1 2: 1:1 3:1:1 Compound 1 metconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 metconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 metconazole pyrametostrobin na 1:1:1 2:1:1 3:1:1 Compound 1 metconazole pyroxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 metconazole trifloxystrobin 1:1:1 2:1:1 3 :1:1 Compound 1 metconazole bixaphene 1:1:2 2:1:2 3:1:2 Compound 1 metconazole boscalide 1:1:2 2:1:2 3:1:2 Compound 1 metconazole cyflufenamide 1:2: 1 2:2:1 3:2:1 Compound 1 metconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 1 metconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 metconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 metconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 1 metconazole proquinazid 1:1:1 2:1: 1 3:1:1 Compound 1 metconazole pyriophenone 1:1:2 2:1:2 3:1:2 Compound 1 metconazole quinoxifene 1:1:1 2:1:1 3:1:1 Compound 1 metconazole sedaxane 1: 1:2 2:1:2 3:1:2 Compound 1 metconazole picoxystrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 metconazole trifloxiestrobin proquinazi d 1:1: 1:1 2:1:1:1 3:1:1: 1 Compound 1 myclobutanyl azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 myclobutanyl kresoxim-methyl 1:1:1 2:1 :1 3:1:1 Compound 1 myclobutanil picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 myclobutanyl pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 myclobutanyl pyrametostrobin na 1:1:1 2:1:1 3:1:1 Compound 1 myclobutanyl pyroxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 myclobutanyl trifloxystrobin 1:1:1 2:1:1 3: 1:1 MA / t / ¿ U / 101 Component (a) Component (b) Illustrative relations(*) Compound 1 myclobutani 0 bixafen 1:1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 boscalide 1:1:2 2:1:2 3 :1:2 Compound 1 myclobutani 0 cyfluphenamide 1:2:1 2:2:1 3:2:1 Compound 1 myclobutani 0 fluopyram 1:1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 isopyrazam 1 :1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 penthiopyrad 1:1:2 2:1:2 3 :1:2 Compound 1 myclobutani 0 proquinazid 1:1:1 2:1:1 3:1:1 Compound 1 myclobutani 0 pyriophenone 1:1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 quinoxyfen 1 :1:1 2:1:1 3:1:1 Compound 1 myclobutani 0 sedaxane 1:1:2 2:1:2 3:1:2 Compound 1 myclobutani 0 picoxystrobin proquinazi d 1:1:1:1 2: 1:1:1 3:1:1: 1 Compound 1 myclobutanil trifloxiestrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 prothioconazole azoxystrobin 1:1:1 2: 1:1 3:1:1 Compound 1 prothioconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole pyraoxystrobin 1:1:1 2:1: 1 3:1:1 Compound 1 prothioconazole trifloxiestrobin 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole bixaphene 1:1:2 2:1:2 3:1:2 Compound 1 prothioconazole boscalide 1: 1:2 2:1:2 3:1:2 Compound 1 prothioconazole cyflufenamide 1:2:1 2:2:1 3:2:1 Compound 1 prothioconazole fluopyram 1:1:2 2:1:2 3:1: 2 Compound 1 prothioconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 prothioconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 prothioconazole penthiopyrad 1:1:2 2: 1:2 3:1:2 Compound 1 prothioconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole pyriophenone 1:1:2 2:1:2 3:1:2 Compound 1 prothioconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 1 prothioconazole sedaxane 1:1:2 2:1:2 3:1:2 102 Component (a) Component (b) Illustrative relations(*) Compound 1 prothioconazole picoxystrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 prothioconazole trifloxiestrobin proquinazi d 1:1 :1:1 2:1:1:1 3:1:1: 1 Compound 1 tebuconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole kresoxim-methyl 1:1:1 2: 1:1 3:1:1 Compound 1 tebuconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole pyrametostrobin na 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole trifloxiestrobin 1:1:1 2:1:1 3 :1:1 Compound 1 tebuconazole bixaphene 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole boscalide 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole cyflufenamide 1:2: 1 2:2:1 3:2:1 Compound 1 tebuconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole proquinazid 1:1:1 2:1: 1 3:1:1 Compound 1 tebuconazole pyriophenone 1:1:2 2:1:2 3:1:2 Compound 1 tebuconazole quinoxifene 1:1:1 2:1:1 3:1:1 Compound 1 tebuconazole sedaxane 1: 1:2 2:1:2 3:1:2 Compound 1 tebuconazole picoxystrobin proquinazi d 1:1:1:1 2:1:1:1 3:1:1: 1 Compound 1 tebuconazole trifloxiestrobin proquinazi d 1:1: 1:1 2:1:1:1 3:1:1: 1 (*) Ratio of Component (a) with respect to Component (b) in sequence, by weight. Tables C2 to C15 are each constructed the same as Table C1 above except that the entries under the Component (a) column heading are replaced by the respective entry in the Component (a) column shown below. Thus, for example, in Table C2, the entries under the column heading Component (a) all list Compound 18. Therefore, the first entry in Table C2 specifically discloses a mixture of Compound 18 with cyproconazole and azoxystrobin, with illustrative weight ratios of 1:1:1, 2:1:1 and 3:1:1 of Compound 18 to cyproconazole to azoxystrobin. Tables C3 to C15 are constructed in a similar way. M A / 103 Component column entry table number (a) Component column entry table number (a) C2 Compound 18 C9 Compound 73 C3 Compound 19 C10 Compound 93 C4 Compound 23 C11 Compound 111 C5 Compound 57 C12 Compound 112 C6 Compound 60 C13 Compound 118 C7 Compound 68 C14 Compound 121 08 Compound 72 C15 Compound 127 It is worth highlighting a composition of the present invention that comprises a compound of Formula (or a / V-oxide or a salt thereof) with at least one other fungicide compound that has a different site of action with respect to the compound of Formula 1. In certain cases, a combination with at least one other fungicide compound that has a similar control spectrum but a different site of action. Therefore, a composition of the present invention may advantageously comprise at least one fungicidal active compound selected from the group consisting of (b1) to (b54) as described above, which has a similar control spectrum, but a site of different action. The compositions of component (a) or component (a) with component (b) may further be mixed with one or more biologically active compounds or agents, including insecticides, nematicides, bactericides, acaricides, herbicides, herbicide protectants, growth regulators such as as insect molting inhibitors and rooting stimulants, chemosterilizers, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, viruses or fungi to form a multicomponent pesticide that provides a spectrum even broader agricultural protection. Therefore, the present invention also relates to a composition comprising a fungicide-effective amount of component (a), or a mixture of component (a) with component (b), and a biologically effective amount of at least one compound or additional biologically active agent and may further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents may also be formulated separately in compositions comprising at least one of a surfactant and a solid or liquid diluent. For compositions of the present invention, one or more biologically active compounds or agents may be formulated together with one or both of components (a) and (b) to form a premix, or one or more other biologically active compounds or agents may be formulated separately from components (a) and (b) and the formulations are combined together before application (for example, in a spray tank) or, alternatively, applied successively. Examples of said compounds or biologically active agents with which compositions of component (a), or of component (a) with component (b), can be formulated are: insecticides such as abamectin, acetate, acequinocyl, acetamiprid, acrinathrin, acinonapyr , afidopyropene, amidoflumet, 104 amitraz, avermectin, azadirachtin, azinphos-methyl, benfuracarb, bensultap, benzpyrimoxane, bifenthrin, kappa-bifenthrin, bifenazate, bistrifluron, borate, broflanilide, buprofezin, cadusaphos, carbaryl, carbofuran, cartap, carzol, chlorantraniliprole, chlorfenazupyr chlorfluazuron, chlorpralethrin, chlorpyrifos, chlorpyrifos-e, chlorpyrifos-methyl, chromafenozide, clofentezine, chlorpralethrin, clothianidin, cyatraniliprole, cyclaniliprol, cycloprothrin, cycloxaprid, cianopyrafen, cyflumethofen, cyfluthrin, beta-cyfluthrin, cyhalodiamide, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin , alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dichloromesothiaz, dieldrin, diflubenzuron, dimefluthrin, dimehipo, dimethoate, dimpropyridaz, dinotefuran, diophenolan, emamectin, emamectin benzoate, endosulfan, esfenvalerate, etiprol, etofenprox , epsilon- metofluthrin, etoxazole, fenbutatin oxide, fenitrothion, fenotiocarb, fenoxicarb, fenpropatrin, fenvalerate, fipronil, flomethoquin, flonicamid, fluazaindolizine, flubendiamide, flucitrinate, flufenerim, flufenoxuron, flufenoxystrobin, fluensulfone, fluhexafon, fluopyram, flupiprole, flupira difurone, flupirimin, fluvalinate, tau-fluvalinate, fluxametamide, fonophos, formethanate, fosthiazate, gamma-cyhalothrin, halofenozide, heptafluthrin, hexaflumuron, hexithiazox, hydramethylnon, imidacloprid, indoxacarb, insecticidal soaps, isofenphos, isocycloseram, kappa-tefluthrin, lambda-cyhalothrin, lufenuron, malathion, meper fluthrin , metaflumizone, metaldehyde, metamidophos, methidathion, methiocarb, metomyl, methoprene, methoxychlor, metofluthrin, methoxyfenozide, epsilonmetofluthrin, epsilon-momfluorothrin, monocrotophos, monofluorothrin, nicotine, nitenpyram, nithiazine, novaluron, noviflumurone, oxamyl, oxazosulfil, parathion, parathion-methyl , permethrin, phorate, fosalone, fosmet, fosfamidon, pirimicarb, profenophos, profluthrin, propargite, protriphenbuto, piflubumide, pymetrozine, pyrafluprole, pyrethrin, pyridaben, pyridalyl, pyrifluquinazon, pyriminostrobin, pyriprole, pyriproxyfen, rotenone, ryanodine, silafluofen, spinetoram, spinosad , spirodiclofen, spiromesifen, spiropidion, spirotetramat, sulfoprox, sulfoxaflor, tebufenozide, tebufenpyrad, teflubenzuron, tefluthrin, kappa-tefluthrin, terbufos, tetrachlorantraniliprole, tetrachlorvinfos, tetramethrin, tetramethylfluthrin, tetraniliprol, thiacloprid, thiamethoxam, thiodicarb, tiosult ap-sodium, thioxazafen, tolfenpyrad , tralomethrin, triazamate, trichlorfon, triflumezopyrim, triflumuron, ticlopyrazoflor, zeta-cypermethrin, Bacillus thuringiensis delta-endotoxins, entomopathogenic bacteria, entomopathogenic viruses or entomopathogenic fungi. General references for agricultural protectants (i.e. insecticides, fungicides, nematicides, acaricides, herbicides and biological agents) include The Pesticide Manual, 13th Edition, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, United Kingdom, 2003 and The BioPesticide Manual, 2nd Edition, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, United Kingdom, 2001. For embodiments in which one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) with respect to component (a), or a mixture of component (a) with component (b), is generally between about 1:3000 and about 3000:1. Noteworthy are weight ratios of between about 1:100 and about 3000:1, or between about 1:30 and about 300:1 (e.g., ratios between about 1:1 and about 30:1). It will be evident that the inclusion of these M A / t / ZUZZ / U / 105 additional components can broaden the spectrum of diseases controlled beyond the spectrum controlled by component (a), or a mixture of component (a) with component (b). The compounds of component (a) and / or combinations thereof with compounds of component (b) and / or one or more biologically active compounds or agents can be applied to plants genetically transformed to express proteins toxic to invertebrate pests (such as delta -endotoxins from Bacillus thuringiensis). The effect of the present component (a) applied exogenously alone or in combination with component (b) may be synergistic with the expressed toxin proteins. Noteworthy is the combination or composition comprising component (a), or components (a) and (b), as described in the Summary of the Invention that also comprises at least one compound or agent for controlling invertebrate pests. (e.g. insecticide, acaricide). Noteworthy is a composition comprising component (a) and at least one (i.e., one or more) invertebrate pest control compound or agent, which may subsequently be combined with component (b) to provide a composition comprising the components (a) and (b) and the one or more invertebrate pest control compounds or agents. Alternatively, without first mixing with component (b), a biologically effective amount of the composition comprising component (a) with at least one invertebrate pest control agent can be applied to a plant or plant seed (directly or through the environment of the plant or plant seed) to protect the plant or plant seed from diseases caused by fungal pathogens and from injuries caused by invertebrate pests. Noteworthy is a composition of the present invention that further comprises a compound of component (a), alone or in combination with component (b), at least one invertebrate pest control compound or agent selected from the group consisting of abamectin, acetamiprid, acrinathrin, acinonapir, aphidopyropene, amitraz, avermectin, azadirachtin, benfuracarb, bensultap, bifenthrin, buprofezin, broflanilide, cadusaphos, carbaryl, cartap, chlorantraniliprole, chloropraletrin, chlorfenapyr, chlorpyrifos, clothianidin, cyantraniliprole, cyclani liprol, cycloprothrin, cyfluthrin, beta- cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diophenolan, emamectin, endosulfan, epsilon-metofluthrin, esfenvalerate, etiprol, etofenprox, etoxazole, fenitrothion, fenotiocarb, fenoxycarb, fenvalerate, fipronil, flomethoquin, fluxametamide, flonicamid, flubendiamide, fluensulfone, flufenoxuron, flufenoxystrobin, flufensulfone, flupiprole, flupyramine, flupyradifurone, fluvalinate, formethanate, fosthiazate, gamma-cyhalothrin, heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isocycloseram, kappa-tefluthrin, lambda-cyhalothrin, lufenuron, meperfluthrin, metaflumizone, methiodicarb, methomyl, methoprene, methoxyfenozide, metofluthrin, monofluorothrin, nitenpyram, nithiazine, novaluron, oxamyl, piflubumide, pymetrozine, pyrethrin, pyridaben, pyridalyl, pyriminostrobin , pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor, tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumezopyrim, triflumuron, ticlopyrazoflor, zeta-cypermethrin, delta-endotoxins Bacillus thuringiensis , all strains of Bacillus thuringiensis and all strains of nucleopolyhedrosis viruses. 106 In certain cases, combinations of a compound of component (a) of the present invention, alone or in admixture with component (b), with other biologically active compounds or agents (particularly fungicides) (i.e., active ingredients) can give resulting in an effect superior to the additive (i.e. synergistic). It is always desirable to reduce the amount of active ingredients released into the environment while ensuring effective pest control. When an enhanced effect of fungicide active ingredients occurs at application rates that provide agronomically satisfactory levels of fungal control, such combinations can be advantageous in reducing the cost of crop production and reducing the environmental burden. Table D1 lists specific combinations of invertebrate pest control agents with Compound 1 (compound numbers refer to compounds in Index Tables A-B) as component compound (a) illustrative of mixtures and compositions comprising these active ingredients and methods using them according to the present invention. The second column of Table D1 lists specific invertebrate pest control agents (e.g., Abamectin in the first line). The third column of Table D1 lists the mode of action (if known) or chemical class of invertebrate pest control agents. The fourth column of Table D1 lists the embodiment(s) of weight ratio ranges for the rates at which the invertebrate pest control agent is typically applied with respect to Compound 1 alone or in combination with component (b ) (for example, from 50:1 to 1:50 abamectin with respect to Compound 1 by weight). Therefore, for example, the first line of Table D1 specifically discloses that the combination of Compound 1 with abamectin is typically applied in a weight ratio between 50:1 and 1:50. The remaining lines of Table D1 are to be interpreted in a similar way. Table D1 Component (a) Invertebrate pest control agent Mode of action or chemical class Typical weight ratio Compound 1 Abamectin macrocyclic lactones from 50:1 to 1:50 Compound 1 Acetamiprid neonicotinoids from 150:1 to 1:200 Compound 1 Amitraz octopamine receptor ligands from 200:1 to 1:100 Compound 1 Avermectin macrocyclic lactones from 50:1 to 1:50 Compound 1 Azadirachtin ecdysone agonists from 100:1 to 1:120 Compound 1 Beta-cyfluthrin channel modulators sodium from 150:1 to 1:200 Compound 1 Bifenthrin sodium channel modulators from 100:1 to 1:10 Compound 1 Buprofezin chitin synthesis inhibitors from 500:1 to 1:50 107 Component (a) Invertebrate pest control agent Mode of action or chemical class Typical weight ratio Compound 1 Cartap nereistoxin analogues 100:1 to 1:200 Compound 1 Chlorantraniliprole ryanodine receptor ligands 100:1 to 1 :120 Compound 1 Chlorfenapyr inhibitors of mitochondrial electron transport from 300:1 to 1:200 Compound 1 Chlorpyrifos cholinesterase inhibitors from 500:1 to 1:200 Compound 1 Clothianidin neonicotinoids from 100:1 to 1:400 Compound 1 Cyantraniliprole ligands ryanodine receptor from 100:1 to 1:120 Compound 1 Cyfluthrin sodium channel modulators from 150:1 to 1:200 Compound 1 Cyhalothrin sodium channel modulators from 150:1 to 1:200 Compound 1 Cypermethrin sodium channel modulators sodium channels from 150:1 to 1:200 Compound 1 Cyromazine chitin synthesis inhibitors from 400:1 to 1:50 Compound 1 Deltamethrin sodium channel modulators from 50:1 to 1:400 Compound 1 Dieldrin insecticides cyclodiene from 200:1 to 1:100 Compound 1 Dinotefuran neonicotinoids from 150:1 to 1:200 Compound 1 Diophenolan molt inhibitor from 150:1 to 1:200 Compound 1 Emamectin macrocyclic lactones from 50:1 to 1:10 Compound 1 Endosulfan cyclodiene insecticides from 200:1 to 1:100 Compound 1 Esfenvalerate sodium channel modulators from 100:1 to 1:400 Compound 1 Etiprol GABA-regulated chloride channel blockers from 200:1 to 1:100 Compound 1 Fenotiocarb from 150:1 to 1:200 Compound 1 Fenoxicarb juvenile hormone mimetics from 500:1 to 1:100 Compound 1 Fenvalerate sodium channel modulators from 150:1 to 1:200 108 Component (a) Invertebrate pest control agent Mode of action or chemical class Typical weight ratio Compound 1 Fipronil GABA-regulated chloride channel blockers 150:1 to 1:100 Compound 1 Flonicamide 200:1 to 1 :100 Compound 1 Flubendiamide ryanodine receptor ligands from 100:1 to 1:120 Compound 1 Flufenoxuron chitin synthesis inhibitors from 200:1 to 1:100 Compound 1 Hexaflumuron chitin synthesis inhibitors from 300:1 to 1 :50 Compound 1 Hydramethylnon mitochondrial electron transport inhibitors from 150:1 to 1:250 Compound 1 Imidacloprid neonicotinoids from 1000:1 to 1:1000 Compound 1 Indoxacarb sodium channel modulators from 200:1 to 1:50 Compound 1 Lambda-cyhalothrin sodium channel modulators from 50:1 to 1:250 Compound 1 Lufenuron chitin synthesis inhibitors from 500:1 to 1:250 Compound 1 Meperfluthrin sodium channel modulators from 100:1 to 1: 400 Compound 1 Metaflumizone from 200:1 to 1:200 Compound 1 Methomyl cholinesterase inhibitors from 500:1 to 1:100 Compound 1 Methoprene juvenile hormone mimetics from 500:1 to 1:100 Compound 1 Methoxyfenozide ecdysone agonists from 50: 1 to 1:50 Compound 1 Nitenpyram neonicotinoids from 150:1 to 1:200 Compound 1 Nithiazine neonicotinoids from 150:1 to 1:200 Compound 1 Novaluron chitin synthesis inhibitors from 500:1 to 1:150 Compound 1 Oxamyl inhibitors cholinesterase from 200:1 to 1:200 Compound 1 Pymetrozine from 200:1 to 1:100 Compound 1 Pyrethrin sodium channel modulators from 100:1 to 1:10 ΜΛ / 1 / ¿l U í 109 ΜΛ / Component (a) Invertebrate pest control agent Mode of action or chemical class Typical weight ratio Compound 1 Pyridabene inhibitors of mitochondrial electron transport from 200:1 to 1:100 Compound 1 Pyridalyl from 200:1 to 1:100 Compound 1 Pyriproxyfen juvenile hormone mimetics from 500:1 to 1:100 Compound 1 Ryanodine ryanodine receptor ligands from 100:1 to 1:120 Compound 1 Spinetoram macrocyclic lactones from 150:1 to 1:100 Compound 1 Spinosad macrocyclic lactones 500:1 to 1:10 Compound 1 Spirodiclofen inhibitors of lipid biosynthesis from 200:1 to 1:200 Compound 1 Spiromesifen inhibitors of lipid biosynthesis from 200:1 to 1:200 Compound 1 Sulfoxaflor from 200:1 to 1 :200 Compound 1 Tebufenozide ecdysone agonists from 500:1 to 1:250 Compound 1 Tetramethylfluthrin sodium channel modulators from 100:1 to 1:40 Compound 1 Thiacloprid neonicotinoids from 100:1 to 1:200 Compound 1 Thiamethoxam neonicotinoids 1250:1 to 1:1000 Compound 1 Thiodicarb cholinesterase inhibitors from 500:1 to 1:400 Compound 1 Thiosultap-sodium from 150:1 to 1:100 Compound 1 Tralomethrin sodium channel modulators from 150:1 to 1: 200 Compound 1 Triazamate cholinesterase inhibitors from 250:1 to 1:100 Compound 1 Triflumuron chitin synthesis inhibitors from 200:1 to 1:100 Compound 1 Bacillus thuringiensis biological agents from 50:1 to 1:10 Compound 1 delta- endotoxin from Bacillus thuringiensis biological agents from 50:1 to 1:10 Compound 1 NPV (e.g. e.g. Gemstar) biological agents from 50:1 to 1:10 Tables D2 to D15 are each constructed the same as Table D1 above except that the entries under the Component (a) column heading are replaced by the respective entry in the Component (a) column shown below. Therefore, for example, in Table D2, the entries under the column heading Component (a) cite all ΜΛ / 110 Compound 18, and the first line below the column headings in Table D2 specifically discloses a mixture of Compound 18 with abamectin. Tables D3 to D15 are constructed similarly. Component column entry table number (a) Component column entry table number (a) D2 Compound 18 D9 Compound 73 D3 Compound 19 D10 Compound 93 D4 Compound 23 D11 Compound 111 D5 Compound 57 D12 Compound 112 D6 Compound 60 D13 Compound 118 D7 Compound 68 D14 Compound 121 D8 Compound 72 D15 Compound 127 Compositions comprising compounds of Formula 1 useful for the treatment of Seeds may further comprise bacteria and fungi that have the capacity to provide protection against the harmful effects of phytopathogenic bacteria or fungi and / or soil animals, such as nematodes. Bacteria exhibiting nematicidal properties may include, but are not limited to, Bacillus firmus, Bacillus cereus, Bacillus subtiliis, and Pasteuria penetraos. A suitable strain of Bacülus firmus is strain CNCM 1-1582 (GB-126) marketed as BioNem™. A suitable strain of Bacillus cereus is strain NCMM 1-1592. Both Bacillus strains are disclosed in US 6,406,690. Other suitable bacteria that exhibit nematicidal activity are B. amyloliquefaciens strain IN937a and B. subtilis strain GB03. Bacteria exhibiting fungicidal properties may include, but are not limited to, B. pumilus strain GB34. Fungal species exhibiting nematicidal properties may include, but are not limited to, Myrothecium verrucaria, Paecilomyces lilacinus, and Purpureocillium lilacinum. Seed treatments may also include one or more naturally occurring nematicidal agents, such as the inducer protein harpin, which is isolated from certain bacterial phytopathogens such as Erwinia amylovora. An example is HarpinN-Tek seed treatment technology available as N-Hibit™ Gold CST. Seed treatments may also include one or more species of legume root nodulating bacteria such as the microsymbiotic nitrogen-fixing bacteria Bradyrhizobium japonicum. These inoculants may optionally include one or more lipo-chitooligosaccharides (LQO), which are nodulation factors (Nod) produced by rhizobium bacteria during the initiation of nodule formation in legume roots. For example, Optimize® brand seed treatment technology incorporates LCO Promoter Technology™ in combination with an inoculant. Seed treatments may also include one or more isoflavones that may increase the level of root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by enhancing the uptake of nutrients by the roots such as water, 111 sulfates, nitrates, phosphates and metals. Examples of isoflavones include, but are not limited to, genistein, biochanin A, formononetin, daidzein, glycitein, hesperetin, naringenin and pratensein. Formononetin is available as an active ingredient in mycorrhizal inoculant products such as PHC Colonize® AG. Seed treatments may also include one or more plant activators that induce systemic acquired resistance in plants after contact with a pathogen. An example of a plant activator that induces such protective mechanisms is acibenzolar-S-methyl. In the present fungicidal compositions, the compounds of Formula 1 of component (a) can work synergistically with the additional fungicidal compounds of component (b) to provide said beneficial results such as broadening the spectrum of controlled plant diseases, prolonging the duration of preventive and curative protection, and the suppression of the proliferation of resistant fungal pathogens. In particular embodiments, compositions are provided according to the present invention comprising proportions of component (a) and component (b) that are especially useful for controlling particular fungal diseases (such as Alternaria solani, Blumeria graminis f. sp. tritici, Botrytis cinerea, Puccinia recondita f. sp. tritici, Rhizoctonia solani, Septoria nodorum, Septoria tritici). Fungicide mixtures may also provide significantly better disease control than would be predicted based on the activity of the individual components. This synergy has been described as the cooperative action of two components of a mixture, such that the total effect is greater or longer than the sum of the effects of the two (or more) taken independently (see P. M. L. Tames, Neth. J Plant Pathology 1964, 70, 73-80). In methods that provide control of plant diseases in which synergy occurs from a combination of active ingredients (for example, fungicidal compounds) applied to the plant or seed, the active ingredients are applied in a ratio by synergistic weight and in synergistic (i.e., synergistically effective) amounts. Disease control, inhibition and prevention measures cannot exceed 100%. Therefore, the expression of substantial synergy typically requires the use of active ingredient application rates where the active ingredients separately provide an effect much less than 100%, such that their additive effect is substantially less than 100% for allow the possibility of increasing the effect as a result of synergy. On the other hand, application rates of active ingredients that are too low may not show much activity in mixtures, even with the benefit of synergy. One skilled in the art can easily identify and optimize, through simple experimentation, the weight ratios and application rates (i.e., amounts) of fungicide compounds that provide synergy. The presence of a synergistic effect between two active ingredients was established with the help of the Colby equation (see Colby, S. R. Calculating Synergistic and Antagonistic Responses of Herbicide Combinations, Weeds, (1967), 15,20-22): Sea 112 ρ=Α+ΒΑχΒ 100 Using the Colby method, the presence of a synergistic interaction between two active ingredients is established by first calculating the predicted activity, p, of the mixture based on the activities of the two components applied alone. If p is lower than the experimentally established effect, synergy has occurred. In the above equation, A is the fungicidal activity in percentage of control of a component applied only at dose x. Term B is the fungicidal activity in control percentage of the second component applied at dose y. The equation estimates p, the expected fungicidal activity of the mixture of A at rate x with B at rate y if their effects are strictly additive and no interaction has occurred. Seed treatments may also include one or more plant activators that induce systemic acquired resistance in plants after contact with a pathogen. An example of a plant activator that induces such protective mechanisms is acibenzolar-S-methyl. The following TESTS demonstrate the control efficacy of compounds of the present invention on specific pathogens. However, the pathogen control protection obtained by the compounds is not limited to these species. See Index Tables A-B below for compound descriptions. In Index Table A the following abbreviations are used: Me means methyl, / -Pr means / 'so-propyl, MeO means methoxy and -NO2 means nitro. The abbreviation Comp. stands for Compound and the abbreviation Ex. stands for Example and is followed by a number indicating in which example the compound is prepared. In Index Table A, the locator numbers listed for the substituents R4 and R5 are as indicated in the structure above the table. The order of enumeration of the R4 and R5 substituents may be different from the Chemical Abstracts naming system if the difference does not affect the meaning. For example, Compound 1 in Index Table A lists the substituent R5 which is in position 6 (i.e., 6-F) while the CAS name for Compound 1 is 4-(2-bromo-4,6- difluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine. The numerical value indicated in the AP+ column (M+1), is the molecular weight of the observed molecular ion formed by the addition of H+ (molecular weight of 1) to the molecule that has the highest isotopic abundance (i.e., M); The numerical value indicated in the AP- column (M-1), is the molecular weight of the observed molecular ion formed by the loss of H+ (molecular weight of 1) from the molecule that has the highest isotopic abundance (i.e., M) . The presence of molecular ions containing one or more isotopes of higher atomic weight and lower abundance (for example, 37CI, 81Br) is not reported. The reported M+1 and M-1 peaks were observed by mass spectrometry using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). INDEX TABLE A 113 ΜΛ / í A hyphen in the R5 column means that there is no substitute for R5 and that the remaining carbon valences are occupied by hydrogen atoms. 10 AP+ AP- Comp. N.a R1 R2 R3 (R4)m (RS)n p.f. (°C) (M+1) (M-1) 1 CH3 ch3 Br 4,6-di-F 6-F 133-137 442 2 ch3 ch3 F 4-CH3O, 6-F 4-F, 6-CI 176-180 427 3 ch3 Et F 4-F 4-Br, 6-CI 148-149 437 15 4 ch3 CHa Cl 4-F 4-MeOCH2 106-110 405 5 ch3 ch3 Cl 4-F 4-CHeCCH2O 123-127 415 6 ch3 ch3 Cl 4-F 4-CH3CH2 109-113 389 7 ch3 ch3 Cl 4-F 5,6-di-F 131-135 397 8 ch3 ch3 Cl 4-F 4-Br, 6-CI 180-184 475 20 9 ch3 ch3 Cl 4-CI 4,6-di-F 138-142 414 10 ch3 ch3 Cl 4-CI 4-F, 6-CI 178-182 430 11 ch3 ch3 Cl 4-CI 4-CI, 6 -F 164-168 430 12 ch3 ch3 F 4-CI 6-F 151-155 379 13 ch3 ch3 F 4-CI 4,6-di-F 154-158 397 25 14 ch3 ch3 Cl 4-N^C 4- CH3 166-170 382 15 ch3 CHs F 4-F 4-CH3, 6-CI 393 16 ch3 Et F 4-F 4-CH3, 6-CI 407 17 ch3 Et F 4-F 6-CI 116-118 393 18 ch3 ch3 Cl 4-ΝξΟ 4-F, 6-CI 182-186 420 30 19 ch3 ch3 Cl 4-F 4-F, 6-CI 153-157 413 20 ch3 ch3 Br 4-F 4-F 127-131 424 21 ch3 ch3 Br 4-F 4-Br 112-116 485 22 ch3 ch3 Cl 6-F 4-CI 173-177 396 23 ch3 ch3 Cl 6-F 4-CH3O, 6-F 167-171 409 35 24 ch3 ch3 Cl 6-F 4-CH3, 6-CI 184-188 410 25 ch3 ch3 Cl 6-F 6-F 130-134 379 26 ch3 ch3 Cl q4-F 4-CH3 118-122 375 27 ch3 ch3 Cl 4-CH3O 6-F 145-149 391 114 AP+ AP- Comp. N.a R1 R2 R3 (R4% (R5)n m.p. (°C) (M+1) (M-1) 28 ch3 ch3 Cl 4-F 4-CF2HO 427 29 ch3 ch3 Cl 4-F 4-NeCCH2O 189-193 416 5 30 ch3 ch3 Cl 4-F 5-F 379 31 ch3 ch3 Cl 4-F 4-CH3, 6-CI 164-168 410 32 ch3 ch3 Cl 4-F 4,5-di-F 123-127 397 33 ch3 ch3 Cl 4-F 4-CI, 6-CH3 155-159 410 34 ch3 ch3 Cl 4-F 3-CI 105-109 396 10 35 ch3 ch3 Me 4-CH3O 6-CI 195-199 389 36 ch3 ch3 Cl 4-F 4-CF2HCH2O 442 37 ch3 ch3 Br 4-F 4.6-di-CI 185-189 475 38 ch3 ch3 Cl 6-F 6-CI 159-163 396 39 ch3 ch3 Cl 6-F 4.6- di-F 146-150 397 15 40 ch3 ch3 Br 4-F 4-CH3, 6-F 152-156 438 41 ch3 ch3 Br 4-F 6-CI 161-165 440 42 ch3 ch3 Br 4-F 6-CH3 148-152 420 43 ch3 ch3 Br 4-F 4-F, 6-CI 208-212 458 44 ch3 ch3 Cl 6-F 4-F 138-142 379 20 45 ch3 Et F 4-F 4-CH3O 389 46 ch3 Et F 4-F 6-F 377 47 ch3 ch3 Cl 4-F 4-I, 6-F 143-148 505 48 ch3 ch3 Me 4-CH3O 6-F 145-150 371 49 ch3 ch3 Cl 6-F 4- F, 6-CI 174-178 414 25 50 ch3 Et F 4-F 4,6-di-F 393 51 ch3 ch3 Br 4-F 4,6-di-F 159-163 442 52 ch3 ch3 Br 4-F 4-CH3O 435 53 ch3 ch3 Cl 6-CI 6-F 145-149 396 54 ch3 CH3 Cl 6-CI 4-F 151-155 396 30 55 ch3 ch3 F 4-F 4-Br, 6-CI 179-183 458 56 ch3 ch3 F 4-F 4-Br, 6-F 136-140 442 57 ch3 ch3 F 4-F 4-CH3O, 6-F 143-147 393 58 ch3 ch3 F 4-F 4,6-di- F 131-135 381 59 ch3 ch3 Cl 4-F 4,6-di-CI 180-184 429 35 60 ch3 ch3 Br 4-F 6-F 132-136 423 61 (Ex. 3) ch3 ch3 Cl 4-F 4-Br, 6-F 149-153 457 62 ch3 ch3 F 4,6-di-F 6-F 141-145 381 63 ch3 ch3 F 6-F 6-F 160-164 363 MA / LEFT / ¿U¿¿ / U / 4ZÓU 115 MA / AP+ AP- Comp. N.a R1 R2 R3 (R4)m (R5)n p.f. (°C) (M+1) (M-1) 64 CH3 ch3 Cl 4-CH3O 4,6-di-F 169-174 409 65 ch3 ch3 Cl 4-CH3O 4,6-di-CI 208-213 442 5 66 ch3 ch3 Cl 4-CH3O 4-CH3, 6-CI 164-169 422 67 ch3 ch3 F 4-F 4-F, 6-CI 163-167 397 68 ch3 ch3 Cl 4,6-di-F 6- F 124-128 397 69 ch3 ch3 Cl 4-CI 6-F 169-173 395 70 ch3 ch3 F 4-CH3O, 6-F 6-F 148-152 393 10 71 Et ch3 Cl 4-F 6-F 112- 116 393 72 ch3 Et Cl 4-F 6-F 117-121 394 73 ch3 ch3 Cl 4-CH3O 4-F, 6-CI 167-172 426 74 ch3 ch3 Cl 4-CH3O 4-CI 148-153 408 75 ch3 ch3 F 6-F 4.6-di-F 195-199 381 15 76 ch3 ch3 F 6-F 4-F, 6-CI 184-188 397 77 ch3 ch3 F 6-F 6-CI 154-158 379 78 ch3 ch3 F 4-F 4-CI 178-182 379 79 ch3 ch3 F 4-F 6-CI 139-143 379 80 ch3 ch3 Cl 4-F 4-CH3O, 6-CI 184-189 426 20 81 ch3 ch3 Cl 4-CH3O 4-CI, 6-F 165-170 426 82 ch3 ch3 F 4-CH3O, 6-F 4,6-di-CI 162-167 444 83 ch3 ch3 F 4-CH3O, 6-F 4-F 172-177 393 84 ch3 ch3 F 4-CH3O, 6-F 4,6-di-F 178-182 411 85 ch3 ch3 Cl 4-F 4-CH3O, 6-F 125-130 409 25 86 ch3 ch3 F 4 -CH3O, 6-F 4-CI, 6-F 144-149 427 87 ch3 ch3 F 6-F 4-CH3O 375 88 ch3 ch3 F 4-F 4-CH3O 375 89 ch3 ch3 Cl 4,6-di-F 4-CH3O 409 90 ch3 ch3 Br 4-F 4-CH3 419 30 91 ch3 ch3 Cl 4-F 4-Br 93-97 437 92 ch3 ch3 Cl 4-F 4-CI 98-102 394 93 (Ex. 4) ch3 ch3 Cl 4-F 4-CH3, 6-F 147-151 393 94 ch3 ch3 Cl 4-F 4-CF3O 124-128 445 95 ch3 Et Cl 4-F 4,6-di-F 107-111 412 35 96 ch3 ch3 F 6-F 4.6-di-CI 185-189 414 97 ch3 ch3 F 6-F 4-CH3O, 6-F 159-163 393 98 ch3 ch3 F 6-F 4-CI, 6 -F 180-184 397 99 ch3 ch3 F 6-F 3-CI 379 116 AP+ AP- Comp. N.a R1 R2 R3 (R4)m (R5)n p.f. (°C) (M+1) (M-1) 100 ch3 ch3 F 6-F 4-CH3, 6-CI 100-104 393 101 ch3 ch3 F 4-F 4,6-di-CI 176-180 414 5 102 ch3 ch3 F 4-F 4-CI, 6-F 136-140 397 103 ch3 ch3 Cl 4-F 4-CH3CH2O 95-99 405 104 ch3 ch3 Cl 4-F 4- / -PrO 99-103 419 105 ch3 ch3 F 6-F 4-CH3 359 106 ch3 ch3 Cl 4,6-di-F 4-CH3 392 10 107 ch3 ch3 F 4-F 4-CH3 359 108 ch3 ch3 Cl 4-F 6-CI 145-149 395 109 ch3 ch3 Cl 4-F 4,6-di-F 158-162 397 110 ch3 ch3 Cl 4-F 6-Br 151-155 439 111 ch3 ch3 Cl 4-F 4-F 120-124 379 15 112( Ex.1) ch3 ch3 Cl 4-F 6-F 130-134 379 113 (Ex. 2 and 5) ch3 ch3 Cl 4-N^C 6-F 176-180 386 114 ch3 ch3 F 4-N=C, 6-F 6-F 185-189 388 115 ch3 ch3 Cl 4-N=C 4-CI, 6-F 185-189 420 116 ch3 ch3 Cl 4-N=C 4,6-di-CI 216-220 436 20 117 ch3 ch3 Cl 4-F 6-CH3 154-158 375 118 ch3 ch3 F 4-F 6-F 113-117 363 119 ch3 ch3 Cl 4-F 4-CH3O 79-83 391 120 ch3 ch3 Cl 4-N ^C 4,6-di-F 191-195 404 121 ch3 ch3 Cl 4-F 4-CI, 6-F 131-135 413 25 122 ch3 CEN Cl 4-F 6-F 166-170 390 123 ch3 ch3 Cl 4-NEC 6-CI 196-199 402 124 ch3 ch3 Cl 4-NeC 4-CH3O 137-139 398 125 ch3 ch3 Cl 4-NeC 6-Br 209-211 446 126 ch3 ch3 Cl 4-F - 361 30 127 ch3 ch3 Cl 4-NEC 4-CH3, 6-F 166-170 400 128 ch3 Et Cl 4-F 4-Br, 6-CI 489 129 ch3 Et Cl 4-F 6-CI 423 130 ch3 ch3 Cl 4-F 5 -CI 395 131 ch3 ch3 Br 4-F 4-CI, 6-F 151-155 35 132 ch3 ch3 Cl 4-CI 4-Br, 6-F 159-163 133 ch3 ch3 Cl 4-CI 6-CI 208- 212 134 ch3 ch3 F 4-N^C - 125-129 135 ch3 ch3 F 6-F — 149-153 MA / IZ / ¿U¿¿ / U í Comp. N.a 117 AP+ (M+1) AP(M-1) R1 R2 R3 (R> (R5)n m.p. (°C) 136 ch3 ch3 Cl 6-F - 152-156 137 ch3 Et Cl 4-F 4-CH3 , 6-F 407 138 ch3 ch3 Cl 4-CI 4-CH3O, 6-F 103-107 139 ch3 ch3 Br 4-F - 119-123 140 ch3 ch3 Cl 4-MeO - 105-109 141 ch3 ch3 F 4- F 4-CH3O, 6-CI 156-160 142 ch3 ch3 Cl 4-CI 4-CH3O 407 143 ch3 ch3 Cl 4-CI 4-CH3, 6-F 158-162 144 ch3 ch3 Cl 4-CI 6-CH3 206 -210 145 ch3 ch3 Cl 4-CI 4-CH3, 6-CI 146 ch3 ch3 Cl 4-CI 4,6-di-CI 180-184 147 ch3 ch3 F 4-CH3O, 6-F - 375 148 ch3 ch3 Cl 4.6-di-F - 379 149 ch3 ch3 F 4.6-di-F - 363 150 ch3 ch3 F 4-NeC, 6-F 4-CH3O 186-190 151 ch3 ch3 F 4-CI, 6-F 6-F 397 152 ch3 ch3 Cl 4,6-di-F 6-CI 152-156 153 ch3 ch3 Cl 4,6-di-F 6-CH3 141-145 154 ch3 ch3 Br 4,6-di-F - 423 155 ch3 ch3 Cl 4-NeC 4-Br, 6-F 177-181 156 ch3 ch3 Cl 4-NeC 4-CH3, 6-CI 230-234 157 ch3 ch3 Cl 4-NeC 6-CH3 220-224 158 ch3 ch3 F 4.6-di-F 6-CI 180-184 159 ch3 ch3 F 4.6-di-F 4-CH3O 392 160 ch3 ch3 F 4-CH3O, 6-F 6-CI 168-172 161 ch3 ch3 F 4-CH3O, 6-F 4-CH3O 405 162 ch3 ch3 F 4-CH3O, 6-F 6-CH3 154-158 163 ch3 ch3 Br 4,6-di-F 6-CI 201-205 164 ch3 ch3 Br 4,6-di-F 4-CH3O 453 165 ch3 ch3 Br 4-F 4-CH3O, 6-F 177-181 166 ch3 ch3 Cl 4-NeC 4-CH3O, 6-F 185-189 167 ch3 ch3 F 4 ,6-di-F 6-CH3 151-155 168 ch3 ch3 F 4-CI, 6-F - 118-122 169 ch3 ch3 Br 4,6-di-F 6-CH3 196-200 170 ch3 Et F 4- CI, 6-F 6-F 120-122 171 ch3 Et F 4-F 4-Br, 6-F 455 MA / t / ¿ U / 118 AP+ AP- Comp. N.a R1 R2 R3 (R> (R5)n m.p. (°C) (M+1) (M-1) 173 ch3 Et Cl 4-F 4-CH3O 405 174 ch3 Et Cl 4-F 4-CH3 388 5 175 ch3 Et F 4-F 4-CH3 373 176 ch3 ch3 F 4-CI 4-F, 6-CI 184-188 177 ch3 ch3 F 4-F 6-CH3 130-134 178 ch3 ch3 F 4-F 4-CH3 , 6-F 108-112 179 ch3 ch3 F 4-NeC 4-CH3O 132-136 10 180 ch3 ch3 Br 4-ΝξΟ 4-CH3O 41-45 181 ch3 ch3 Br 4-F 4-CH3, 6-CI 174- 178 182 ch3 ch3 Cl 4-CH3O 4-Br, 6-F 180-184 183 ch3 ch3 Cl 4-CH3O 6-CH3 208-212 184 ch3 ch3 Cl 4-CH3O 6-CI 189-193 15 185 ch3 Et F 4 -F 4-CH3, 6-F 391 186 ch3 ch3 Cl 4-CH3O 4-CH3O, 6-F 156-160 187 ch3 ch3 Cl 4-CH3O 4-CH3O 403 188 ch3 ch3 Cl 4-CH3O 4-CH3, 6 -F 135-139 189 ch3 ch3 Cl 4-CI - 377 20 190 ch3 ch3 F 4-F - 132-136 191 ch3 ch3 Br 4-F 4-Br, 6-F 142-146 192 ch3 ch3 Cl 4-NO2 6-F 162-165 193 ch3 ch3 Cl 4,6-di-F 4-CH3, 6-F 130-133 194 ch3 ch3 F 4,6-di-F 4-CH3, 6-F 129-133 25 195 ch3 ch3 Cl 6-F 4-CH3 142-145 196 ch3 ch3 Br 4,6-di-F 4-CH3 117-120 197 ch3 ch3 Cl 6-F 4-CH3O 133-136 198 ch3 ch3 F 4-ΝξΟ 4 -CH3, 6-F 140-143 199 ch3 ch3 Cl 4,6-di-F 4,6-di-F 415 30 200 ch3 ch3 F 4-N=C, 6-F 4-CH3, 6-F 173 -176 201 ch3 ch3 Cl 6-F 4-CH3, 6-F 194-197 119 ΜΛ / INDEX TABLE B Comp. N.sStructure AP+(M+1) BIOLOGICAL EXAMPLES OF THE INVENTION General protocol for preparing test suspensions for Tests A-F: Test compounds were first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water. (50 / 50 mixture by volume) containing 250 ppm of the surfactant PEG400 (polyhydric alcohol esters). The resulting test suspensions were then used in Tests A-F. ESSAY A The test solution was sprayed to the point of runoff on wheat seedlings. The next day, seedlings were inoculated with a suspension of Septoria tritici spores (the causative agent of wheat leaf spot) and incubated in a saturated atmosphere at 24 °C for 48 h, and then moved to a chamber. growth at 20 °C for 17 days, after which the disease was scored. ESSAY B The test solution was sprayed to the point of runoff on wheat seedlings. The next day, the seedlings were inoculated with a spore suspension of Puccinia recondita f. sp. tritici (the causal agent of wheat leaf rust) and incubated in a saturated atmosphere at 20 °C for 24 h, and then moved to a growth chamber at 20 °C for 7 days, after which the disease. ESSAY C The test suspension was sprayed to the point of runoff on wheat seedlings. The next day, the seedlings were inoculated with a spore powder of Blumería graminist sp. tritici, (also known as Erysiphe graminis f. sp. tritici, the causal agent of wheat powdery mildew) and incubated in a growth chamber at 20 °C for 8 days, after which the disease was scored visually. ESSAY D The test solution was sprayed to the point of runoff on soybean seedlings. The next day, the seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi (the causative agent of Asian soybean rust) and incubated in a saturated atmosphere at 22 °C for 24 hours and then moved to a chamber. growth at 22 °C for 8 days, after which the disease was scored visually. 120 ESSAY E The test suspension was sprayed to the point of runoff on tomato seedlings. The next day, seedlings were inoculated with a spore suspension of Botrytis cinerea (the causative agent of tomato gray rot) and incubated in a saturated atmosphere at 20 °C for 48 h, 5 and then moved to a chamber. growth at 24 °C for 3 days, after which the disease was scored visually. ESSAY F The test suspension was sprayed to the point of runoff on tomato seedlings. The next day, seedlings were inoculated with a spore suspension of Alternaria solani (the causal agent of tomato early blight) and incubated in a saturated atmosphere at 27°C for 48 h and then moved to a growth chamber at 20°C for 3 days, after which visual grading of the disease was performed. The results of Tests A-F are provided in Table A below. A score of 100 indicates 100% disease control and a score of 0 indicates no disease control (relative to controls). A dash (-) indicates that the compound was not tested. TABLE A ΜΛ / t / ZUZZ / U / 4ZÓU Rate in Essay Essay Essay Comp. N.s ppm Test A Test B Test C D E F 1 50 100 100 100 84 100 99 20 2 50 100 100 99 94 99 61 3 50 100 89 56 0 70 0 4 50 - 86 76 0 74 0 5 50 97 86 76 19 95 0 6 50 - 74 27 0 55 0 25 7 50 100 99 94 96 99 89 8 50 99 99 92 73 99 73 9 50 100 100 97 0 97 99 10 50 100 99 48 0 68 9 11 50 1 00 98 97 0 98 99 30 12 50 100 99 81 0 97 53 13 50 100 99 97 19 68 89 14 50 100 97 83 48 96 83 15 50 100 100 98 61 99 53 16 50 100 99 98 50 99 0 35 17 50 100 92 94 0 99 9 18 50 100 100 89 92 100 99 19 50 100 100 100 98 100 99 20 50 100 89 92 0 99 26 121 Rate in Essay Essay Essay Comp. N.s ppm Test A Test B Test C D E F 21 50 100 86 84 0 95 17 22 50 100 93 97 0 99 64 5 23 50 100 100 100 99 97 99 24 50 100 89 0 0 97 0 25 50 100 100 99 98 100 98 26 50 100 99 94 77 100 68 27 50 100 100 91 87 100 99 10 28 50 91 68 69 0 99 0 29 50 97 98 87 81 99 26 30 50 100 86 91 0 67 0 31 50 100 100 100 98 99 76 32 50 93 85 56 98 99 0 15 33 50 100 100 99 92 99 85 34 50 100 54 13 0 71 0 35 50 99 85 0 0 0 0 36 50 100 89 56 25 100 0 37 50 1 00 100 98 0 88 78 20 38 50 100 99 95 0 88 0 39 50 100 100 99 73 88 99 40 50 100 100 100 82 98 100 41 50 100 100 94 77 77 0 42 50 100 100 96 0 91 0 2 5 43 50 100 100 97 65 96 64 44 50 100 99 98 0 95 46 45 50 100 86 95 0 99 33 46 50 100 98 99 0 99 81 47 50 100 97 89 92 95 96 30 48 50 100 95 89 0 97 97 49 50 1 00 100 95 25 94 26 50 50 100 98 100 0 92 98 51 50 100 100 100 79 98 99 52 50 100 100 90 59 99 94 35 53 50 100 100 98 0 98 98 54 50 100 91 93 0 21 0 55 50 100 99 90 0 34 0 56 50 100 100 100 65 99 99 MA / t / ZUZZ / U / 4ZÓU 122 Rate in Essay Essay Essay Comp. N.s ppm Test A Test B Test C D E F 57 50 100 100 100 96 100 100 58 50 100 100 99 36 99 99 5 59 50 100 100 99 96 99 92 60 50 100 100 100 97 99 99 60 10 99 100 85 0 99 75 61 50 100 100 99 84 99 99 62 50 100 100 100 100 99 99 10 63 50 100 99 86 0 100 96 64 50 100 100 98 97 98 99 65 50 94 89 56 6 6 16 46 66 50 100 100 98 97 98 96 67 50 100 100 89 69 98 33 15 68 50 100 100 100 99 100 99 68 10 100 100 96 32 100 98 69 50 100 100 97 77 100 99 70 50 100 100 99 84 99 99 71 50 100 100 99 82 99 98 20 72 50 100 100 99 31 98 99 72 10 100 85 81 12 98 63 73 50 100 100 96 98 99 97 74 50 99 86 81 74 99 85 75 50 100 99 90 0 57 98 25 76 50 100 99 95 25 87 0 77 50 100 100 95 73 72 9 78 50 100 89 95 0 68 0 79 50 100 100 91 44 98 0 80 50 100 100 97 50 95 98 30 81 50 100 99 89 0 95 99 82 50 100 100 58 59 96 97 83 50 99 91 99 0 98 99 84 50 100 100 99 48 90 99 85 50 100 100 97 96 94 98 35 86 50 100 100 98 77 96 99 87 50 - 99 98 0 98 93 88 50 - 9 7 84 0 99 9 89 50 — 100 99 80 99 99 ΜΛ / 1 / ¿l U í 123 Rate in Essay Essay Essay Comp. N.s ppm Test A Test B Test C D E F 90 50 100 95 87 0 99 9 91 50 99 88 84 0 99 26 5 92 50 100 96 89 0 100 79 93 50 100 100 99 100 100 99 93 10 99 100 97 87 99 99 94 50 73 0 72 73 0 9 95 50 100 100 100 84 99 99 10 96 50 100 95 0 0 80 0 97 50 100 100 100 96 100 99 98 50 100 97 93 0 99 98 99 50 99 0 0 0 24 0 100 50 100 89 21 0 26 0 15 101 50 100 99 89 44 99 0 102 50 100 100 100 48 99 99 103 50 97 80 50 0 83 0 104 50 60 0 72 0 0 0 105 50 99 74 86 0 73 0 20 106 50 - 100 98 0 99 68 107 50 - 91 61 0 98 0 108 50 100 100 97 86 100 77 109 50 100 100 100 93 100 99 110 50 100 98 56 73 99 0 25 111 50 100 99 99 0 100 93 112 50 88 100 100 99 100 100 112 10 72 100 98 52 100 98 113 50 100 99 97 13 99 99 114 50 100 98 99 73 100 99 30 115 50 100 100 94 7 7 99 99 116 50 99 99 56 0 63 82 117 50 99 100 95 0 99 76 118 50 100 100 98 0 100 99 118 10 100 80 27 0 99 60 35 119 50 100 100 99 92 100 99 120 50 100 100 89 44 100 99 121 50 100 100 100 99 100 100 122 50 100 100 94 0 100 99 124 Rate in Essay Essay Essay Comp. N.s ppm Test A Test B Test C D E F 123 50 100 97 81 0 100 66 124 50 100 100 99 25 100 99 5 125 50 100 96 0 0 99 9 126 50 98 85 96 0 100 68 127 50 100 ...

Claims

1. A fungicidal composition comprising: (a) at least one compound selected from the compounds of Formula 1, / V-oxides and salts thereof: MA / t / ZUZZ / U / 4ZÓU wherein R1 is C1-C2 alkyl; R2 is cyano, halogen, C1-C2 alkyl or C1-C2 haloalkyl; R3 is halogen or methyl; each R4 is independently halogen, cyano, nitro, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy, C2-C6 alkoxyalkyl or C2-C6 alkoxyalkoxy; each R5 is independently halogen, C1-C3 alkyl, C2-C6 alkoxyalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C2-C6 cyanoalkoxy, or C2-C6 alkoxyalkoxy; m and n are each independently 0, 1, 2, or 3; R6 is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents selected independently of R6a; or amino, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, CH(=O), S(=O)2OM, S(=O)uR7, (C=W)R8, or OR9;each R6a is independently cyano, Cs-Ce cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 alkylsulfinyl, or C1-C3 alkylsulfonyl; M is K or Na; u is 0, 1, or 2; R7 is C1-C3 alkyl or C1-C3 haloalkyl; W is O or S; R8 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio, or C2-C4 alkylthioalkyl; R9 is H; or C1-C3 alkyl or C1-C3 haloalkyl, each optionally substituted with up to 2 substituents selected independently of R9a; or CH(=O), C3-C6 cycloalkyl, S(=O)2OM or (C=W)R10; 129 each R9a is independently cyano, Cs-Cs cycloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio, C1-C3 alkylsulfinyl or C1-C3 alkylsulfonyl; and R10 is C1-C3 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C1-C3 alkoxy, C1-C3 alkylthio or C2-C4 alkylthioalkyl; and (b) at least one additional fungicidal compound;a condición de que el compuesto de Fórmula 1 no sea: 4-(2,6-difluoro-4-metoxifenil)-A / -(2,4-d¡fluoro-6-nitrofenil)-1,3-dimetil-1 / 7-pirazol-5-amina; 4-(2-cloro-4-fluorofenil)-1,3-dimetil-A / -(2-n¡trofenil)-1 H-pirazol-5-amina; 4-(2-cloro-4-fluorofenil)-A / -(2,4-difluoro-6-n itrofenil)-1,3-dimeti 1-1 H-pirazol-5-amina; 4-(2-chloro-4-fluorophenyl)-3-ethyl-1-methyl-A / -(2-nitrophenyl)-1-pyrazol-5-amine; 4-(2-chloro-4-fluorophenyl)-1-methyl-A / -(2-n¡trophenyl)-3-(trifluoromethyl)-1-pyrazol-5-amine; 4-(2,6-difluoro-4-methoxphenyl)-A / -(2-methox-6-nitrophenyl)-1,3-d¡ methyl-1-pyrazol-5-amine; 4-(2-chloro-4-fluorophenyl)-A / -(2-methox-6-n¡trophenyl)-1,3-dimethyl-1-pyrazol-5-amine; A / -(2-chloro-6-nitrofen¡l)-4-(2,6-d¡fluoro-4-methoxyphenyl)-1,3-d¡methyl-1 / - / -p¡razol-5-am¡na; / V-(2-chloro-3-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxifen¡l)-1,3-dimethyl-1 H-pyrazol-5amine; 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl- / \ / -(2-methyl-6-nitrophenyl)-1 / 7-pyrazol-5-amine; / N-(2-bromo-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 / - / -pyrazol-5-amine; 4-(2-chloro-4-fluorophenyl)- / N-(4-methoxy-2-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazol-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-N-(4-fluoro-2-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazol-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-N-(4-methoxy-2-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazol-5-amine; N-(4-chloro-2-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / 7-pyrazol-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl- / N-[2-nitro-4-(2-propin-1-yloxy)fenil]-1 / - / -pyrazol-5-amine; 4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl- N -[2-nitro-4-(2-propen-1-yloxy)phenyl]-1 / 7-pyrazol-5-amine; N-(4-bromo-2-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1-(N-pyrazol-5-amine); N-(4-chloro-2-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 / - / -pyrazol-5-amine; 3-chloro-4-(2-chloro-4-fluorophenyl)- / / -(2,4-difluoro-6-nitrophenyl)-1-methyl-1 H-pyrazol-5-amine;4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl- / \ / -[4-methyl-2-nitrophenyl]-1 / 7-pyrazol-5-amine; 4-(2-chloro-4-fluorophenyl)-1,3-dimethyl- / \ / -(4-methyl-2-nitrophenyl)-1 / 7-pyrazol-5-amine; and N-(4-bromo-2-fluoro-6-nitrophenyl)-4-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1 H-pyrazol-5-amine.; 2. The composition of claim 1, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R1 is methyl; R2 is cyano, halogen, or C1-C2 alkyl; R3 is halogen; each R4 is independently halogen, cyano, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, or C2-C4 cyanoalkoxy; each R5 is independently halogen, methyl, methoxy, halomethoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, or C2-C4 cyanoalkoxy; R6 is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to one substituent selected from R6a; or S(=O)uR7 or OR9; R6a is cyano, C3-C6 cycloalkyl or C1-C3 alkoxy; R7 is methyl or halomethyl; R9 is H; or C1-C2 alkyl or C1-C2 haloalkyl, each optionally substituted with up to 1 substituent selected from R9a; and R9a is cyano, Cs-Ce cycloalkyl or C1-C3 alkoxy.

3. The composition of claim 2, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R2 is methyl or ethyl; R3 is Br, Cl, or F; each R4 is independently halogen, cyano, methyl, or methoxy; m is 1 and R4 is in the para position; om is 1 and R4 is in the ortho position; om is 2 and one R4 is in the para position, and the other is in the ortho position; each R5 is independently halogen, methyl, or methoxy; n is 1 and R5 is in the para position; on is 1 and R5 is in the ortho position; on is 2 and one R5 is in the para position, and the other is in the ortho position; and R6 is H or methyl.

4. The composition of claim 3, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R2 is methyl; each R4 is independently Br, Cl, F, cyano or methoxy; each R5 is independently Br, Cl, F, methyl or methoxy; and R6 is H.

5. The composition of claim 4, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein each R4 is independently Br, Cl or F; ymyn are each 1 and R4 is in the para position and R5 is in the ortho position; or mes 1 and R4 is in the para position, yn is 2 and one R5 is in the para position and the other is in the ortho position; om is 2 and one R4 is in the para position and the other is in the ortho position, yn is 1 and R5 is in the ortho position.

6. The composition of claim 5, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R4 is Cl or F; each R5 is independently Cl, F or methyl; ymyn are each 1 and R4 is in the para position and R5 is in the ortho position; om is 1 and R4 is in the para position, yn is 2 and one R5 is in the para position and the other is in the ortho position.

7. The composition of claim 1, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R1 is methyl; R2 is methyl or ethyl; R3 is halogen; each R4 is independently Br, Cl, F, cyano or methoxy; m is 1 and R4 is in the para position; om is 1 and R4 is in the ortho position; om is 2 and one R4 is in the para position, and the other is in the ortho position; n is 0; and R6 is H or methyl.

8. The composition of claim 7, wherein component (a) comprises a compound of Formula 1 or a salt thereof, wherein R2 is methyl; R3 is Br, Cl or F; each R4 is independently Br, Cl or F; m is 1 and R4 is in the para position; om is 1 and R4 is in the ortho position; om is 2 and one R4 is in the para position, and the other is in the ortho position; and R6 is H.

9. The composition of claim 1, where component (a) includes a selected compound from the group consisting of 4-(2-bromo-4,6-difluorophenyl)- / V-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 f7-pyrazol-5-amine, 3-chloro-4-[5-[(2-chloro-4-fluoro-6-nitrofen¡l)am¡no]-1,3-d¡ methyl-1 / 7-pyrazol-4-yl]benzon¡tr¡lo, A / -(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-d¡met¡l-1 / 7-pyrazol-5-am¡na, 4-(2-chloro-6-fluorophenyl)-A / -(2-fluoro-4-methox¡-6-nitrophenyl)-1,3-d¡meth¡l-1 H-pyrazol-5-amine, 4-(2-bromo-4-fluorophenyl)-A / -(2-fluoro-6-n¡trofen¡l)-1,3-d¡ methyl-1 / - / -pyrazol-5-amine, 4-(2-chloro-4,6-difluorophenyl)- / \ / -(2-fluoro-6-n¡trofen¡l)-1,3-dimethyl-1 / 7-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)- / \ / -(2-fluoro-6-n¡trofen¡l)-3-ethyl-1-methyl-1 / 7-pyrazol-5-amine, / V-(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-methoxyphen¡l)-1,3-dimethyl-1 / 7-pyrazol-5-amine,4-(2-chloro-4-fluorofenil)- / \ / -(2-fluoro-4-met¡l-6-nitrofenil)-1,3-dimethyl-1 H-pyrazol-5-amina, 4-(2-cloro-4-fluorofenil)-A / -(4-fluoro-2-nitrofenil)-1,3-dimethyl-1 / - / -pyrazol-5-amine, 4-(2-chloro-4-fluorofenil)- / \ / -(2-fluoro-6-nitrofen¡l)-1,3-dimethyl-1 / 7-pyrazol-5-amina, 4-(2,4-difluorofenil)- / \ / -(2-fluoro-6-nitrofen¡l)-1,3-dimethyl-1 / 7-pyrazol-5-amine, A / -(4-chloro-2-fluoro-6-nitrofenil)-4-(2-cloro-4-fluorofenil)-1,3-d¡ metil-1 / 7-pyrazol-5-amine and 3-chloro-4-[5-[(2-fluoro-4-methyl-6-nitrophenyl)amino]-1,3-dimethyl-1 / 7-pyrazol-4-yl]benzonitrile. 132, 10. The composition of claim 8, wherein component (a) comprises a compound selected from the group consisting of 4-(2-bromo-4-fluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazol-5-amine, 4-(2-chloro-4,6-difluorophenyl)- / / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)- / V-(2-fluoro-6-nitrophenyl)-3-ethyl-1-methyl-1 / - / -pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)- / V-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)- / V-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / 7-pyrazole-5-amine and 4-(2,4-difluorophenyl)-A / -(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1 / - / -pyrazole-5-amine.

11. The composition of any one of claims 1 to 7, wherein component (b) includes at least one fungicidal compound selected from the group consisting of: (b1) methylbenzimidazole carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide (PA) fungicides; (b5) amine / morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine (AP) fungicides; (b10) m-phenyl carbamate fungicides; (b11) quinone exterior inhibitor fungicides (Qol); (b12) phenylpyrrole (PP) fungicides; (b13) azanaphthalene fungicides; (b14) cell peroxidation inhibitor fungicides; (b15) melanin reductase biosynthesis inhibitor fungicides (MBI-R);(b16a) melanin dehydratase biosynthesis inhibitors (MBI-D); (b16b) melanin polyketide synthase biosynthesis inhibitors (MBI-P); (b17) keto reductase inhibitors (KRI); (b18) squalene epoxidase inhibitors; (b19) polyoxin fungicides; (b20) phenylurea fungicides; (b21) quinone interior inhibitors (Qil); (b22) benzamide and tlazol carboxamide fungicides; (b23) enopyranuronic acid antibiotic fungicides; (b24) hexopyranosyl antibiotic fungicides; (b25) glucopyranosyl antibiotic fungicides: protein synthesis; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamide-oxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupler fungicides; (b30) organotin fungicides; (b31) carboxylic acid fungicides; (b32) heteroaromatic fungicides; (b33) phosphonate fungicides;(b34) phthalamic acid fungicides; (b35) benzotriazine fungicides; (b36) benzene-sulfonamide fungicides; (b37) pyridazinone fungicides; (b38) thiophene-carboxamide fungicides; (b39) NADH complex I oxidoreductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) quinone exterior and stigmatelin-binding inhibitor (QoSI) fungicides; (b46) plant extract fungicides; (b47) cyanoacrylate fungicides; (b48) polyene fungicides; (b49) oxysterol-binding protein inhibitor (OSBPI) fungicides; (b50) aryl-phenyl-ketone fungicides; (b51) host plant defense-inducing fungicides; (b52) multi-site fungicides; (b53) biological products with multiple modes of action;(b54) fungicides other than fungicides of component (a) and components (b1) to (b53); and salts of compounds of (b1) to (b54).; 12. The composition of claim 11, wherein component (b) comprises at least one fungicidal compound from each of the two different groups selected from (b1) to (b54).

13. The composition of any one of claims 1 to 7, wherein component (b) includes at least one compound selected from acibenzolar-S-methyl, aldimorph, ametoctradine, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl, benalaxyl-M, benodanil, benomyl, bentiavalicarb, bentiavalicarb-isopropyl, benzovindiflupyr, betoxazine, binapacryl, biphenyl, bitertanol, bixaphene, blasticidin-S, boscalide, bromuconazole, bupirimate, carboxin, carpropamid, captafol, captan, carbendazim, chloroneb, chlorothalonil, clozolinate, clotrimazole, copper hydroxide, copper salts, cyazofamid, cyflufenamide, cymoxanil, cyproconazole, cyprodinil, diclofluanid, diclocimet, diclomezine, dichlorane, dietofencarb, difenoconazole, diflumetorim, dimetirimol, dimethomorph, dimoxystrobin, diniconazole, ΜΛ / í 134 diniconazol-M, dinocap, ditianon, dodemorph, dodine, edifenphos, enestroburin, epoxiconazole, etaboxam, etirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole,fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidine, fenpropimorph, fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, fluindapyr, flumetover, flumorph, fluopicolide, fluopiram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fosetyl-aluminum, fuberidazole, furalaxil, furametpyr, hexaconazole, himexazole, guazatine, imazalil, imibenconazole, iminoctadine, iodocarb, ipconazole, ipfentrifluconazole, iprobenphos, iprodione, iprovalicarb, isoprothiolan isopirazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandipropamid, maneb, mepronil, meptildinocap, metalaxyl, metalaxyl-M, metconazole, metasulfocarb, metiram, metominostrobin, mepanipirim, metrafenone, myclobutanil, naftifine, neo-azoline (ferric methanoarsonate), nuarimol, octilinone, ofurace, orisastrobin, oxadixil, oxolinic acid, oxoconazole, oxycarboxin,oxytetracycline, penconazole, pencicuron, penflufen, penthiopyrad, pefurazoate, phosphorous acid and salts thereof, phthalide, picoxystrobin, piperalin, polyoxine, probenazole, prochloraz, procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pidiflumethophen, pyrachloestrobin, pyramethostrobin, pyroxyestrobin, pyrazophos, piribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriophenone, pyrisoxazole, pyroquilon, pyrrolnitrine, quinomethionate, quinoxyfen, quintozene, sedaxane, siltiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquine, teclophthalam technazene, terbinafine, tetraconazole, thiabendazole, tifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclophos-methyl, tolylfluanid, tolnifanide, triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph, triflumizole, tricyclazole, trifloxiestrobin, triforin, trimorfamide, triticonazole, uniconazole, validamicin, valifenalate, vinclozolin,zineb, ziram, zoxamide, / V-[4-[4-chloro-3(trifluoromethyl)phenoxy]-2,5-dimethylphen¡l]- / \ / -ethyl- / \ / -methylmethane¡m¡dam¡da, 5-chloro-6-(2,4,6-trifluorophenyl)-methylperiodin-47-17 -yl)[1,2,4]triazolo[1,5a]pyr¡m¡d¡na (DPX-BAS600F), A / -[2-[4-[[3-(4-chlorophenyl)-2-prop¡n-1 -yl]oxy]3-methoxy¡phen¡l]ethyl]-3-methyl-2-[(met¡lsulfon¡l)amino]butan¡da, / V-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1 -yl]ox¡]-3methox¡phen¡l]et¡l]-3-meth¡l-2-[(ethylsulfon¡l)am¡no]butan¡da, Λ / -[1 -[[[ A / -[[(cyclopropylmethoxy¡)am¡no][6(difluoromethoxy¡)-2,3-d¡fluorophenyl]meth¡len]benzeneacetam¡da, a-(methoxyimino)-A / -methyl-2-[[[1 -[3(tnfluorometh¡l)phenyl]ethoxy¡]im¡no]meth¡l]benzenoacetam¡da, / V-[4-[4-chloro-3-(trifluoromethyl)phenoxy¡]-2,5dimethlphen¡l]-A / -et¡lA / -methl 2-[[[[3-(2,6-dichlorophyl nil) -1 -methyl-2-propene-1 ¡lidene]amino]ox¡]meth¡l]-a-(methoxyimino)-A / -methylbenzeneacetam¡da,1-[(2-propenylthio)carbonyl]-2-(1-methylethyl)4-(2-methylphenyl)-5-amino-1 / - / -pyrazol-3-one, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine., 14. The composition of claim 13, wherein component (b) includes at least one compound selected from azoxystrobin, benzovindiflupyr, bixaphene, chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, phenpropidine, fenpropimorf, fluindapyr, flutriafol, fluxapyroxad, mancozeb, methominostrobin, picoxystrobin, prothioconazole, pidiflumethophen, pyraclostrobin, tebuconazole, and trifloxystrobin. 135 15. A composition comprising the composition of claim 1 and at least one additional component selected from the group consisting of surfactants, solid diluents, and liquid diluents.

16. A method for protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying an effective fungicidal amount of the composition of any one of claims 1 to 14 to the plant or plant seed.